<?xml version='1.0' encoding='UTF-8'?>
<document id="quantitative"><sentence id="quantitative.s0" text=" A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively. "><entity charOffset="112-120" id="quantitative.s0.e0" text="oxycodone" type="active-ingredient" /><entity charOffset="56-63" id="quantitative.s0.e1" text="rifampin" type="active-ingredient" /><pair ddi="true" e1="quantitative.s0.e0" e2="quantitative.s0.e1" id="quantitative.s0.p0" /></sentence><sentence id="quantitative.s1" text=" Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone."><entity charOffset="1-10" id="quantitative.s1.e0" text="fluoxetine" type="active-ingredient" /><entity charOffset="55-74" id="quantitative.s1.e1" text="9-hydroxyrisperidone" type="metabolite" /><pair ddi="false" e1="quantitative.s1.e0" e2="quantitative.s1.e1" id="quantitative.s1.p0" /></sentence><sentence id="quantitative.s2" text=" In a study of healthy subjects neither the pharmacokinetics of warfarin enantiomers nor prothrombin time were affected following single or multiple 60 mg doses of lansoprazole."><entity charOffset="64-71" id="quantitative.s2.e0" text="warfarin" type="active-ingredient" /><entity charOffset="164-175" id="quantitative.s2.e1" text="lansoprazole" type="active-ingredient" /><pair ddi="false" e1="quantitative.s2.e0" e2="quantitative.s2.e1" id="quantitative.s2.p0" /></sentence><sentence id="quantitative.s3" text=" Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%."><entity charOffset="41-60" id="quantitative.s3.e0" text="9-hydroxyrisperidone" type="active-ingredient" /><entity charOffset="1-10" id="quantitative.s3.e1" text="paroxetine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s3.e0" e2="quantitative.s3.e1" id="quantitative.s3.p0" /></sentence><sentence id="quantitative.s4" text=" Propranolol did not have an effect on the pharmacokinetics of fluvastatin."><entity charOffset="63-73" id="quantitative.s4.e0" text="fluvastatin" type="active-ingredient" /><entity charOffset="1-11" id="quantitative.s4.e1" text="propranolol" type="active-ingredient" /><pair ddi="false" e1="quantitative.s4.e0" e2="quantitative.s4.e1" id="quantitative.s4.p0" /></sentence><sentence id="quantitative.s5" text=" Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%). "><entity charOffset="1-10" id="quantitative.s5.e0" text="Ranitidine" type="active-ingredient" /><entity charOffset="67-77" id="quantitative.s5.e1" text="nisoldipine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s5.e0" e2="quantitative.s5.e1" id="quantitative.s5.p0" /></sentence><sentence id="quantitative.s6" text=" The effect of short-term administration of ritonavir (200 mg twice daily, 4 doses) on the pharmacokinetics of a single dose of trazodone (50 mg) has been studied in 10 healthy subjects. The Cmax of trazodone increased by 34%, the AUC increased 2.4 fold, the half-life increased by 2.2 fold, and the clearance decreased by 52%. Adverse effects including nausea, hypotension, and syncope were observed when ritonavir and trazodone were coadministered."><entity charOffset="44-52" id="quantitative.s6.e0" text="ritonavir" type="active-ingredient" /><entity charOffset="406-414" id="quantitative.s6.e1" text="ritonavir" type="active-ingredient" /><entity charOffset="128-136" id="quantitative.s6.e2" text="trazodone" type="active-ingredient" /><entity charOffset="199-207" id="quantitative.s6.e3" text="trazodone" type="active-ingredient" /><entity charOffset="420-428" id="quantitative.s6.e4" text="trazodone" type="active-ingredient" /><pair ddi="true" e1="quantitative.s6.e1" e2="quantitative.s6.e4" id="quantitative.s6.p0" /></sentence><sentence id="quantitative.s7" text=" The exposure to quinidine was not importantly changed in the presence of nifedipine."><entity charOffset="17-25" id="quantitative.s7.e0" text="quinidine" type="active-ingredient" /><entity charOffset="74-83" id="quantitative.s7.e1" text="nifedipine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s7.e0" e2="quantitative.s7.e1" id="quantitative.s7.p0" /></sentence><sentence id="quantitative.s8" text=" The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day."><entity charOffset="183-192" id="quantitative.s8.e0" text="alprazolam" type="active-ingredient" /><entity charOffset="43-52" id="quantitative.s8.e1" text="imipramine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s8.e0" e2="quantitative.s8.e1" id="quantitative.s8.p0" /></sentence><sentence id="quantitative.s9" text=" The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day."><entity charOffset="58-68" id="quantitative.s9.e0" text="desipramine" type="active-ingredient" /><entity charOffset="183-192" id="quantitative.s9.e1" text="alprazolam" type="active-ingredient" /><pair ddi="true" e1="quantitative.s9.e0" e2="quantitative.s9.e1" id="quantitative.s9.p0" /></sentence><sentence id="quantitative.s10" text="7.2 Cimetidine\n\nConcomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects. The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%."><entity charOffset="63-73" id="quantitative.s10.e0" text="venlafaxine" type="active-ingredient" /><entity charOffset="165-175" id="quantitative.s10.e1" text="venlafaxine" type="active-ingredient" /><entity charOffset="223-233" id="quantitative.s10.e2" text="venlafaxine" type="active-ingredient" /><entity charOffset="4-13" id="quantitative.s10.e3" text="Cimetidine" type="active-ingredient" /><entity charOffset="48-57" id="quantitative.s10.e4" text="Cimetidine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s10.e2" e2="quantitative.s10.e4" id="quantitative.s10.p0" /></sentence><sentence id="quantitative.s11" text="7.2 Cimetidine\n\nConcomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects. The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%. However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine. "><entity charOffset="448-450" id="quantitative.s11.e0" text="ODV" type="metabolite" /><entity charOffset="4-13" id="quantitative.s11.e1" text="Cimetidine" type="active-ingredient" /><entity charOffset="48-57" id="quantitative.s11.e2" text="Cimetidine" type="active-ingredient" /><entity charOffset="387-396" id="quantitative.s11.e3" text="Cimetidine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s11.e0" e2="quantitative.s11.e3" id="quantitative.s11.p0" /></sentence><sentence id="quantitative.s12" text="7.4 Haloperidol\n\nVenlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC. In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged. The mechanism explaining this finding is unknown."><entity charOffset="4-14" id="quantitative.s12.e0" text="Haloperidol" type="active-ingredient" /><entity charOffset="179-189" id="quantitative.s12.e1" text="Haloperidol" type="active-ingredient" /><entity charOffset="235-245" id="quantitative.s12.e2" text="Haloperidol" type="active-ingredient" /><entity charOffset="269-279" id="quantitative.s12.e3" text="Haloperidol" type="active-ingredient" /><entity charOffset="346-356" id="quantitative.s12.e4" text="Haloperidol" type="active-ingredient" /><entity charOffset="19-29" id="quantitative.s12.e5" text="venlafaxine" type="active-ingredient" /><entity charOffset="325-335" id="quantitative.s12.e6" text="venlafaxine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s12.e4" e2="quantitative.s12.e6" id="quantitative.s12.p0" /></sentence><sentence id="quantitative.s13" text="7.5 Lithium\n\nThe steady-state pharmacokinetics of venlafaxine administered at 150 mg/day were not affected when a single 600 mg oral dose of lithium was administered to 12 healthy male subjects. ODV also was unaffected. Venlafaxine had no effect on the pharmacokinetics of lithium"><entity charOffset="4-10" id="quantitative.s13.e0" text="Lithium" type="active-ingredient" /><entity charOffset="143-149" id="quantitative.s13.e1" text="Lithium" type="active-ingredient" /><entity charOffset="275-281" id="quantitative.s13.e2" text="Lithium" type="active-ingredient" /><entity charOffset="52-62" id="quantitative.s13.e3" text="venlafaxine" type="active-ingredient" /><entity charOffset="222-232" id="quantitative.s13.e4" text="venlafaxine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s13.e2" e2="quantitative.s13.e4" id="quantitative.s13.p0" /></sentence><sentence id="quantitative.s14" text="7.5 Lithium\n\nThe steady-state pharmacokinetics of venlafaxine administered at 150 mg/day were not affected when a single 600 mg oral dose of lithium was administered to 12 healthy male subjects. ODV also was unaffected. Venlafaxine had no effect on the pharmacokinetics of lithium"><entity charOffset="4-10" id="quantitative.s14.e0" text="Lithium" type="active-ingredient" /><entity charOffset="143-149" id="quantitative.s14.e1" text="Lithium" type="active-ingredient" /><entity charOffset="275-281" id="quantitative.s14.e2" text="Lithium" type="active-ingredient" /><entity charOffset="52-62" id="quantitative.s14.e3" text="venlafaxine" type="active-ingredient" /><entity charOffset="222-232" id="quantitative.s14.e4" text="venlafaxine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s14.e2" e2="quantitative.s14.e4" id="quantitative.s14.p0" /></sentence><sentence id="quantitative.s15" text="7.5 Lithium\n\nThe steady-state pharmacokinetics of venlafaxine administered at 150 mg/day were not affected when a single 600 mg oral dose of lithium was administered to 12 healthy male subjects. ODV also was unaffected. Venlafaxine had no effect on the pharmacokinetics of lithium"><entity charOffset="197-199" id="quantitative.s15.e0" text="ODV" type="metabolite" /><entity charOffset="4-10" id="quantitative.s15.e1" text="Lithium" type="active-ingredient" /><entity charOffset="143-149" id="quantitative.s15.e2" text="Lithium" type="active-ingredient" /><entity charOffset="275-281" id="quantitative.s15.e3" text="Lithium" type="active-ingredient" /><pair ddi="false" e1="quantitative.s15.e0" e2="quantitative.s15.e3" id="quantitative.s15.p0" /></sentence><sentence id="quantitative.s16" text="A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily. "><entity charOffset="40-50" id="quantitative.s16.e0" text="nisoldipine" type="active-ingredient" /><entity charOffset="100-109" id="quantitative.s16.e1" text="cimetidine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s16.e0" e2="quantitative.s16.e1" id="quantitative.s16.p0" /></sentence><sentence id="quantitative.s17" text="A group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 µg ethinyl estradiol and 75 µg gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles. Felbamate treatment resulted in a 42% decrease in the gestodene AUC 0-24, but no clinically relevant effect was observed on the pharmacokinetic parameters of ethinyl estradiol."><entity charOffset="121-137" id="quantitative.s17.e0" text="ethinyl estradiol" type="active-ingredient" /><entity charOffset="464-480" id="quantitative.s17.e1" text="ethinyl estradiol" type="active-ingredient" /><entity charOffset="206-214" id="quantitative.s17.e2" text="felbamate" type="active-ingredient" /><entity charOffset="306-314" id="quantitative.s17.e3" text="felbamate" type="active-ingredient" /><pair ddi="false" e1="quantitative.s17.e1" e2="quantitative.s17.e3" id="quantitative.s17.p0" /></sentence><sentence id="quantitative.s18" text="A multiple-dose study with immediate-release paroxetine hydrochloride has shown that there is no pharmacokinetic interaction between paroxetine and lithium carbonate."><entity charOffset="148-164" id="quantitative.s18.e0" text="lithium carbonate" type="active-ingredient" /><entity charOffset="45-68" id="quantitative.s18.e1" text="paroxetine hydrochloride" type="active-ingredient" /><pair ddi="false" e1="quantitative.s18.e0" e2="quantitative.s18.e1" id="quantitative.s18.p0" /></sentence><sentence id="quantitative.s19" text="A multiple-dose study with immediate-release paroxetine hydrochloride has shown that there is no pharmacokinetic interaction between paroxetine and lithium carbonate."><entity charOffset="45-68" id="quantitative.s19.e0" text="paroxetine hydrochloride" type="active-ingredient" /><entity charOffset="148-164" id="quantitative.s19.e1" text="lithium carbonate" type="active-ingredient" /><pair ddi="false" e1="quantitative.s19.e0" e2="quantitative.s19.e1" id="quantitative.s19.p0" /></sentence><sentence id="quantitative.s20" text="A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported. Whether this interaction also occurs with the intravenous, topical, or vaginal preparations of miconazole is not known. The effect of concomitant administration of fluconazole and glipizide has been demonstrated in a placebo-controlled crossover study in normal volunteers. All subjects received glipizide alone and following treatment with 100 mg of fluconazole as a single daily oral dose for 7 days. The mean percentage increase in the glipizide AUC after fluconazole administration was 56.9% (range: 35 to 81)."><entity charOffset="307-315" id="quantitative.s20.e0" text="glipizide" type="active-ingredient" /><entity charOffset="423-431" id="quantitative.s20.e1" text="glipizide" type="active-ingredient" /><entity charOffset="566-574" id="quantitative.s20.e2" text="glipizide" type="active-ingredient" /><entity charOffset="37-46" id="quantitative.s20.e3" text="miconazole" type="active-ingredient" /><entity charOffset="222-231" id="quantitative.s20.e4" text="miconazole" type="active-ingredient" /><pair ddi="true" e1="quantitative.s20.e2" e2="quantitative.s20.e4" id="quantitative.s20.p0" /></sentence><sentence id="quantitative.s21" text="A single 100 mg dose of sildenafil in subjects with essential hypertension had no effect on the pharmacokinetic parameters of amlodipine besylate."><entity charOffset="126-144" id="quantitative.s21.e0" text="amlodipine besylate" type="active-ingredient" /><entity charOffset="24-33" id="quantitative.s21.e1" text="sildenafil" type="active-ingredient" /><pair ddi="false" e1="quantitative.s21.e0" e2="quantitative.s21.e1" id="quantitative.s21.p0" /></sentence><sentence id="quantitative.s22" text="A third study evaluated the potential interaction of once weekly dosing of fluconazole 300 mg to 21 normal females taking an oral contraceptive containing ethinyl estradiol and norethindrone. In this placebo-controlled, double-blind, randomized, two-way crossover study carried out over three cycles of oral contraceptive treatment, fluconazole dosing resulted in small increases in the mean AUCs of ethinyl estradiol and norethindrone compared to similar placebo dosing. The mean AUCs of ethinyl estradiol and norethindrone increased by 24% (95% C.I. range 18 to 31%) and 13% (95% C.I. range 8 to 18%), respectively relative to placebo. Fluconazole treatment did not cause a decrease in the ethinyl estradiol AUC of any individual subject in this study compared to placebo dosing. The individual AUC values of norethindrone decreased very slightly (&lt;5%) in 3 of the 21 subjects after fluconazole treatment."><entity charOffset="75-85" id="quantitative.s22.e0" text="fluconazole" type="active-ingredient" /><entity charOffset="333-343" id="quantitative.s22.e1" text="fluconazole" type="active-ingredient" /><entity charOffset="638-648" id="quantitative.s22.e2" text="fluconazole" type="active-ingredient" /><entity charOffset="885-895" id="quantitative.s22.e3" text="fluconazole" type="active-ingredient" /><entity charOffset="155-171" id="quantitative.s22.e4" text="ethinyl estradiol" type="active-ingredient" /><entity charOffset="400-416" id="quantitative.s22.e5" text="ethinyl estradiol" type="active-ingredient" /><entity charOffset="489-505" id="quantitative.s22.e6" text="ethinyl estradiol" type="active-ingredient" /><entity charOffset="692-708" id="quantitative.s22.e7" text="ethinyl estradiol" type="active-ingredient" /><pair ddi="true" e1="quantitative.s22.e3" e2="quantitative.s22.e7" id="quantitative.s22.p0" /></sentence><sentence id="quantitative.s23" text="A third study evaluated the potential interaction of once weekly dosing of fluconazole 300 mg to 21 normal females taking an oral contraceptive containing ethinyl estradiol and norethindrone. In this placebo-controlled, double-blind, randomized, two-way crossover study carried out over three cycles of oral contraceptive treatment, fluconazole dosing resulted in small increases in the mean AUCs of ethinyl estradiol and norethindrone compared to similar placebo dosing. The mean AUCs of ethinyl estradiol and norethindrone increased by 24% (95% C.I. range 18 to 31%) and 13% (95% C.I. range 8 to 18%), respectively relative to placebo. Fluconazole treatment did not cause a decrease in the ethinyl estradiol AUC of any individual subject in this study compared to placebo dosing. The individual AUC values of norethindrone decreased very slightly (&lt;5%) in 3 of the 21 subjects after fluconazole treatment."><entity charOffset="177-189" id="quantitative.s23.e0" text="norethindrone" type="active-ingredient" /><entity charOffset="422-434" id="quantitative.s23.e1" text="norethindrone" type="active-ingredient" /><entity charOffset="511-523" id="quantitative.s23.e2" text="norethindrone" type="active-ingredient" /><entity charOffset="811-823" id="quantitative.s23.e3" text="norethindrone" type="active-ingredient" /><entity charOffset="75-85" id="quantitative.s23.e4" text="fluconazole" type="active-ingredient" /><entity charOffset="333-343" id="quantitative.s23.e5" text="fluconazole" type="active-ingredient" /><entity charOffset="638-648" id="quantitative.s23.e6" text="fluconazole" type="active-ingredient" /><entity charOffset="885-895" id="quantitative.s23.e7" text="fluconazole" type="active-ingredient" /><pair ddi="true" e1="quantitative.s23.e3" e2="quantitative.s23.e7" id="quantitative.s23.p0" /></sentence><sentence id="quantitative.s24" text="Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol. [See Clinical Pharmacology, Tables 16 and 17 (12.3).]"><entity charOffset="151-158" id="quantitative.s24.e0" text="atenolol" type="active-ingredient" /><entity charOffset="77-83" id="quantitative.s24.e1" text="REYATAZ" type="drug-product" /><pair ddi="false" e1="quantitative.s24.e0" e2="quantitative.s24.e1" id="quantitative.s24.p0" /></sentence><sentence id="quantitative.s25" text="Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol. [See Clinical Pharmacology, Tables 16 and 17 (12.3).]"><entity charOffset="120-130" id="quantitative.s25.e0" text="fluconazole" type="active-ingredient" /><entity charOffset="77-83" id="quantitative.s25.e1" text="REYATAZ" type="drug-product" /><pair ddi="false" e1="quantitative.s25.e0" e2="quantitative.s25.e1" id="quantitative.s25.p0" /></sentence><sentence id="quantitative.s26" text="Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol. [See Clinical Pharmacology, Tables 16 and 17 (12.3).]"><entity charOffset="109-117" id="quantitative.s26.e0" text="methadone" type="active-ingredient" /><entity charOffset="77-83" id="quantitative.s26.e1" text="REYATAZ" type="drug-product" /><pair ddi="false" e1="quantitative.s26.e0" e2="quantitative.s26.e1" id="quantitative.s26.p0" /></sentence><sentence id="quantitative.s27" text="Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol. [See Clinical Pharmacology, Tables 16 and 17 (12.3).]"><entity charOffset="77-83" id="quantitative.s27.e0" text="REYATAZ" type="drug-product" /><entity charOffset="133-145" id="quantitative.s27.e1" text="acetaminophen" type="active-ingredient" /><pair ddi="false" e1="quantitative.s27.e0" e2="quantitative.s27.e1" id="quantitative.s27.p0" /></sentence><sentence id="quantitative.s28" text="Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol. [See Clinical Pharmacology, Tables 16 and 17 (12.3).]"><entity charOffset="77-83" id="quantitative.s28.e0" text="REYATAZ" type="drug-product" /><entity charOffset="151-158" id="quantitative.s28.e1" text="atenolol" type="active-ingredient" /><pair ddi="false" e1="quantitative.s28.e0" e2="quantitative.s28.e1" id="quantitative.s28.p0" /></sentence><sentence id="quantitative.s29" text="Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol. [See Clinical Pharmacology, Tables 16 and 17 (12.3).]"><entity charOffset="77-83" id="quantitative.s29.e0" text="REYATAZ" type="drug-product" /><entity charOffset="133-145" id="quantitative.s29.e1" text="acetaminophen" type="active-ingredient" /><pair ddi="false" e1="quantitative.s29.e0" e2="quantitative.s29.e1" id="quantitative.s29.p0" /></sentence><sentence id="quantitative.s30" text="Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol. [See Clinical Pharmacology, Tables 16 and 17 (12.3).]"><entity charOffset="77-83" id="quantitative.s30.e0" text="REYATAZ" type="drug-product" /><entity charOffset="120-130" id="quantitative.s30.e1" text="fluconazole" type="active-ingredient" /><pair ddi="false" e1="quantitative.s30.e0" e2="quantitative.s30.e1" id="quantitative.s30.p0" /></sentence><sentence id="quantitative.s31" text="Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol. [See Clinical Pharmacology, Tables 16 and 17 (12.3).]"><entity charOffset="77-83" id="quantitative.s31.e0" text="REYATAZ" type="drug-product" /><entity charOffset="109-117" id="quantitative.s31.e1" text="methadone" type="active-ingredient" /><pair ddi="false" e1="quantitative.s31.e0" e2="quantitative.s31.e1" id="quantitative.s31.p0" /></sentence><sentence id="quantitative.s32" text="Administration of 40 mg/day citalopram for 21 days did not affect the pharmacokinetics of warfarin, a CYP3A4 substrate. "><entity charOffset="90-97" id="quantitative.s32.e0" text="warfarin" type="active-ingredient" /><entity charOffset="28-37" id="quantitative.s32.e1" text="citalopram" type="active-ingredient" /><pair ddi="false" e1="quantitative.s32.e0" e2="quantitative.s32.e1" id="quantitative.s32.p0" /></sentence><sentence id="quantitative.s33" text="Administration of a single oral 200 mg dose of fluconazole after 15 days of rifampin administered as 600 mg daily in eight healthy male volunteers resulted in a significant decrease in fluconazole AUC and a significant increase in apparent oral clearance of fluconazole. There was a mean ± SD reduction in fluconazole AUC of 23% ± 9% (range: -13 to -42%). Apparent oral clearance of fluconazole increased 32% ± 17% (range: 16 to 72%). Fluconazole half-life decreased from 33.4 ± 4.4 hours to 26.8 ± 3.9 hours."><entity charOffset="76-83" id="quantitative.s33.e0" text="rifampin" type="active-ingredient" /><entity charOffset="47-57" id="quantitative.s33.e1" text="fluconazole" type="active-ingredient" /><entity charOffset="185-195" id="quantitative.s33.e2" text="fluconazole" type="active-ingredient" /><entity charOffset="258-268" id="quantitative.s33.e3" text="fluconazole" type="active-ingredient" /><entity charOffset="307-317" id="quantitative.s33.e4" text="fluconazole" type="active-ingredient" /><entity charOffset="385-395" id="quantitative.s33.e5" text="fluconazole" type="active-ingredient" /><entity charOffset="438-448" id="quantitative.s33.e6" text="fluconazole" type="active-ingredient" /><pair ddi="true" e1="quantitative.s33.e0" e2="quantitative.s33.e6" id="quantitative.s33.p0" /></sentence><sentence id="quantitative.s34" text="Administration of sotalol within 2 hours of antacids containing aluminum oxide and magnesium hydroxide should be avoided because it may result in a reduction in Cmax and AUC of 26% and 20%, respectively and consequently in a 25% reduction in the bradycardic effect at rest. Administration of the antacid two hours after sotalol has no effect on the pharmacokinetics or pharmacodynamics of sotalol."><entity charOffset="83-101" id="quantitative.s34.e0" text="magnesium hydroxide" type="active-ingredient" /><entity charOffset="18-24" id="quantitative.s34.e1" text="sotalol" type="active-ingredient" /><entity charOffset="320-326" id="quantitative.s34.e2" text="sotalol" type="active-ingredient" /><entity charOffset="389-395" id="quantitative.s34.e3" text="sotalol" type="active-ingredient" /><pair ddi="false" e1="quantitative.s34.e0" e2="quantitative.s34.e3" id="quantitative.s34.p0" /></sentence><sentence id="quantitative.s35" text="Administration of sotalol within 2 hours of antacids containing aluminum oxide and magnesium hydroxide should be avoided because it may result in a reduction in Cmax and AUC of 26% and 20%, respectively and consequently in a 25% reduction in the bradycardic effect at rest. Administration of the antacid two hours after sotalol has no effect on the pharmacokinetics or pharmacodynamics of sotalol."><entity charOffset="83-101" id="quantitative.s35.e0" text="magnesium hydroxide" type="active-ingredient" /><entity charOffset="18-24" id="quantitative.s35.e1" text="sotalol" type="active-ingredient" /><entity charOffset="320-326" id="quantitative.s35.e2" text="sotalol" type="active-ingredient" /><entity charOffset="389-395" id="quantitative.s35.e3" text="sotalol" type="active-ingredient" /><pair ddi="true" e1="quantitative.s35.e0" e2="quantitative.s35.e3" id="quantitative.s35.p0" /></sentence><sentence id="quantitative.s36" text="Administration of sotalol within 2 hours of antacids containing aluminum oxide and magnesium hydroxide should be avoided because it may result in a reduction in Cmax and AUC of 26% and 20%, respectively and consequently in a 25% reduction in the bradycardic effect at rest. Administration of the antacid two hours after sotalol has no effect on the pharmacokinetics or pharmacodynamics of sotalol."><entity charOffset="18-24" id="quantitative.s36.e0" text="sotalol" type="active-ingredient" /><entity charOffset="320-326" id="quantitative.s36.e1" text="sotalol" type="active-ingredient" /><entity charOffset="389-395" id="quantitative.s36.e2" text="sotalol" type="active-ingredient" /><entity charOffset="64-77" id="quantitative.s36.e3" text="aluminum oxide" type="active-ingredient" /><pair ddi="false" e1="quantitative.s36.e2" e2="quantitative.s36.e3" id="quantitative.s36.p0" /></sentence><sentence id="quantitative.s37" text="Administration of sotalol within 2 hours of antacids containing aluminum oxide and magnesium hydroxide should be avoided because it may result in a reduction in Cmax and AUC of 26% and 20%, respectively and consequently in a 25% reduction in the bradycardic effect at rest. Administration of the antacid two hours after sotalol has no effect on the pharmacokinetics or pharmacodynamics of sotalol."><entity charOffset="18-24" id="quantitative.s37.e0" text="sotalol" type="active-ingredient" /><entity charOffset="320-326" id="quantitative.s37.e1" text="sotalol" type="active-ingredient" /><entity charOffset="389-395" id="quantitative.s37.e2" text="sotalol" type="active-ingredient" /><entity charOffset="64-77" id="quantitative.s37.e3" text="aluminum oxide" type="active-ingredient" /><pair ddi="true" e1="quantitative.s37.e2" e2="quantitative.s37.e3" id="quantitative.s37.p0" /></sentence><sentence id="quantitative.s38" text="Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined"><entity charOffset="0-12" id="quantitative.s38.e0" text="amitriptyline" type="active-ingredient" /><entity charOffset="53-63" id="quantitative.s38.e1" text="risperidone" type="active-ingredient" /><entity charOffset="68-78" id="quantitative.s38.e2" text="risperidone" type="active-ingredient" /><entity charOffset="93-103" id="quantitative.s38.e3" text="risperidone" type="active-ingredient" /><pair ddi="false" e1="quantitative.s38.e0" e2="quantitative.s38.e3" id="quantitative.s38.p0" /></sentence><sentence id="quantitative.s39" text="Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined"><entity charOffset="0-12" id="quantitative.s39.e0" text="amitriptyline" type="active-ingredient" /><entity charOffset="84-103" id="quantitative.s39.e1" text="9-hydroxyrisperidone" type="active-ingredient" /><pair ddi="false" e1="quantitative.s39.e0" e2="quantitative.s39.e1" id="quantitative.s39.p0" /></sentence><sentence id="quantitative.s40" text="An in vivo interaction study involving the coadministration under steady-state conditions of paroxetine and terfenadine, a substrate for CYP3A4, revealed no effect of paroxetine on terfenadine pharmacokinetics."><entity charOffset="93-102" id="quantitative.s40.e0" text="paroxetine" type="active-ingredient" /><entity charOffset="167-176" id="quantitative.s40.e1" text="paroxetine" type="active-ingredient" /><entity charOffset="108-118" id="quantitative.s40.e2" text="terfenadine" type="active-ingredient" /><entity charOffset="181-191" id="quantitative.s40.e3" text="terfenadine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s40.e1" e2="quantitative.s40.e3" id="quantitative.s40.p0" /></sentence><sentence id="quantitative.s41" text="An open-label, randomized, three-way crossover study in 18 healthy subjects assessed the effect of a single 800 mg oral dose of fluconazole on the pharmacokinetics of a single 1200 mg oral dose of azithromycin as well as the effects of azithromycin on the pharmacokinetics of fluconazole. There was no significant pharmacokinetic interaction between fluconazole and azithromycin"><entity charOffset="197-208" id="quantitative.s41.e0" text="azithromycin" type="active-ingredient" /><entity charOffset="236-247" id="quantitative.s41.e1" text="azithromycin" type="active-ingredient" /><entity charOffset="366-377" id="quantitative.s41.e2" text="azithromycin" type="active-ingredient" /><entity charOffset="128-138" id="quantitative.s41.e3" text="fluconazole" type="active-ingredient" /><entity charOffset="276-286" id="quantitative.s41.e4" text="fluconazole" type="active-ingredient" /><entity charOffset="350-360" id="quantitative.s41.e5" text="fluconazole" type="active-ingredient" /><pair ddi="false" e1="quantitative.s41.e2" e2="quantitative.s41.e5" id="quantitative.s41.p0" /></sentence><sentence id="quantitative.s42" text="An open-label, randomized, three-way crossover study in 18 healthy subjects assessed the effect of a single 800 mg oral dose of fluconazole on the pharmacokinetics of a single 1200 mg oral dose of azithromycin as well as the effects of azithromycin on the pharmacokinetics of fluconazole. There was no significant pharmacokinetic interaction between fluconazole and azithromycin."><entity charOffset="128-138" id="quantitative.s42.e0" text="fluconazole" type="active-ingredient" /><entity charOffset="276-286" id="quantitative.s42.e1" text="fluconazole" type="active-ingredient" /><entity charOffset="350-360" id="quantitative.s42.e2" text="fluconazole" type="active-ingredient" /><entity charOffset="197-208" id="quantitative.s42.e3" text="azithromycin" type="active-ingredient" /><entity charOffset="236-247" id="quantitative.s42.e4" text="azithromycin" type="active-ingredient" /><entity charOffset="366-377" id="quantitative.s42.e5" text="azithromycin" type="active-ingredient" /><pair ddi="false" e1="quantitative.s42.e2" e2="quantitative.s42.e5" id="quantitative.s42.p0" /></sentence><sentence id="quantitative.s43" text="Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing."><entity charOffset="0-11" id="quantitative.s43.e0" text="atorvastatin" type="active-ingredient" /><entity charOffset="34-45" id="quantitative.s43.e1" text="atorvastatin" type="active-ingredient" /><entity charOffset="83-91" id="quantitative.s43.e2" text="aliskiren" type="active-ingredient" /><pair ddi="true" e1="quantitative.s43.e1" e2="quantitative.s43.e2" id="quantitative.s43.p0" /></sentence><sentence id="quantitative.s44" text="AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy. Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%. In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA"><entity charOffset="0-6" id="quantitative.s44.e0" text="avandia" type="drug-product" /><entity charOffset="237-243" id="quantitative.s44.e1" text="avandia" type="drug-product" /><entity charOffset="470-476" id="quantitative.s44.e2" text="avandia" type="drug-product" /><entity charOffset="52-60" id="quantitative.s44.e3" text="glyburide" type="drug-product" /><entity charOffset="202-210" id="quantitative.s44.e4" text="glyburide" type="drug-product" /><entity charOffset="331-339" id="quantitative.s44.e5" text="glyburide" type="drug-product" /><entity charOffset="398-406" id="quantitative.s44.e6" text="glyburide" type="drug-product" /><pair ddi="true" e1="quantitative.s44.e2" e2="quantitative.s44.e6" id="quantitative.s44.p0" /></sentence><sentence id="quantitative.s45" text="Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin. REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol). "><entity charOffset="200-211" id="quantitative.s45.e0" text="azithromycin" type="active-ingredient" /><entity charOffset="101-107" id="quantitative.s45.e1" text="REYATAZ" type="drug-product" /><entity charOffset="231-237" id="quantitative.s45.e2" text="REYATAZ" type="drug-product" /><pair ddi="false" e1="quantitative.s45.e0" e2="quantitative.s45.e2" id="quantitative.s45.p0" /></sentence><sentence id="quantitative.s46" text="Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin. REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol). "><entity charOffset="160-166" id="quantitative.s46.e0" text="dapsone" type="active-ingredient" /><entity charOffset="101-107" id="quantitative.s46.e1" text="REYATAZ" type="drug-product" /><entity charOffset="231-237" id="quantitative.s46.e2" text="REYATAZ" type="drug-product" /><pair ddi="false" e1="quantitative.s46.e0" e2="quantitative.s46.e2" id="quantitative.s46.p0" /></sentence><sentence id="quantitative.s47" text="Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin. REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol). "><entity charOffset="217-228" id="quantitative.s47.e0" text="erythromycin" type="active-ingredient" /><entity charOffset="101-107" id="quantitative.s47.e1" text="REYATAZ" type="drug-product" /><entity charOffset="231-237" id="quantitative.s47.e2" text="REYATAZ" type="drug-product" /><pair ddi="false" e1="quantitative.s47.e0" e2="quantitative.s47.e2" id="quantitative.s47.p0" /></sentence><sentence id="quantitative.s48" text="Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin. REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol). "><entity charOffset="134-144" id="quantitative.s48.e0" text="fluvastatin" type="active-ingredient" /><entity charOffset="101-107" id="quantitative.s48.e1" text="REYATAZ" type="drug-product" /><entity charOffset="231-237" id="quantitative.s48.e2" text="REYATAZ" type="drug-product" /><pair ddi="false" e1="quantitative.s48.e0" e2="quantitative.s48.e2" id="quantitative.s48.p0" /></sentence><sentence id="quantitative.s49" text="Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin. REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol). "><entity charOffset="316-325" id="quantitative.s49.e0" text="metoprolol" type="active-ingredient" /><entity charOffset="101-107" id="quantitative.s49.e1" text="REYATAZ" type="drug-product" /><entity charOffset="231-237" id="quantitative.s49.e2" text="REYATAZ" type="drug-product" /><pair ddi="false" e1="quantitative.s49.e0" e2="quantitative.s49.e2" id="quantitative.s49.p0" /></sentence><sentence id="quantitative.s50" text="Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin. REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol). "><entity charOffset="147-157" id="quantitative.s50.e0" text="pravastatin" type="active-ingredient" /><entity charOffset="101-107" id="quantitative.s50.e1" text="REYATAZ" type="drug-product" /><entity charOffset="231-237" id="quantitative.s50.e2" text="REYATAZ" type="drug-product" /><pair ddi="false" e1="quantitative.s50.e0" e2="quantitative.s50.e2" id="quantitative.s50.p0" /></sentence><sentence id="quantitative.s51" text="Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin. REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol). "><entity charOffset="101-107" id="quantitative.s51.e0" text="REYATAZ" type="drug-product" /><entity charOffset="231-237" id="quantitative.s51.e1" text="REYATAZ" type="drug-product" /><entity charOffset="200-211" id="quantitative.s51.e2" text="azithromycin" type="active-ingredient" /><pair ddi="false" e1="quantitative.s51.e1" e2="quantitative.s51.e2" id="quantitative.s51.p0" /></sentence><sentence id="quantitative.s52" text="Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin. REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol). "><entity charOffset="101-107" id="quantitative.s52.e0" text="REYATAZ" type="drug-product" /><entity charOffset="231-237" id="quantitative.s52.e1" text="REYATAZ" type="drug-product" /><entity charOffset="147-157" id="quantitative.s52.e2" text="pravastatin" type="active-ingredient" /><pair ddi="false" e1="quantitative.s52.e1" e2="quantitative.s52.e2" id="quantitative.s52.p0" /></sentence><sentence id="quantitative.s53" text="Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin. REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol). "><entity charOffset="101-107" id="quantitative.s53.e0" text="REYATAZ" type="drug-product" /><entity charOffset="231-237" id="quantitative.s53.e1" text="REYATAZ" type="drug-product" /><entity charOffset="303-313" id="quantitative.s53.e2" text="desipramine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s53.e1" e2="quantitative.s53.e2" id="quantitative.s53.p0" /></sentence><sentence id="quantitative.s54" text="Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin. REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol). "><entity charOffset="101-107" id="quantitative.s54.e0" text="REYATAZ" type="drug-product" /><entity charOffset="231-237" id="quantitative.s54.e1" text="REYATAZ" type="drug-product" /><entity charOffset="288-300" id="quantitative.s54.e2" text="nortriptyline" type="active-ingredient" /><pair ddi="false" e1="quantitative.s54.e1" e2="quantitative.s54.e2" id="quantitative.s54.p0" /></sentence><sentence id="quantitative.s55" text="Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin. REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol). "><entity charOffset="101-107" id="quantitative.s55.e0" text="REYATAZ" type="drug-product" /><entity charOffset="231-237" id="quantitative.s55.e1" text="REYATAZ" type="drug-product" /><entity charOffset="217-228" id="quantitative.s55.e2" text="erythromycin" type="active-ingredient" /><pair ddi="false" e1="quantitative.s55.e1" e2="quantitative.s55.e2" id="quantitative.s55.p0" /></sentence><sentence id="quantitative.s56" text="Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%. Plasma concentrations of carbamazepine did not appear to be affected. The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy."><entity charOffset="0-12" id="quantitative.s56.e0" text="carbamazepine" type="active-ingredient" /><entity charOffset="160-172" id="quantitative.s56.e1" text="carbamazepine" type="active-ingredient" /><entity charOffset="288-300" id="quantitative.s56.e2" text="carbamazepine" type="active-ingredient" /><entity charOffset="356-368" id="quantitative.s56.e3" text="carbamazepine" type="active-ingredient" /><entity charOffset="84-94" id="quantitative.s56.e4" text="risperidone" type="active-ingredient" /><entity charOffset="109-119" id="quantitative.s56.e5" text="risperidone" type="active-ingredient" /><entity charOffset="217-227" id="quantitative.s56.e6" text="risperidone" type="active-ingredient" /><pair ddi="false" e1="quantitative.s56.e3" e2="quantitative.s56.e6" id="quantitative.s56.p0" /></sentence><sentence id="quantitative.s57" text="Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%. Plasma concentrations of carbamazepine did not appear to be affected. The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy."><entity charOffset="0-12" id="quantitative.s57.e0" text="carbamazepine" type="active-ingredient" /><entity charOffset="160-172" id="quantitative.s57.e1" text="carbamazepine" type="active-ingredient" /><entity charOffset="288-300" id="quantitative.s57.e2" text="carbamazepine" type="active-ingredient" /><entity charOffset="356-368" id="quantitative.s57.e3" text="carbamazepine" type="active-ingredient" /><entity charOffset="100-119" id="quantitative.s57.e4" text="9-hydroxyrisperidone" type="metabolite" /><pair ddi="true" e1="quantitative.s57.e3" e2="quantitative.s57.e4" id="quantitative.s57.p0" /></sentence><sentence id="quantitative.s58" text="Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%. Plasma concentrations of carbamazepine did not appear to be affected. The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy."><entity charOffset="0-12" id="quantitative.s58.e0" text="carbamazepine" type="active-ingredient" /><entity charOffset="160-172" id="quantitative.s58.e1" text="carbamazepine" type="active-ingredient" /><entity charOffset="288-300" id="quantitative.s58.e2" text="carbamazepine" type="active-ingredient" /><entity charOffset="356-368" id="quantitative.s58.e3" text="carbamazepine" type="active-ingredient" /><entity charOffset="84-94" id="quantitative.s58.e4" text="risperidone" type="active-ingredient" /><entity charOffset="109-119" id="quantitative.s58.e5" text="risperidone" type="active-ingredient" /><entity charOffset="217-227" id="quantitative.s58.e6" text="risperidone" type="active-ingredient" /><pair ddi="true" e1="quantitative.s58.e3" e2="quantitative.s58.e6" id="quantitative.s58.p0" /></sentence><sentence id="quantitative.s59" text="Carbamazepine induces CYP3A4. Following coadministration of carbamazepine 400 mg/day with trazodone 100 mg to 300 mg daily, carbamazepine reduced plasma concentrations of trazodone (as well as mCPP) by 76 and 60%, respectively, compared to pre-carbamazepine values."><entity charOffset="90-98" id="quantitative.s59.e0" text="trazodone" type="active-ingredient" /><entity charOffset="171-179" id="quantitative.s59.e1" text="trazodone" type="active-ingredient" /><entity charOffset="0-12" id="quantitative.s59.e2" text="carbamazepine" type="active-ingredient" /><entity charOffset="60-72" id="quantitative.s59.e3" text="carbamazepine" type="active-ingredient" /><entity charOffset="124-136" id="quantitative.s59.e4" text="carbamazepine" type="active-ingredient" /><entity charOffset="244-256" id="quantitative.s59.e5" text="carbamazepine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s59.e1" e2="quantitative.s59.e5" id="quantitative.s59.p0" /></sentence><sentence id="quantitative.s60" text="Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol® at steady-state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol® as compared to the same dose of Felbatol® given as monotherapy. "><entity charOffset="84-91" id="quantitative.s60.e0" text="Felbatol" type="drug-product" /><entity charOffset="241-248" id="quantitative.s60.e1" text="Felbatol" type="drug-product" /><entity charOffset="284-291" id="quantitative.s60.e2" text="Felbatol" type="drug-product" /><entity charOffset="0-12" id="quantitative.s60.e3" text="carbamazepine" type="active-ingredient" /><entity charOffset="15-27" id="quantitative.s60.e4" text="carbamazepine" type="active-ingredient" /><entity charOffset="143-155" id="quantitative.s60.e5" text="carbamazepine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s60.e2" e2="quantitative.s60.e5" id="quantitative.s60.p0" /></sentence><sentence id="quantitative.s61" text="Cholestyramine and Colestipol Resins: absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins. Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively."><entity charOffset="19-28" id="quantitative.s61.e0" text="Colestipol" type="active-ingredient" /><entity charOffset="169-178" id="quantitative.s61.e1" text="Colestipol" type="active-ingredient" /><entity charOffset="52-70" id="quantitative.s61.e2" text="hydrochlorothiazide" type="active-ingredient" /><entity charOffset="196-214" id="quantitative.s61.e3" text="hydrochlorothiazide" type="active-ingredient" /><pair ddi="true" e1="quantitative.s61.e1" e2="quantitative.s61.e3" id="quantitative.s61.p0" /></sentence><sentence id="quantitative.s62" text="Cholestyramine and Colestipol Resins: absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins. Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively."><entity charOffset="52-70" id="quantitative.s62.e0" text="hydrochlorothiazide" type="active-ingredient" /><entity charOffset="196-214" id="quantitative.s62.e1" text="hydrochlorothiazide" type="active-ingredient" /><entity charOffset="0-13" id="quantitative.s62.e2" text="Cholestyramine" type="active-ingredient" /><entity charOffset="151-164" id="quantitative.s62.e3" text="Cholestyramine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s62.e1" e2="quantitative.s62.e3" id="quantitative.s62.p0" /></sentence><sentence id="quantitative.s63" text="Cimetidine (800 mg), a nonspecific CYP inhibitor, caused a 56% increase in plasma sildenafil concentrations when co-administered with sildenafil (50 mg) to healthy volunteers"><entity charOffset="0-9" id="quantitative.s63.e0" text="cimetidine" type="active-ingredient" /><entity charOffset="82-91" id="quantitative.s63.e1" text="sildenafil" type="active-ingredient" /><entity charOffset="134-143" id="quantitative.s63.e2" text="sildenafil" type="active-ingredient" /><pair ddi="true" e1="quantitative.s63.e0" e2="quantitative.s63.e2" id="quantitative.s63.p0" /></sentence><sentence id="quantitative.s64" text="Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively"><entity charOffset="0-9" id="quantitative.s64.e0" text="cimetidine" type="active-ingredient" /><entity charOffset="59-69" id="quantitative.s64.e1" text="risperidone" type="active-ingredient" /><pair ddi="true" e1="quantitative.s64.e0" e2="quantitative.s64.e1" id="quantitative.s64.p0" /></sentence><sentence id="quantitative.s65" text="Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively"><entity charOffset="59-69" id="quantitative.s65.e0" text="risperidone" type="active-ingredient" /><entity charOffset="15-24" id="quantitative.s65.e1" text="ranitidine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s65.e0" e2="quantitative.s65.e1" id="quantitative.s65.p0" /></sentence><sentence id="quantitative.s66" text="cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined"><entity charOffset="53-72" id="quantitative.s66.e0" text="9-hydroxyrisperidone" type="metabolite" /><entity charOffset="0-9" id="quantitative.s66.e1" text="cimetidine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s66.e0" e2="quantitative.s66.e1" id="quantitative.s66.p0" /></sentence><sentence id="quantitative.s67" text="cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined"><entity charOffset="0-9" id="quantitative.s67.e0" text="cimetidine" type="active-ingredient" /><entity charOffset="37-47" id="quantitative.s67.e1" text="risperidone" type="active-ingredient" /><entity charOffset="62-72" id="quantitative.s67.e2" text="risperidone" type="active-ingredient" /><pair ddi="false" e1="quantitative.s67.e0" e2="quantitative.s67.e2" id="quantitative.s67.p0" /></sentence><sentence id="quantitative.s68" text="Cimetidine increased the Cmax and AUC of tacrine by approximately 54% and 64%, respectively."><entity charOffset="0-9" id="quantitative.s68.e0" text="cimetidine" type="active-ingredient" /><entity charOffset="41-47" id="quantitative.s68.e1" text="tacrine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s68.e0" e2="quantitative.s68.e1" id="quantitative.s68.p0" /></sentence><sentence id="quantitative.s69" text="Cimetidine: Five studies in healthy volunteers investigated the impact of multiple cimetidine doses on the single or multiple dose pharmacokinetics of nifedipine. Two studies investigated the impact of coadministered cimetidine on blood pressure in hypertensive subjects on nifedipine. In normotensive subjects receiving single doses of 10 mg or multiple doses of up to 20 mg nifedipine t.i.d. alone or together with cimetidine up to 1000 mg/day, the AUC values of nifedipine in the presence of cimetidine were between 1.52 and 2.01 times those in the absence of cimetidine. The Cmax values of nifedipine in the presence of cimetidine were increased by factors ranging between 1.60 and 2.02. The increase in exposure to nifedipine by cimetidine was accompanied by relevant changes in blood pressure or heart rate in normotensive subjects. Hypertensive subjects receiving 10 mg q.d. nifedipine alone or in combination with cimetidine 1000 mg q.d. also experienced relevant changes in blood pressure when cimetidine was added to nifedipine. The interaction between cimetidine and nifedipine is of clinical relevance and blood pressure should be monitored and a reduction of the dose of nifedipine considered."><entity charOffset="0-9" id="quantitative.s69.e0" text="cimetidine" type="active-ingredient" /><entity charOffset="83-92" id="quantitative.s69.e1" text="cimetidine" type="active-ingredient" /><entity charOffset="217-226" id="quantitative.s69.e2" text="cimetidine" type="active-ingredient" /><entity charOffset="417-426" id="quantitative.s69.e3" text="cimetidine" type="active-ingredient" /><entity charOffset="495-504" id="quantitative.s69.e4" text="cimetidine" type="active-ingredient" /><entity charOffset="563-572" id="quantitative.s69.e5" text="cimetidine" type="active-ingredient" /><entity charOffset="624-633" id="quantitative.s69.e6" text="cimetidine" type="active-ingredient" /><entity charOffset="734-743" id="quantitative.s69.e7" text="cimetidine" type="active-ingredient" /><entity charOffset="922-931" id="quantitative.s69.e8" text="cimetidine" type="active-ingredient" /><entity charOffset="1003-1012" id="quantitative.s69.e9" text="cimetidine" type="active-ingredient" /><entity charOffset="1063-1072" id="quantitative.s69.e10" text="cimetidine" type="active-ingredient" /><entity charOffset="151-160" id="quantitative.s69.e11" text="nifedipine" type="active-ingredient" /><entity charOffset="274-283" id="quantitative.s69.e12" text="nifedipine" type="active-ingredient" /><entity charOffset="376-385" id="quantitative.s69.e13" text="nifedipine" type="active-ingredient" /><entity charOffset="465-474" id="quantitative.s69.e14" text="nifedipine" type="active-ingredient" /><entity charOffset="594-603" id="quantitative.s69.e15" text="nifedipine" type="active-ingredient" /><entity charOffset="720-729" id="quantitative.s69.e16" text="nifedipine" type="active-ingredient" /><entity charOffset="882-891" id="quantitative.s69.e17" text="nifedipine" type="active-ingredient" /><entity charOffset="1027-1036" id="quantitative.s69.e18" text="nifedipine" type="active-ingredient" /><entity charOffset="1078-1087" id="quantitative.s69.e19" text="nifedipine" type="active-ingredient" /><entity charOffset="1184-1193" id="quantitative.s69.e20" text="nifedipine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s69.e10" e2="quantitative.s69.e20" id="quantitative.s69.p0" /></sentence><sentence id="quantitative.s70" text="Co-administration of chlorpromazine with propranolol resulted in a 70% increase in propranolol plasma level."><entity charOffset="21-34" id="quantitative.s70.e0" text="chlorpromazine" type="active-ingredient" /><entity charOffset="41-51" id="quantitative.s70.e1" text="propranolol" type="active-ingredient" /><entity charOffset="83-93" id="quantitative.s70.e2" text="propranolol" type="active-ingredient" /><pair ddi="true" e1="quantitative.s70.e0" e2="quantitative.s70.e2" id="quantitative.s70.p0" /></sentence><sentence id="quantitative.s71" text="Co-administration of cholestyramine or colestipol with propranolol resulted in up to 50% decrease in propranolol concentrations"><entity charOffset="21-34" id="quantitative.s71.e0" text="cholestyramine" type="active-ingredient" /><entity charOffset="55-65" id="quantitative.s71.e1" text="propranolol" type="active-ingredient" /><entity charOffset="101-111" id="quantitative.s71.e2" text="propranolol" type="active-ingredient" /><pair ddi="true" e1="quantitative.s71.e0" e2="quantitative.s71.e2" id="quantitative.s71.p0" /></sentence><sentence id="quantitative.s72" text="Co-administration of cholestyramine or colestipol with propranolol resulted in up to 50% decrease in propranolol concentrations"><entity charOffset="39-48" id="quantitative.s72.e0" text="colestipol" type="active-ingredient" /><entity charOffset="55-65" id="quantitative.s72.e1" text="propranolol" type="active-ingredient" /><entity charOffset="101-111" id="quantitative.s72.e2" text="propranolol" type="active-ingredient" /><pair ddi="true" e1="quantitative.s72.e0" e2="quantitative.s72.e2" id="quantitative.s72.p0" /></sentence><sentence id="quantitative.s73" text="Co-administration of long-acting propranolol at doses greater than or equal to 160 mg/day resulted in increased thioridazine plasma concentrations ranging from 55% to 369% and increased thioridazine metabolite (mesoridazine) concentrations ranging from 33% to 209%."><entity charOffset="33-43" id="quantitative.s73.e0" text="propranolol" type="active-ingredient" /><entity charOffset="112-123" id="quantitative.s73.e1" text="thioridazine" type="active-ingredient" /><entity charOffset="186-197" id="quantitative.s73.e2" text="thioridazine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s73.e0" e2="quantitative.s73.e2" id="quantitative.s73.p0" /></sentence><sentence id="quantitative.s74" text="Co-administration of long-acting propranolol at doses greater than or equal to 160 mg/day resulted in increased thioridazine plasma concentrations ranging from 55% to 369% and increased thioridazine metabolite (mesoridazine) concentrations ranging from 33% to 209%."><entity charOffset="33-43" id="quantitative.s74.e0" text="propranolol" type="active-ingredient" /><entity charOffset="211-222" id="quantitative.s74.e1" text="mesoridazine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s74.e0" e2="quantitative.s74.e1" id="quantitative.s74.p0" /></sentence><sentence id="quantitative.s75" text="Co-administration of metoclopramide with the long-acting propranolol did not have a significant effect on propranolol’s pharmacokinetics."><entity charOffset="21-34" id="quantitative.s75.e0" text="metoclopramide" type="active-ingredient" /><entity charOffset="57-67" id="quantitative.s75.e1" text="propranolol" type="active-ingredient" /><entity charOffset="106-116" id="quantitative.s75.e2" text="propranolol" type="active-ingredient" /><pair ddi="false" e1="quantitative.s75.e0" e2="quantitative.s75.e2" id="quantitative.s75.p0" /></sentence><sentence id="quantitative.s76" text="Co-administration of propranolol with cimetidine, a non-specific CYP450 inhibitor, increased propranolol AUC and Cmax by 46% and 35%, respectively."><entity charOffset="38-47" id="quantitative.s76.e0" text="cimetidine" type="active-ingredient" /><entity charOffset="21-31" id="quantitative.s76.e1" text="propranolol" type="active-ingredient" /><entity charOffset="93-103" id="quantitative.s76.e2" text="propranolol" type="active-ingredient" /><pair ddi="true" e1="quantitative.s76.e0" e2="quantitative.s76.e2" id="quantitative.s76.p0" /></sentence><sentence id="quantitative.s77" text="Co-administration of propranolol with lovastatin or pravastatin, decreased 18% to 23% the AUC of both, but did not alter their pharmacodynamics."><entity charOffset="21-31" id="quantitative.s77.e0" text="propranolol" type="active-ingredient" /><entity charOffset="38-47" id="quantitative.s77.e1" text="lovastatin" type="active-ingredient" /><pair ddi="true" e1="quantitative.s77.e0" e2="quantitative.s77.e1" id="quantitative.s77.p0" /></sentence><sentence id="quantitative.s78" text="Co-administration of propranolol with lovastatin or pravastatin, decreased 18% to 23% the AUC of both, but did not alter their pharmacodynamics."><entity charOffset="21-31" id="quantitative.s78.e0" text="propranolol" type="active-ingredient" /><entity charOffset="52-62" id="quantitative.s78.e1" text="pravastatin" type="active-ingredient" /><pair ddi="true" e1="quantitative.s78.e0" e2="quantitative.s78.e1" id="quantitative.s78.p0" /></sentence><sentence id="quantitative.s79" text="Coadministration of a 0.5 mg dose of digoxin, a P-glycoprotein substrate, with oral conivaptan hydrochloride 40 mg twice daily resulted in a 30% reduction in clearance and 79% and 43% increases in digoxin Cmax and AUC values, respectively"><entity charOffset="37-43" id="quantitative.s79.e0" text="digoxin" type="active-ingredient" /><entity charOffset="197-203" id="quantitative.s79.e1" text="digoxin" type="active-ingredient" /><entity charOffset="84-107" id="quantitative.s79.e2" text="conivaptan hydrochloride" type="active-ingredient" /><pair ddi="true" e1="quantitative.s79.e1" e2="quantitative.s79.e2" id="quantitative.s79.p0" /></sentence><sentence id="quantitative.s80" text="Coadministration of a magnesium and aluminum hydroxide antacid with a single dose of amlodipine besylate had no significant effect on the pharmacokinetics of amlodipine besylate."><entity charOffset="85-103" id="quantitative.s80.e0" text="amlodipine besylate" type="active-ingredient" /><entity charOffset="158-176" id="quantitative.s80.e1" text="amlodipine besylate" type="active-ingredient" /><entity charOffset="36-53" id="quantitative.s80.e2" text="aluminum hydroxide" type="active-ingredient" /><pair ddi="false" e1="quantitative.s80.e1" e2="quantitative.s80.e2" id="quantitative.s80.p0" /></sentence><sentence id="quantitative.s81" text="Coadministration of a magnesium and aluminum hydroxide antacid with a single dose of amlodipine besylate had no significant effect on the pharmacokinetics of amlodipine besylate."><entity charOffset="22-30" id="quantitative.s81.e0" text="magnesium" type="active-ingredient" /><entity charOffset="85-103" id="quantitative.s81.e1" text="amlodipine besylate" type="active-ingredient" /><entity charOffset="158-176" id="quantitative.s81.e2" text="amlodipine besylate" type="active-ingredient" /><pair ddi="false" e1="quantitative.s81.e0" e2="quantitative.s81.e2" id="quantitative.s81.p0" /></sentence><sentence id="quantitative.s82" text="Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA"><entity charOffset="20-27" id="quantitative.s82.e0" text="acarbose" type="active-ingredient" /><entity charOffset="172-178" id="quantitative.s82.e1" text="avandia" type="drug-product" /><pair ddi="false" e1="quantitative.s82.e0" e2="quantitative.s82.e1" id="quantitative.s82.p0" /></sentence><sentence id="quantitative.s83" text="Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide."><entity charOffset="20-28" id="quantitative.s83.e0" text="aliskiren" type="active-ingredient" /><entity charOffset="95-101" id="quantitative.s83.e1" text="digoxin" type="active-ingredient" /><pair ddi="false" e1="quantitative.s83.e0" e2="quantitative.s83.e1" id="quantitative.s83.p0" /></sentence><sentence id="quantitative.s84" text="Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide."><entity charOffset="20-28" id="quantitative.s84.e0" text="aliskiren" type="active-ingredient" /><entity charOffset="138-146" id="quantitative.s84.e1" text="celecoxib" type="active-ingredient" /><pair ddi="false" e1="quantitative.s84.e0" e2="quantitative.s84.e1" id="quantitative.s84.p0" /></sentence><sentence id="quantitative.s85" text="Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide."><entity charOffset="20-28" id="quantitative.s85.e0" text="aliskiren" type="active-ingredient" /><entity charOffset="83-92" id="quantitative.s85.e1" text="lovastatin" type="active-ingredient" /><pair ddi="false" e1="quantitative.s85.e0" e2="quantitative.s85.e1" id="quantitative.s85.p0" /></sentence><sentence id="quantitative.s86" text="Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide."><entity charOffset="20-28" id="quantitative.s86.e0" text="aliskiren" type="active-ingredient" /><entity charOffset="159-170" id="quantitative.s86.e1" text="atorvastatin" type="active-ingredient" /><pair ddi="false" e1="quantitative.s86.e0" e2="quantitative.s86.e1" id="quantitative.s86.p0" /></sentence><sentence id="quantitative.s87" text="Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide."><entity charOffset="115-124" id="quantitative.s87.e0" text="amlodipine" type="active-ingredient" /><entity charOffset="20-28" id="quantitative.s87.e1" text="aliskiren" type="active-ingredient" /><pair ddi="false" e1="quantitative.s87.e0" e2="quantitative.s87.e1" id="quantitative.s87.p0" /></sentence><sentence id="quantitative.s88" text="Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide."><entity charOffset="149-156" id="quantitative.s88.e0" text="atenolol" type="active-ingredient" /><entity charOffset="20-28" id="quantitative.s88.e1" text="aliskiren" type="active-ingredient" /><pair ddi="false" e1="quantitative.s88.e0" e2="quantitative.s88.e1" id="quantitative.s88.p0" /></sentence><sentence id="quantitative.s89" text="Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide."><entity charOffset="185-203" id="quantitative.s89.e0" text="hydrochlorothiazide" type="active-ingredient" /><entity charOffset="20-28" id="quantitative.s89.e1" text="aliskiren" type="active-ingredient" /><pair ddi="false" e1="quantitative.s89.e0" e2="quantitative.s89.e1" id="quantitative.s89.p0" /></sentence><sentence id="quantitative.s90" text="Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide."><entity charOffset="127-135" id="quantitative.s90.e0" text="metformin" type="active-ingredient" /><entity charOffset="20-28" id="quantitative.s90.e1" text="aliskiren" type="active-ingredient" /><pair ddi="false" e1="quantitative.s90.e0" e2="quantitative.s90.e1" id="quantitative.s90.p0" /></sentence><sentence id="quantitative.s91" text="Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide."><entity charOffset="173-180" id="quantitative.s91.e0" text="ramipril" type="active-ingredient" /><entity charOffset="20-28" id="quantitative.s91.e1" text="aliskiren" type="active-ingredient" /><pair ddi="false" e1="quantitative.s91.e0" e2="quantitative.s91.e1" id="quantitative.s91.p0" /></sentence><sentence id="quantitative.s92" text="Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide."><entity charOffset="104-112" id="quantitative.s92.e0" text="valsartan" type="active-ingredient" /><entity charOffset="20-28" id="quantitative.s92.e1" text="aliskiren" type="active-ingredient" /><pair ddi="false" e1="quantitative.s92.e0" e2="quantitative.s92.e1" id="quantitative.s92.p0" /></sentence><sentence id="quantitative.s93" text="Coadministration of amlodipine besylate with cimetidine did not alter the pharmacokinetics of amlodipine besylate"><entity charOffset="20-38" id="quantitative.s93.e0" text="amlodipine besylate" type="active-ingredient" /><entity charOffset="94-112" id="quantitative.s93.e1" text="amlodipine besylate" type="active-ingredient" /><entity charOffset="45-54" id="quantitative.s93.e2" text="cimetidine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s93.e1" e2="quantitative.s93.e2" id="quantitative.s93.p0" /></sentence><sentence id="quantitative.s94" text="Coadministration of amlodipine besylate with digoxin did not change serum digoxin levels or digoxin renal clearance in normal volunteers"><entity charOffset="45-51" id="quantitative.s94.e0" text="digoxin" type="active-ingredient" /><entity charOffset="74-80" id="quantitative.s94.e1" text="digoxin" type="active-ingredient" /><entity charOffset="92-98" id="quantitative.s94.e2" text="digoxin" type="active-ingredient" /><entity charOffset="20-38" id="quantitative.s94.e3" text="amlodipine besylate" type="active-ingredient" /><pair ddi="false" e1="quantitative.s94.e2" e2="quantitative.s94.e3" id="quantitative.s94.p0" /></sentence><sentence id="quantitative.s95" text="Coadministration of cimetidine increased the maximum plasma concentration of alprazolam by 86%, decreased clearance by 42%, and increased half-life by 16%."><entity charOffset="20-29" id="quantitative.s95.e0" text="cimetidine" type="active-ingredient" /><entity charOffset="77-86" id="quantitative.s95.e1" text="alprazolam" type="active-ingredient" /><pair ddi="true" e1="quantitative.s95.e0" e2="quantitative.s95.e1" id="quantitative.s95.p0" /></sentence><sentence id="quantitative.s96" text="Coadministration of fluvoxamine approximately doubled the maximum plasma concentration of alprazolam, decreased clearance by 49%, increased half-life by 71%, and decreased measured psychomotor performance."><entity charOffset="20-30" id="quantitative.s96.e0" text="fluvoxamine" type="active-ingredient" /><entity charOffset="90-99" id="quantitative.s96.e1" text="alprazolam" type="active-ingredient" /><pair ddi="true" e1="quantitative.s96.e0" e2="quantitative.s96.e1" id="quantitative.s96.p0" /></sentence><sentence id="quantitative.s97" text="Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure."><entity charOffset="205-213" id="quantitative.s97.e0" text="aliskiren" type="active-ingredient" /><entity charOffset="52-61" id="quantitative.s97.e1" text="furosemide" type="active-ingredient" /><pair ddi="false" e1="quantitative.s97.e0" e2="quantitative.s97.e1" id="quantitative.s97.p0" /></sentence><sentence id="quantitative.s98" text="Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure."><entity charOffset="205-213" id="quantitative.s98.e0" text="aliskiren" type="active-ingredient" /><entity charOffset="32-39" id="quantitative.s98.e1" text="atenolol" type="active-ingredient" /><pair ddi="false" e1="quantitative.s98.e0" e2="quantitative.s98.e1" id="quantitative.s98.p0" /></sentence><sentence id="quantitative.s99" text="Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure."><entity charOffset="205-213" id="quantitative.s99.e0" text="aliskiren" type="active-ingredient" /><entity charOffset="105-112" id="quantitative.s99.e1" text="ramipril" type="active-ingredient" /><pair ddi="false" e1="quantitative.s99.e0" e2="quantitative.s99.e1" id="quantitative.s99.p0" /></sentence><sentence id="quantitative.s100" text="Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure."><entity charOffset="205-213" id="quantitative.s100.e0" text="aliskiren" type="active-ingredient" /><entity charOffset="42-49" id="quantitative.s100.e1" text="warfarin" type="active-ingredient" /><pair ddi="false" e1="quantitative.s100.e0" e2="quantitative.s100.e1" id="quantitative.s100.p0" /></sentence><sentence id="quantitative.s101" text="Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure."><entity charOffset="205-213" id="quantitative.s101.e0" text="aliskiren" type="active-ingredient" /><entity charOffset="64-70" id="quantitative.s101.e1" text="digoxin" type="active-ingredient" /><pair ddi="false" e1="quantitative.s101.e0" e2="quantitative.s101.e1" id="quantitative.s101.p0" /></sentence><sentence id="quantitative.s102" text="Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure."><entity charOffset="140-149" id="quantitative.s102.e0" text="amlodipine" type="active-ingredient" /><entity charOffset="205-213" id="quantitative.s102.e1" text="aliskiren" type="active-ingredient" /><pair ddi="false" e1="quantitative.s102.e0" e2="quantitative.s102.e1" id="quantitative.s102.p0" /></sentence><sentence id="quantitative.s103" text="Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure."><entity charOffset="73-81" id="quantitative.s103.e0" text="celecoxib" type="active-ingredient" /><entity charOffset="205-213" id="quantitative.s103.e1" text="aliskiren" type="active-ingredient" /><pair ddi="false" e1="quantitative.s103.e0" e2="quantitative.s103.e1" id="quantitative.s103.p0" /></sentence><sentence id="quantitative.s104" text="Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure."><entity charOffset="84-102" id="quantitative.s104.e0" text="hydrochlorothiazide" type="active-ingredient" /><entity charOffset="205-213" id="quantitative.s104.e1" text="aliskiren" type="active-ingredient" /><pair ddi="false" e1="quantitative.s104.e0" e2="quantitative.s104.e1" id="quantitative.s104.p0" /></sentence><sentence id="quantitative.s105" text="Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure."><entity charOffset="20-29" id="quantitative.s105.e0" text="lovastatin" type="active-ingredient" /><entity charOffset="205-213" id="quantitative.s105.e1" text="aliskiren" type="active-ingredient" /><pair ddi="false" e1="quantitative.s105.e0" e2="quantitative.s105.e1" id="quantitative.s105.p0" /></sentence><sentence id="quantitative.s106" text="Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure."><entity charOffset="126-134" id="quantitative.s106.e0" text="metformin" type="active-ingredient" /><entity charOffset="205-213" id="quantitative.s106.e1" text="aliskiren" type="active-ingredient" /><pair ddi="false" e1="quantitative.s106.e0" e2="quantitative.s106.e1" id="quantitative.s106.p0" /></sentence><sentence id="quantitative.s107" text="Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure."><entity charOffset="105-112" id="quantitative.s107.e0" text="ramipril" type="active-ingredient" /><entity charOffset="205-213" id="quantitative.s107.e1" text="aliskiren" type="active-ingredient" /><pair ddi="false" e1="quantitative.s107.e0" e2="quantitative.s107.e1" id="quantitative.s107.p0" /></sentence><sentence id="quantitative.s108" text="Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure."><entity charOffset="115-123" id="quantitative.s108.e0" text="valsartan" type="active-ingredient" /><entity charOffset="205-213" id="quantitative.s108.e1" text="aliskiren" type="active-ingredient" /><pair ddi="false" e1="quantitative.s108.e0" e2="quantitative.s108.e1" id="quantitative.s108.p0" /></sentence><sentence id="quantitative.s109" text="Coadministration of multiple 10 mg doses of amlodipine besylate with 80 mg of atorvastatin resulted in no significant change in the steady-state pharmacokinetic parameters of atorvastatin"><entity charOffset="44-62" id="quantitative.s109.e0" text="amlodipine besylate" type="active-ingredient" /><entity charOffset="78-89" id="quantitative.s109.e1" text="atorvastatin" type="active-ingredient" /><entity charOffset="175-186" id="quantitative.s109.e2" text="atorvastatin" type="active-ingredient" /><pair ddi="false" e1="quantitative.s109.e0" e2="quantitative.s109.e2" id="quantitative.s109.p0" /></sentence><sentence id="quantitative.s110" text="Coadministration of multiple doses of quinidine sulfate, 200 mg t.i.d., and nifedipine, 20 mg t.i.d., increased Cmax and AUC of nifedipine in healthy volunteers by factors of 2.30 and 1.37, respectively."><entity charOffset="38-54" id="quantitative.s110.e0" text="quinidine sulfate" type="active-ingredient" /><entity charOffset="76-85" id="quantitative.s110.e1" text="nifedipine" type="active-ingredient" /><entity charOffset="128-137" id="quantitative.s110.e2" text="nifedipine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s110.e0" e2="quantitative.s110.e2" id="quantitative.s110.p0" /></sentence><sentence id="quantitative.s111" text="Coadministration of propoxyphene decreased the maximum plasma concentration of alprazolam by 6%, decreased clearance by 38%, and increased half-life by 58%."><entity charOffset="20-31" id="quantitative.s111.e0" text="propoxyphene" type="active-ingredient" /><entity charOffset="79-88" id="quantitative.s111.e1" text="alprazolam" type="active-ingredient" /><pair ddi="true" e1="quantitative.s111.e0" e2="quantitative.s111.e1" id="quantitative.s111.p0" /></sentence><sentence id="quantitative.s112" text="Coadministration of simvastatin (40 mg QD for 10 days) resulted in an increase in the maximum mean levels of cardioactive digoxin (given as a single 0.4 mg dose on day 10) by approximately 0.3 ng/mL."><entity charOffset="20-30" id="quantitative.s112.e0" text="simvastatin" type="active-ingredient" /><entity charOffset="122-128" id="quantitative.s112.e1" text="digoxin" type="active-ingredient" /><pair ddi="true" e1="quantitative.s112.e0" e2="quantitative.s112.e1" id="quantitative.s112.p0" /></sentence><sentence id="quantitative.s113" text="Combined administration of citalopram (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram."><entity charOffset="50-61" id="quantitative.s113.e0" text="ketoconazole" type="active-ingredient" /><entity charOffset="102-113" id="quantitative.s113.e1" text="ketoconazole" type="active-ingredient" /><entity charOffset="27-36" id="quantitative.s113.e2" text="citalopram" type="active-ingredient" /><entity charOffset="202-211" id="quantitative.s113.e3" text="citalopram" type="active-ingredient" /><pair ddi="true" e1="quantitative.s113.e1" e2="quantitative.s113.e3" id="quantitative.s113.p0" /></sentence><sentence id="quantitative.s114" text="Combined administration of citalopram (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram."><entity charOffset="50-61" id="quantitative.s114.e0" text="ketoconazole" type="active-ingredient" /><entity charOffset="102-113" id="quantitative.s114.e1" text="ketoconazole" type="active-ingredient" /><entity charOffset="27-36" id="quantitative.s114.e2" text="citalopram" type="active-ingredient" /><entity charOffset="202-211" id="quantitative.s114.e3" text="citalopram" type="active-ingredient" /><pair ddi="false" e1="quantitative.s114.e1" e2="quantitative.s114.e3" id="quantitative.s114.p0" /></sentence><sentence id="quantitative.s115" text="Concomitant administration of fluvastatin (40 mg) and itraconazole (100 mg daily x 4 days) does not affect plasma itraconazole or fluvastatin levels."><entity charOffset="54-65" id="quantitative.s115.e0" text="itraconazole" type="active-ingredient" /><entity charOffset="114-125" id="quantitative.s115.e1" text="itraconazole" type="active-ingredient" /><entity charOffset="30-40" id="quantitative.s115.e2" text="fluvastatin" type="active-ingredient" /><entity charOffset="130-140" id="quantitative.s115.e3" text="fluvastatin" type="active-ingredient" /><pair ddi="false" e1="quantitative.s115.e1" e2="quantitative.s115.e3" id="quantitative.s115.p0" /></sentence><sentence id="quantitative.s116" text="Concomitant administration of fluvastatin (40 mg) and itraconazole (100 mg daily x 4 days) does not affect plasma itraconazole or fluvastatin levels."><entity charOffset="54-65" id="quantitative.s116.e0" text="itraconazole" type="active-ingredient" /><entity charOffset="114-125" id="quantitative.s116.e1" text="itraconazole" type="active-ingredient" /><entity charOffset="30-40" id="quantitative.s116.e2" text="fluvastatin" type="active-ingredient" /><entity charOffset="130-140" id="quantitative.s116.e3" text="fluvastatin" type="active-ingredient" /><pair ddi="false" e1="quantitative.s116.e1" e2="quantitative.s116.e3" id="quantitative.s116.p0" /></sentence><sentence id="quantitative.s117" text="Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone. Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced "><entity charOffset="92-104" id="quantitative.s117.e0" text="rosiglitazone" type="active-ingredient" /><entity charOffset="145-157" id="quantitative.s117.e1" text="rosiglitazone" type="active-ingredient" /><entity charOffset="206-218" id="quantitative.s117.e2" text="rosiglitazone" type="active-ingredient" /><entity charOffset="302-314" id="quantitative.s117.e3" text="rosiglitazone" type="active-ingredient" /><entity charOffset="343-355" id="quantitative.s117.e4" text="rosiglitazone" type="active-ingredient" /><entity charOffset="30-40" id="quantitative.s117.e5" text="gemfibrozil" type="active-ingredient" /><entity charOffset="376-386" id="quantitative.s117.e6" text="gemfibrozil" type="active-ingredient" /><pair ddi="true" e1="quantitative.s117.e4" e2="quantitative.s117.e6" id="quantitative.s117.p0" /></sentence><sentence id="quantitative.s118" text="Concomitant administration of propafenone and fluoxetine in extensive metabolizers increased the S propafenone Cmax and AUC by 39 and 50% and the R propafenone Cmax and AUC by 71 and 50%"><entity charOffset="46-55" id="quantitative.s118.e0" text="fluoxetine" type="active-ingredient" /><entity charOffset="30-40" id="quantitative.s118.e1" text="propafenone" type="active-ingredient" /><entity charOffset="99-109" id="quantitative.s118.e2" text="propafenone" type="active-ingredient" /><entity charOffset="148-158" id="quantitative.s118.e3" text="propafenone" type="active-ingredient" /><pair ddi="true" e1="quantitative.s118.e0" e2="quantitative.s118.e3" id="quantitative.s118.p0" /></sentence><sentence id="quantitative.s119" text="Concomitant administration of propafenone immediate release tablets and cimetidine in 12 healthy subjects resulted in a 20% increase in steady-state plasma concentrations of propafenone."><entity charOffset="72-81" id="quantitative.s119.e0" text="cimetidine" type="active-ingredient" /><entity charOffset="30-40" id="quantitative.s119.e1" text="propafenone" type="active-ingredient" /><entity charOffset="174-184" id="quantitative.s119.e2" text="propafenone" type="active-ingredient" /><pair ddi="true" e1="quantitative.s119.e0" e2="quantitative.s119.e2" id="quantitative.s119.p0" /></sentence><sentence id="quantitative.s120" text="Concomitant administration of rifampin and propafenone in extensive metabolizers decreased the plasma concentrations of propafenone by 67% with a corresponding decrease of 5OH-propafenone by 65%. The concentrations of norpropafenone increased by 30%. In poor metabolizers, there was a 50% decrease in propafenone plasma concentrations and increased the AUC and Cmax of norpropafenone by 74 and 20%, respectively. Urinary excretion of propafenone and its metabolites decreased significantly. Similar results were noted in elderly patients: Both the AUC and Cmax propafenone decreased by 84%, with a corresponding decrease in AUC and Cmax of 5OH-propafenone by 69 and 57%."><entity charOffset="30-37" id="quantitative.s120.e0" text="rifampin" type="active-ingredient" /><entity charOffset="218-231" id="quantitative.s120.e1" text="norpropafenone" type="metabolite" /><entity charOffset="369-382" id="quantitative.s120.e2" text="norpropafenone" type="metabolite" /><pair ddi="true" e1="quantitative.s120.e0" e2="quantitative.s120.e2" id="quantitative.s120.p0" /></sentence><sentence id="quantitative.s121" text="Concomitant administration of rifampin and propafenone in extensive metabolizers decreased the plasma concentrations of propafenone by 67% with a corresponding decrease of 5OH-propafenone by 65%. The concentrations of norpropafenone increased by 30%. In poor metabolizers, there was a 50% decrease in propafenone plasma concentrations and increased the AUC and Cmax of norpropafenone by 74 and 20%, respectively. Urinary excretion of propafenone and its metabolites decreased significantly. Similar results were noted in elderly patients: Both the AUC and Cmax propafenone decreased by 84%, with a corresponding decrease in AUC and Cmax of 5OH-propafenone by 69 and 57%."><entity charOffset="30-37" id="quantitative.s121.e0" text="rifampin" type="active-ingredient" /><entity charOffset="43-53" id="quantitative.s121.e1" text="propafenone" type="active-ingredient" /><entity charOffset="120-130" id="quantitative.s121.e2" text="propafenone" type="active-ingredient" /><entity charOffset="176-186" id="quantitative.s121.e3" text="propafenone" type="active-ingredient" /><entity charOffset="221-231" id="quantitative.s121.e4" text="propafenone" type="active-ingredient" /><entity charOffset="301-311" id="quantitative.s121.e5" text="propafenone" type="active-ingredient" /><entity charOffset="372-382" id="quantitative.s121.e6" text="propafenone" type="active-ingredient" /><entity charOffset="434-444" id="quantitative.s121.e7" text="propafenone" type="active-ingredient" /><entity charOffset="561-571" id="quantitative.s121.e8" text="propafenone" type="active-ingredient" /><entity charOffset="644-654" id="quantitative.s121.e9" text="propafenone" type="active-ingredient" /><pair ddi="true" e1="quantitative.s121.e0" e2="quantitative.s121.e9" id="quantitative.s121.p0" /></sentence><sentence id="quantitative.s122" text="Concomitant administration of Synercid and nifedipine (repeated oral doses) and midazolam (intravenous bolus dose) in healthy volunteers led to elevated plasma concentrations of these drugs. The Cmax increased by 18% and 14% (median values) and the AUC increased by 44% and 33% for nifedipine and midazolam, respectively"><entity charOffset="43-52" id="quantitative.s122.e0" text="nifedipine" type="active-ingredient" /><entity charOffset="282-291" id="quantitative.s122.e1" text="nifedipine" type="active-ingredient" /><entity charOffset="30-37" id="quantitative.s122.e2" text="synercid" type="drug-product" /><pair ddi="true" e1="quantitative.s122.e1" e2="quantitative.s122.e2" id="quantitative.s122.p0" /></sentence><sentence id="quantitative.s123" text="Concomitant administration of Synercid and nifedipine (repeated oral doses) and midazolam (intravenous bolus dose) in healthy volunteers led to elevated plasma concentrations of these drugs. The Cmax increased by 18% and 14% (median values) and the AUC increased by 44% and 33% for nifedipine and midazolam, respectively"><entity charOffset="30-37" id="quantitative.s123.e0" text="synercid" type="drug-product" /><entity charOffset="80-88" id="quantitative.s123.e1" text="midazolam" type="active-ingredient" /><entity charOffset="297-305" id="quantitative.s123.e2" text="midazolam" type="active-ingredient" /><pair ddi="true" e1="quantitative.s123.e0" e2="quantitative.s123.e2" id="quantitative.s123.p0" /></sentence><sentence id="quantitative.s124" text="Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics."><entity charOffset="63-72" id="quantitative.s124.e0" text="irbesartan" type="active-ingredient" /><entity charOffset="26-44" id="quantitative.s124.e1" text="hydrochlorothiazide" type="active-ingredient" /><pair ddi="false" e1="quantitative.s124.e0" e2="quantitative.s124.e1" id="quantitative.s124.p0" /></sentence><sentence id="quantitative.s125" text="Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics."><entity charOffset="63-72" id="quantitative.s125.e0" text="irbesartan" type="active-ingredient" /><entity charOffset="12-21" id="quantitative.s125.e1" text="nifedipine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s125.e0" e2="quantitative.s125.e1" id="quantitative.s125.p0" /></sentence><sentence id="quantitative.s126" text="Concomitant use of propafenone and digoxin increased steady-state serum digoxin exposure (AUC) in patients by 60 to 270%, and decreased the clearance of digoxin by 31 to 67%. Monitor plasma digoxin levels of patients receiving propafenone and adjust digoxin dosage as needed."><entity charOffset="19-29" id="quantitative.s126.e0" text="propafenone" type="active-ingredient" /><entity charOffset="227-237" id="quantitative.s126.e1" text="propafenone" type="active-ingredient" /><entity charOffset="35-41" id="quantitative.s126.e2" text="digoxin" type="active-ingredient" /><entity charOffset="72-78" id="quantitative.s126.e3" text="digoxin" type="active-ingredient" /><entity charOffset="153-159" id="quantitative.s126.e4" text="digoxin" type="active-ingredient" /><entity charOffset="190-196" id="quantitative.s126.e5" text="digoxin" type="active-ingredient" /><entity charOffset="250-256" id="quantitative.s126.e6" text="digoxin" type="active-ingredient" /><pair ddi="true" e1="quantitative.s126.e1" e2="quantitative.s126.e6" id="quantitative.s126.p0" /></sentence><sentence id="quantitative.s127" text="Concomitant use of propafenone and propranolol in healthy subjects increased propranolol plasma concentrations at steady state by 113%. In 4 patients, administration of metoprolol with propafenone increased the metoprolol plasma concentrations at steady state by 100-400%."><entity charOffset="35-45" id="quantitative.s127.e0" text="propranolol" type="active-ingredient" /><entity charOffset="77-87" id="quantitative.s127.e1" text="propranolol" type="active-ingredient" /><entity charOffset="19-29" id="quantitative.s127.e2" text="propafenone" type="active-ingredient" /><entity charOffset="185-195" id="quantitative.s127.e3" text="propafenone" type="active-ingredient" /><pair ddi="true" e1="quantitative.s127.e1" e2="quantitative.s127.e3" id="quantitative.s127.p0" /></sentence><sentence id="quantitative.s128" text="Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone"><entity charOffset="29-35" id="quantitative.s128.e0" text="avandia" type="drug-product" /><entity charOffset="60-68" id="quantitative.s128.e1" text="metformin" type="active-ingredient" /><entity charOffset="185-193" id="quantitative.s128.e2" text="metformin" type="active-ingredient" /><pair ddi="false" e1="quantitative.s128.e0" e2="quantitative.s128.e2" id="quantitative.s128.p0" /></sentence><sentence id="quantitative.s129" text="Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone"><entity charOffset="29-35" id="quantitative.s129.e0" text="avandia" type="drug-product" /><entity charOffset="60-68" id="quantitative.s129.e1" text="metformin" type="active-ingredient" /><entity charOffset="185-193" id="quantitative.s129.e2" text="metformin" type="active-ingredient" /><pair ddi="false" e1="quantitative.s129.e0" e2="quantitative.s129.e2" id="quantitative.s129.p0" /></sentence><sentence id="quantitative.s130" text="Concurrent use of rifampin increases the metabolic clearance of bisoprolol fumarate shortening its elimination half-life. However, initial dose modification is generally not necessary. Pharmacokinetic studies document no clinically relevant interactions with other agents given concomitantly, including thiazide diuretics and cimetidine."><entity charOffset="326-335" id="quantitative.s130.e0" text="cimetidine" type="active-ingredient" /><entity charOffset="64-82" id="quantitative.s130.e1" text="bisoprolol fumarate" type="active-ingredient" /><pair ddi="false" e1="quantitative.s130.e0" e2="quantitative.s130.e1" id="quantitative.s130.p0" /></sentence><sentence id="quantitative.s131" text="Concurrent use of rifampin increases the metabolic clearance of bisoprolol fumarate shortening its elimination half-life. However, initial dose modification is generally not necessary. Pharmacokinetic studies document no clinically relevant interactions with other agents given concomitantly, including thiazide diuretics and cimetidine. "><entity charOffset="326-335" id="quantitative.s131.e0" text="cimetidine" type="active-ingredient" /><entity charOffset="64-82" id="quantitative.s131.e1" text="bisoprolol fumarate" type="active-ingredient" /><pair ddi="false" e1="quantitative.s131.e0" e2="quantitative.s131.e1" id="quantitative.s131.p0" /></sentence><sentence id="quantitative.s132" text="Conivaptan is a sensitive substrate of CYP3A. The effect of ketoconazole, a potent CYP3A inhibitor, on the pharmacokinetics of intravenous conivaptan has not been evaluated. Coadministration of oral conivaptan hydrochloride 10 mg with ketoconazole 200 mg resulted in 4- and 11-fold increases in Cmax and AUC of conivaptan, respectively "><entity charOffset="0-9" id="quantitative.s132.e0" text="conivaptan" type="active-ingredient" /><entity charOffset="139-148" id="quantitative.s132.e1" text="conivaptan" type="active-ingredient" /><entity charOffset="199-208" id="quantitative.s132.e2" text="conivaptan" type="active-ingredient" /><entity charOffset="311-320" id="quantitative.s132.e3" text="conivaptan" type="active-ingredient" /><entity charOffset="60-71" id="quantitative.s132.e4" text="ketoconazole" type="active-ingredient" /><entity charOffset="235-246" id="quantitative.s132.e5" text="ketoconazole" type="active-ingredient" /><pair ddi="true" e1="quantitative.s132.e3" e2="quantitative.s132.e5" id="quantitative.s132.p0" /></sentence><sentence id="quantitative.s133" text="Cyclosporine AUC and Cmax were determined before and after the administration of fluconazole 200 mg daily for 14 days in eight renal transplant patients who had been on cyclosporine therapy for at least 6 months and on a stable cyclosporine dose for at least 6 weeks. There was a significant increase in cyclosporine AUC, Cmax, Cmin (24-hour concentration), and a significant reduction in apparent oral clearance following the administration of fluconazole. The mean ± SD increase in AUC was 92% ± 43% (range: 18 to 147%). The Cmax increased 60% ± 48% (range: -5 to 133%). The Cmin increased 157% ± 96% (range: 33 to 360%). The apparent oral clearance decreased 45% ± 15% (range: -15 to -60%)."><entity charOffset="81-91" id="quantitative.s133.e0" text="fluconazole" type="active-ingredient" /><entity charOffset="445-455" id="quantitative.s133.e1" text="fluconazole" type="active-ingredient" /><entity charOffset="0-11" id="quantitative.s133.e2" text="cyclosporine" type="active-ingredient" /><entity charOffset="169-180" id="quantitative.s133.e3" text="cyclosporine" type="active-ingredient" /><entity charOffset="228-239" id="quantitative.s133.e4" text="cyclosporine" type="active-ingredient" /><entity charOffset="304-315" id="quantitative.s133.e5" text="cyclosporine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s133.e1" e2="quantitative.s133.e5" id="quantitative.s133.p0" /></sentence><sentence id="quantitative.s134" text="Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren."><entity charOffset="76-84" id="quantitative.s134.e0" text="aliskiren" type="active-ingredient" /><entity charOffset="171-179" id="quantitative.s134.e1" text="aliskiren" type="active-ingredient" /><entity charOffset="0-11" id="quantitative.s134.e2" text="cyclosporine" type="active-ingredient" /><entity charOffset="52-63" id="quantitative.s134.e3" text="cyclosporine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s134.e1" e2="quantitative.s134.e3" id="quantitative.s134.p0" /></sentence><sentence id="quantitative.s135" text="CYP2D6 Substrate (e.g., Desipramine) — Coadministration of atomoxetine hydrochloride (40 or 60 mg BID for 13 days) with desipramine, a model compound for CYP2D6 metabolized drugs (single dose of 50 mg), did not alter the pharmacokinetics of desipramine. No dose adjustment is recommended for drugs metabolized by CYP2D6."><entity charOffset="61-85" id="quantitative.s135.e0" text="atomoxetine hydrochloride" type="active-ingredient" /><entity charOffset="24-34" id="quantitative.s135.e1" text="desipramine" type="active-ingredient" /><entity charOffset="122-132" id="quantitative.s135.e2" text="desipramine" type="active-ingredient" /><entity charOffset="243-253" id="quantitative.s135.e3" text="desipramine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s135.e0" e2="quantitative.s135.e3" id="quantitative.s135.p0" /></sentence><sentence id="quantitative.s136" text="CYP3A Substrate (e.g., Midazolam) — Coadministration of atomoxetine hydrochloride (60 mg BID for 12 days) with midazolam, a model compound for CYP3A4 metabolized drugs (single dose of 5 mg), resulted in 15% increase in AUC of midazolam. No dose adjustment is recommended for drugs metabolized by CYP3A."><entity charOffset="58-82" id="quantitative.s136.e0" text="atomoxetine hydrochloride" type="active-ingredient" /><entity charOffset="23-31" id="quantitative.s136.e1" text="midazolam" type="active-ingredient" /><entity charOffset="113-121" id="quantitative.s136.e2" text="midazolam" type="active-ingredient" /><entity charOffset="228-236" id="quantitative.s136.e3" text="midazolam" type="active-ingredient" /><pair ddi="true" e1="quantitative.s136.e0" e2="quantitative.s136.e3" id="quantitative.s136.p0" /></sentence><sentence id="quantitative.s137" text="Daily oral dosing of immediate-release paroxetine (30 mg once daily) increased steady-state AUC0-24, Cmax, and Cmin values of procyclidine (5 mg oral once daily) by 35%, 37%, and 67%, respectively, compared to procyclidine alone at steady state. If anticholinergic effects are seen, the dose of procyclidine should be reduced."><entity charOffset="126-137" id="quantitative.s137.e0" text="procyclidine" type="active-ingredient" /><entity charOffset="210-221" id="quantitative.s137.e1" text="procyclidine" type="active-ingredient" /><entity charOffset="295-306" id="quantitative.s137.e2" text="procyclidine" type="active-ingredient" /><entity charOffset="39-48" id="quantitative.s137.e3" text="paroxetine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s137.e2" e2="quantitative.s137.e3" id="quantitative.s137.p0" /></sentence><sentence id="quantitative.s138" text="Diazepam does not alter the pharmacokinetics of propranolol"><entity charOffset="48-58" id="quantitative.s138.e0" text="propranolol" type="active-ingredient" /><entity charOffset="0-7" id="quantitative.s138.e1" text="diazepam" type="active-ingredient" /><pair ddi="false" e1="quantitative.s138.e0" e2="quantitative.s138.e1" id="quantitative.s138.p0" /></sentence><sentence id="quantitative.s139" text="Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin."><entity charOffset="0-6" id="quantitative.s139.e0" text="digoxin" type="active-ingredient" /><entity charOffset="170-176" id="quantitative.s139.e1" text="digoxin" type="active-ingredient" /><entity charOffset="27-45" id="quantitative.s139.e2" text="fluvoxamine maleate" type="active-ingredient" /><pair ddi="false" e1="quantitative.s139.e1" e2="quantitative.s139.e2" id="quantitative.s139.p0" /></sentence><sentence id="quantitative.s140" text="Diltiazem: Pretreatment of healthy volunteers with 30 mg or 90 mg t.i.d. diltiazem p.o. increased the AUC of nifedipine after a single dose of 20 mg nifedipine by factors of 2.2 and 3.1, respectively. The corresponding Cmax values of nifedipine increased by factors of 2.0 and 1.7, respectively. Caution should be exercised when coadministering diltiazem and nifedipine and a reduction of the dose of nifedipine should be considered."><entity charOffset="109-118" id="quantitative.s140.e0" text="nifedipine" type="active-ingredient" /><entity charOffset="149-158" id="quantitative.s140.e1" text="nifedipine" type="active-ingredient" /><entity charOffset="234-243" id="quantitative.s140.e2" text="nifedipine" type="active-ingredient" /><entity charOffset="359-368" id="quantitative.s140.e3" text="nifedipine" type="active-ingredient" /><entity charOffset="401-410" id="quantitative.s140.e4" text="nifedipine" type="active-ingredient" /><entity charOffset="0-8" id="quantitative.s140.e5" text="diltiazem" type="active-ingredient" /><entity charOffset="73-81" id="quantitative.s140.e6" text="diltiazem" type="active-ingredient" /><entity charOffset="345-353" id="quantitative.s140.e7" text="diltiazem" type="active-ingredient" /><pair ddi="true" e1="quantitative.s140.e4" e2="quantitative.s140.e7" id="quantitative.s140.p0" /></sentence><sentence id="quantitative.s141" text="Doxazosin: Healthy volunteers participating in a multiple dose doxazosin-nifedipine interaction study received 2 mg doxazosin q.d. alone or combined with 20 mg nifedipine ER b.i.d. Coadministration of nifedipine resulted in a decrease in AUC and Cmax of doxazosin to 83% and 86% of the values in the absence of nifedipine, respectively. In the presence of doxazosin, AUC and Cmax of nifedipine were increased by factors of 1.13 and 1.23, respectively. Compared to nifedipine monotherapy, blood pressure was lower in the presence of doxazosin. Blood pressure should be monitored when doxazosin is coadministered with nifedipine and dose reduction of nifedipine considered."><entity charOffset="0-8" id="quantitative.s141.e0" text="doxazosin" type="active-ingredient" /><entity charOffset="63-71" id="quantitative.s141.e1" text="doxazosin" type="active-ingredient" /><entity charOffset="116-124" id="quantitative.s141.e2" text="doxazosin" type="active-ingredient" /><entity charOffset="254-262" id="quantitative.s141.e3" text="doxazosin" type="active-ingredient" /><entity charOffset="356-364" id="quantitative.s141.e4" text="doxazosin" type="active-ingredient" /><entity charOffset="532-540" id="quantitative.s141.e5" text="doxazosin" type="active-ingredient" /><entity charOffset="583-591" id="quantitative.s141.e6" text="doxazosin" type="active-ingredient" /><entity charOffset="73-82" id="quantitative.s141.e7" text="nifedipine" type="active-ingredient" /><entity charOffset="160-169" id="quantitative.s141.e8" text="nifedipine" type="active-ingredient" /><entity charOffset="201-210" id="quantitative.s141.e9" text="nifedipine" type="active-ingredient" /><entity charOffset="311-320" id="quantitative.s141.e10" text="nifedipine" type="active-ingredient" /><entity charOffset="383-392" id="quantitative.s141.e11" text="nifedipine" type="active-ingredient" /><entity charOffset="464-473" id="quantitative.s141.e12" text="nifedipine" type="active-ingredient" /><entity charOffset="616-625" id="quantitative.s141.e13" text="nifedipine" type="active-ingredient" /><entity charOffset="649-658" id="quantitative.s141.e14" text="nifedipine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s141.e6" e2="quantitative.s141.e14" id="quantitative.s141.p0" /></sentence><sentence id="quantitative.s142" text="Doxazosin: Healthy volunteers participating in a multiple dose doxazosin-nifedipine interaction study received 2 mg doxazosin q.d. alone or combined with 20 mg nifedipine ER b.i.d. Coadministration of nifedipine resulted in a decrease in AUC and Cmax of doxazosin to 83% and 86% of the values in the absence of nifedipine, respectively. In the presence of doxazosin, AUC and Cmax of nifedipine were increased by factors of 1.13 and 1.23, respectively. Compared to nifedipine monotherapy, blood pressure was lower in the presence of doxazosin. Blood pressure should be monitored when doxazosin is coadministered with nifedipine and dose reduction of nifedipine considered."><entity charOffset="73-82" id="quantitative.s142.e0" text="nifedipine" type="active-ingredient" /><entity charOffset="160-169" id="quantitative.s142.e1" text="nifedipine" type="active-ingredient" /><entity charOffset="201-210" id="quantitative.s142.e2" text="nifedipine" type="active-ingredient" /><entity charOffset="311-320" id="quantitative.s142.e3" text="nifedipine" type="active-ingredient" /><entity charOffset="383-392" id="quantitative.s142.e4" text="nifedipine" type="active-ingredient" /><entity charOffset="464-473" id="quantitative.s142.e5" text="nifedipine" type="active-ingredient" /><entity charOffset="616-625" id="quantitative.s142.e6" text="nifedipine" type="active-ingredient" /><entity charOffset="649-658" id="quantitative.s142.e7" text="nifedipine" type="active-ingredient" /><entity charOffset="0-8" id="quantitative.s142.e8" text="doxazosin" type="active-ingredient" /><entity charOffset="63-71" id="quantitative.s142.e9" text="doxazosin" type="active-ingredient" /><entity charOffset="116-124" id="quantitative.s142.e10" text="doxazosin" type="active-ingredient" /><entity charOffset="254-262" id="quantitative.s142.e11" text="doxazosin" type="active-ingredient" /><entity charOffset="356-364" id="quantitative.s142.e12" text="doxazosin" type="active-ingredient" /><entity charOffset="532-540" id="quantitative.s142.e13" text="doxazosin" type="active-ingredient" /><entity charOffset="583-591" id="quantitative.s142.e14" text="doxazosin" type="active-ingredient" /><pair ddi="true" e1="quantitative.s142.e7" e2="quantitative.s142.e14" id="quantitative.s142.p0" /></sentence><sentence id="quantitative.s143" text="Effect Of Clonazepam On The Pharmacokinetics Of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of phenytoin, carbamazepine or phenobarbital. "><entity charOffset="132-144" id="quantitative.s143.e0" text="carbamazepine" type="active-ingredient" /><entity charOffset="10-19" id="quantitative.s143.e1" text="Clonazepam" type="active-ingredient" /><entity charOffset="61-70" id="quantitative.s143.e2" text="Clonazepam" type="active-ingredient" /><pair ddi="false" e1="quantitative.s143.e0" e2="quantitative.s143.e2" id="quantitative.s143.p0" /></sentence><sentence id="quantitative.s144" text="Effect Of Clonazepam On The Pharmacokinetics Of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of phenytoin, carbamazepine or phenobarbital. "><entity charOffset="149-161" id="quantitative.s144.e0" text="phenobarbital" type="active-ingredient" /><entity charOffset="10-19" id="quantitative.s144.e1" text="Clonazepam" type="active-ingredient" /><entity charOffset="61-70" id="quantitative.s144.e2" text="Clonazepam" type="active-ingredient" /><pair ddi="false" e1="quantitative.s144.e0" e2="quantitative.s144.e2" id="quantitative.s144.p0" /></sentence><sentence id="quantitative.s145" text="Effect Of Clonazepam On The Pharmacokinetics Of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of phenytoin, carbamazepine or phenobarbital. "><entity charOffset="121-129" id="quantitative.s145.e0" text="phenytoin" type="active-ingredient" /><entity charOffset="10-19" id="quantitative.s145.e1" text="Clonazepam" type="active-ingredient" /><entity charOffset="61-70" id="quantitative.s145.e2" text="Clonazepam" type="active-ingredient" /><pair ddi="false" e1="quantitative.s145.e0" e2="quantitative.s145.e2" id="quantitative.s145.p0" /></sentence><sentence id="quantitative.s146" text="Erythromycin (500 mg, single dose) did not affect steady-state plasma levels of fluvastatin (40 mg daily)."><entity charOffset="80-90" id="quantitative.s146.e0" text="fluvastatin" type="active-ingredient" /><entity charOffset="0-11" id="quantitative.s146.e1" text="erythromycin" type="active-ingredient" /><pair ddi="false" e1="quantitative.s146.e0" e2="quantitative.s146.e1" id="quantitative.s146.p0" /></sentence><sentence id="quantitative.s147" text="Erythromycin:There were no significant interactions between risperidone and erythromycin"><entity charOffset="60-70" id="quantitative.s147.e0" text="risperidone" type="active-ingredient" /><entity charOffset="0-11" id="quantitative.s147.e1" text="erythromycin" type="active-ingredient" /><entity charOffset="76-87" id="quantitative.s147.e2" text="erythromycin" type="active-ingredient" /><pair ddi="false" e1="quantitative.s147.e0" e2="quantitative.s147.e2" id="quantitative.s147.p0" /></sentence><sentence id="quantitative.s148" text="Erythromycin:There were no significant interactions between risperidone and erythromycin."><entity charOffset="60-70" id="quantitative.s148.e0" text="risperidone" type="active-ingredient" /><entity charOffset="0-11" id="quantitative.s148.e1" text="erythromycin" type="active-ingredient" /><entity charOffset="76-87" id="quantitative.s148.e2" text="erythromycin" type="active-ingredient" /><pair ddi="false" e1="quantitative.s148.e0" e2="quantitative.s148.e2" id="quantitative.s148.p0" /></sentence><sentence id="quantitative.s149" text="Experimental evidence demonstrated that methadone decreased the AUC and peak levels for didanosine and stavudine, with a more significant decrease for didanosine. Methadone disposition was not substantially altered."><entity charOffset="40-48" id="quantitative.s149.e0" text="methadone" type="active-ingredient" /><entity charOffset="163-171" id="quantitative.s149.e1" text="methadone" type="active-ingredient" /><entity charOffset="103-111" id="quantitative.s149.e2" text="stavudine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s149.e1" e2="quantitative.s149.e2" id="quantitative.s149.p0" /></sentence><sentence id="quantitative.s150" text="Experimental evidence demonstrated that methadone decreased the AUC and peak levels for didanosine and stavudine, with a more significant decrease for didanosine. Methadone disposition was not substantially altered."><entity charOffset="40-48" id="quantitative.s150.e0" text="methadone" type="active-ingredient" /><entity charOffset="163-171" id="quantitative.s150.e1" text="methadone" type="active-ingredient" /><entity charOffset="88-97" id="quantitative.s150.e2" text="didanosine" type="active-ingredient" /><entity charOffset="151-160" id="quantitative.s150.e3" text="didanosine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s150.e1" e2="quantitative.s150.e3" id="quantitative.s150.p0" /></sentence><sentence id="quantitative.s151" text="Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole."><entity charOffset="0-11" id="quantitative.s151.e0" text="fexofenadine" type="active-ingredient" /><entity charOffset="61-72" id="quantitative.s151.e1" text="erythromycin" type="active-ingredient" /><pair ddi="false" e1="quantitative.s151.e0" e2="quantitative.s151.e1" id="quantitative.s151.p0" /></sentence><sentence id="quantitative.s152" text="Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole."><entity charOffset="0-11" id="quantitative.s152.e0" text="fexofenadine" type="active-ingredient" /><entity charOffset="77-88" id="quantitative.s152.e1" text="ketoconazole" type="active-ingredient" /><pair ddi="false" e1="quantitative.s152.e0" e2="quantitative.s152.e1" id="quantitative.s152.p0" /></sentence><sentence id="quantitative.s153" text="Fexofenadine hydrochloride should not be taken closely in time with aluminum and magnesium containing antacids. In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%"><entity charOffset="0-25" id="quantitative.s153.e0" text="fexofenadine hydrochloride" type="active-ingredient" /><entity charOffset="167-192" id="quantitative.s153.e1" text="fexofenadine hydrochloride" type="active-ingredient" /><entity charOffset="68-75" id="quantitative.s153.e2" text="aluminum" type="active-ingredient" /><entity charOffset="239-246" id="quantitative.s153.e3" text="aluminum" type="active-ingredient" /><pair ddi="true" e1="quantitative.s153.e1" e2="quantitative.s153.e3" id="quantitative.s153.p0" /></sentence><sentence id="quantitative.s154" text="Fexofenadine hydrochloride should not be taken closely in time with aluminum and magnesium containing antacids. In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%"><entity charOffset="81-89" id="quantitative.s154.e0" text="magnesium" type="active-ingredient" /><entity charOffset="252-260" id="quantitative.s154.e1" text="magnesium" type="active-ingredient" /><entity charOffset="0-25" id="quantitative.s154.e2" text="fexofenadine hydrochloride" type="active-ingredient" /><entity charOffset="167-192" id="quantitative.s154.e3" text="fexofenadine hydrochloride" type="active-ingredient" /><pair ddi="true" e1="quantitative.s154.e1" e2="quantitative.s154.e3" id="quantitative.s154.p0" /></sentence><sentence id="quantitative.s155" text="Fluconazole 100 mg was administered as a single oral dose alone and two hours after a single dose of cimetidine 400 mg to six healthy male volunteers. After the administration of cimetidine, there was a significant decrease in fluconazole AUC and Cmax. There was a mean ± SD decrease in fluconazole AUC of 13% ± 11% (range: -3.4 to -31%) and Cmax decreased 19% ± 14% (range: -5 to -40%). However, the administration of cimetidine 600 mg to 900 mg intravenously over a four-hour period (from one hour before to 3 hours after a single oral dose of fluconazole 200 mg) did not affect the bioavailability or pharmacokinetics of fluconazole in 24 healthy male volunteers."><entity charOffset="0-10" id="quantitative.s155.e0" text="fluconazole" type="active-ingredient" /><entity charOffset="227-237" id="quantitative.s155.e1" text="fluconazole" type="active-ingredient" /><entity charOffset="288-298" id="quantitative.s155.e2" text="fluconazole" type="active-ingredient" /><entity charOffset="549-559" id="quantitative.s155.e3" text="fluconazole" type="active-ingredient" /><entity charOffset="627-637" id="quantitative.s155.e4" text="fluconazole" type="active-ingredient" /><entity charOffset="101-110" id="quantitative.s155.e5" text="cimetidine" type="active-ingredient" /><entity charOffset="179-188" id="quantitative.s155.e6" text="cimetidine" type="active-ingredient" /><entity charOffset="422-431" id="quantitative.s155.e7" text="cimetidine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s155.e4" e2="quantitative.s155.e7" id="quantitative.s155.p0" /></sentence><sentence id="quantitative.s156" text="For other antiretroviral drugs, such as saquinavir, elevated serum levels have been reported with an increase in AUC by 82%, in Cmax by 75% and in Cmin by 106% following multiple dosing of saquinavir/ritonavir (1000/100 mg) bid for 15 days with omeprazole 40 mg qd co-administered days 11 to 15. "><entity charOffset="245-254" id="quantitative.s156.e0" text="omeprazole" type="active-ingredient" /><entity charOffset="40-49" id="quantitative.s156.e1" text="saquinavir" type="active-ingredient" /><entity charOffset="189-198" id="quantitative.s156.e2" text="saquinavir" type="active-ingredient" /><pair ddi="true" e1="quantitative.s156.e0" e2="quantitative.s156.e2" id="quantitative.s156.p0" /></sentence><sentence id="quantitative.s157" text="Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively"><entity charOffset="0-9" id="quantitative.s157.e0" text="furosemide" type="active-ingredient" /><entity charOffset="51-60" id="quantitative.s157.e1" text="furosemide" type="active-ingredient" /><entity charOffset="83-92" id="quantitative.s157.e2" text="furosemide" type="active-ingredient" /><entity charOffset="17-25" id="quantitative.s157.e3" text="aliskiren" type="active-ingredient" /><pair ddi="true" e1="quantitative.s157.e2" e2="quantitative.s157.e3" id="quantitative.s157.p0" /></sentence><sentence id="quantitative.s158" text="Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine. However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine. The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h). Imipramine did not affect the pharmacokinetics of venlafaxine and ODV. The clinical significance of elevated 2-OH-desipramine levels is unknown."><entity charOffset="79-93" id="quantitative.s158.e0" text="2-OH-imipramine" type="metabolite" /><entity charOffset="13-23" id="quantitative.s158.e1" text="venlafaxine" type="active-ingredient" /><entity charOffset="179-189" id="quantitative.s158.e2" text="venlafaxine" type="active-ingredient" /><entity charOffset="256-266" id="quantitative.s158.e3" text="venlafaxine" type="active-ingredient" /><entity charOffset="304-314" id="quantitative.s158.e4" text="venlafaxine" type="active-ingredient" /><entity charOffset="379-389" id="quantitative.s158.e5" text="venlafaxine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s158.e0" e2="quantitative.s158.e5" id="quantitative.s158.p0" /></sentence><sentence id="quantitative.s159" text="Immediate release nisoldipine increased plasma quinidine concentrations by about 20%."><entity charOffset="47-55" id="quantitative.s159.e0" text="quinidine" type="active-ingredient" /><entity charOffset="18-28" id="quantitative.s159.e1" text="nisoldipine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s159.e0" e2="quantitative.s159.e1" id="quantitative.s159.p0" /></sentence><sentence id="quantitative.s160" text="In 1 study, daily dosing of immediate-release paroxetine (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively."><entity charOffset="128-138" id="quantitative.s160.e0" text="desipramine" type="active-ingredient" /><entity charOffset="46-55" id="quantitative.s160.e1" text="paroxetine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s160.e0" e2="quantitative.s160.e1" id="quantitative.s160.p0" /></sentence><sentence id="quantitative.s161" text="In 13 normal male volunteers, there was significant increase in tolbutamide (500 mg single dose) AUC and Cmax following the administration of fluconazole. There was a mean ± SD increase in tolbutamide AUC of 26% ± 9% (range: 12 to 39%). Tolbutamide Cmax increased 11% ± 9% (range: -6 to 27%)."><entity charOffset="64-74" id="quantitative.s161.e0" text="tolbutamide" type="active-ingredient" /><entity charOffset="190-200" id="quantitative.s161.e1" text="tolbutamide" type="active-ingredient" /><entity charOffset="239-249" id="quantitative.s161.e2" text="tolbutamide" type="active-ingredient" /><entity charOffset="142-152" id="quantitative.s161.e3" text="fluconazole" type="active-ingredient" /><pair ddi="true" e1="quantitative.s161.e2" e2="quantitative.s161.e3" id="quantitative.s161.p0" /></sentence><sentence id="quantitative.s162" text="In a controlled study of a single dose (2 mg) of pimozide, 200 mg sertraline (q.d.) co-adminis-tration to steady state was associated with a mean increase in pimozide AUC and C max of about 40%, but was not associated with any changes in EKG. "><entity charOffset="66-75" id="quantitative.s162.e0" text="sertraline" type="active-ingredient" /><entity charOffset="49-56" id="quantitative.s162.e1" text="pimozide" type="active-ingredient" /><entity charOffset="158-165" id="quantitative.s162.e2" text="pimozide" type="active-ingredient" /><pair ddi="true" e1="quantitative.s162.e0" e2="quantitative.s162.e2" id="quantitative.s162.p0" /></sentence><sentence id="quantitative.s163" text="In a controlled study of healthy volunteers, after immediate-release paroxetine hydrochloride was titrated to 60 mg daily, co-administration of a single dose of 2 mg pimozide was associated with mean increases in pimozide AUC of 151% and Cmax of 62%, compared to pimozide administered alone. The increase in pimozide AUC and Cmax is due to the CYP2D6 inhibitory properties of paroxetine. Due to the narrow therapeutic index of pimozide and its known ability to prolong the QT interval, concomitant use of pimozide and Paroxetine Hydrochloride Controlled-Release Tablets is contraindicated (see CONTRAINDICATIONS)."><entity charOffset="166-173" id="quantitative.s163.e0" text="pimozide" type="active-ingredient" /><entity charOffset="213-220" id="quantitative.s163.e1" text="pimozide" type="active-ingredient" /><entity charOffset="263-270" id="quantitative.s163.e2" text="pimozide" type="active-ingredient" /><entity charOffset="308-315" id="quantitative.s163.e3" text="pimozide" type="active-ingredient" /><entity charOffset="427-434" id="quantitative.s163.e4" text="pimozide" type="active-ingredient" /><entity charOffset="505-512" id="quantitative.s163.e5" text="pimozide" type="active-ingredient" /><entity charOffset="69-92" id="quantitative.s163.e6" text="paroxetine hydrochloride" type="active-ingredient" /><entity charOffset="518-541" id="quantitative.s163.e7" text="paroxetine hydrochloride" type="active-ingredient" /><pair ddi="true" e1="quantitative.s163.e5" e2="quantitative.s163.e7" id="quantitative.s163.p0" /></sentence><sentence id="quantitative.s164" text="In a controlled study, a single dose of pimozide 2 mg coadministered with citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone. Citalopram did not alter the mean AUC or Cmax of pimozide."><entity charOffset="40-47" id="quantitative.s164.e0" text="pimozide" type="active-ingredient" /><entity charOffset="207-214" id="quantitative.s164.e1" text="pimozide" type="active-ingredient" /><entity charOffset="278-285" id="quantitative.s164.e2" text="pimozide" type="active-ingredient" /><entity charOffset="74-83" id="quantitative.s164.e3" text="citalopram" type="active-ingredient" /><entity charOffset="229-238" id="quantitative.s164.e4" text="citalopram" type="active-ingredient" /><pair ddi="true" e1="quantitative.s164.e2" e2="quantitative.s164.e4" id="quantitative.s164.p0" /></sentence><sentence id="quantitative.s165" text="In a controlled study, a single dose of pimozide 2 mg coadministered with citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone. Citalopram did not alter the mean AUC or Cmax of pimozide. "><entity charOffset="40-47" id="quantitative.s165.e0" text="pimozide" type="active-ingredient" /><entity charOffset="207-214" id="quantitative.s165.e1" text="pimozide" type="active-ingredient" /><entity charOffset="278-285" id="quantitative.s165.e2" text="pimozide" type="active-ingredient" /><entity charOffset="74-83" id="quantitative.s165.e3" text="citalopram" type="active-ingredient" /><entity charOffset="229-238" id="quantitative.s165.e4" text="citalopram" type="active-ingredient" /><pair ddi="false" e1="quantitative.s165.e2" e2="quantitative.s165.e4" id="quantitative.s165.p0" /></sentence><sentence id="quantitative.s166" text="In a formal, single-dose interaction study (n = 6 males) the clearance of mexiletine was decreased by 38% following the coadministration of fluvoxamine, an inhibitor of CYP1A2."><entity charOffset="74-83" id="quantitative.s166.e0" text="mexiletine" type="active-ingredient" /><entity charOffset="140-150" id="quantitative.s166.e1" text="fluvoxamine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s166.e0" e2="quantitative.s166.e1" id="quantitative.s166.p0" /></sentence><sentence id="quantitative.s167" text="In a pharmacokinetic study with patients on methadone maintenance therapy, phenytoin administration (250 mg b.i.d. initially for 1 day followed by 300 mg QD for 3 to 4 days) resulted in an approximately 50% reduction in methadone exposure and withdrawal symptoms occurred concurrently. Upon discontinuation of phenytoin, the incidence of withdrawal symptoms decreased and methadone exposure increased to a level comparable to that prior to phenytoin administration."><entity charOffset="44-52" id="quantitative.s167.e0" text="methadone" type="active-ingredient" /><entity charOffset="220-228" id="quantitative.s167.e1" text="methadone" type="active-ingredient" /><entity charOffset="372-380" id="quantitative.s167.e2" text="methadone" type="active-ingredient" /><entity charOffset="75-83" id="quantitative.s167.e3" text="phenytoin" type="active-ingredient" /><entity charOffset="310-318" id="quantitative.s167.e4" text="phenytoin" type="active-ingredient" /><entity charOffset="440-448" id="quantitative.s167.e5" text="phenytoin" type="active-ingredient" /><pair ddi="true" e1="quantitative.s167.e2" e2="quantitative.s167.e5" id="quantitative.s167.p0" /></sentence><sentence id="quantitative.s168" text="In a placebo-controlled trial in normal volunteers, administration of sertraline for 17 days (including 200 mg/day for the last 10 days) did not change serum digoxin levels or digoxin renal clearance."><entity charOffset="70-79" id="quantitative.s168.e0" text="sertraline" type="active-ingredient" /><entity charOffset="158-164" id="quantitative.s168.e1" text="digoxin" type="active-ingredient" /><entity charOffset="176-182" id="quantitative.s168.e2" text="digoxin" type="active-ingredient" /><pair ddi="false" e1="quantitative.s168.e0" e2="quantitative.s168.e2" id="quantitative.s168.p0" /></sentence><sentence id="quantitative.s169" text="In a placebo-controlled trial in normal volunteers, administration of sertraline for 22 days (including 200 mg/day for the final 13 days) caused a statistically significant 16% decrease from baseline in the clearance of tolbutamide following an intravenous 1000 mg dose."><entity charOffset="70-79" id="quantitative.s169.e0" text="sertraline" type="active-ingredient" /><entity charOffset="220-230" id="quantitative.s169.e1" text="tolbutamide" type="active-ingredient" /><pair ddi="true" e1="quantitative.s169.e0" e2="quantitative.s169.e1" id="quantitative.s169.p0" /></sentence><sentence id="quantitative.s170" text="In a separate study, when a single oral 300-mg dose of phenytoin was administered at paroxetine steady state (30 mg once daily for 14 days), phenytoin AUC was slightly reduced (12% on average) compared to phenytoin administered alone."><entity charOffset="85-94" id="quantitative.s170.e0" text="paroxetine" type="active-ingredient" /><entity charOffset="55-63" id="quantitative.s170.e1" text="phenytoin" type="active-ingredient" /><entity charOffset="141-149" id="quantitative.s170.e2" text="phenytoin" type="active-ingredient" /><entity charOffset="205-213" id="quantitative.s170.e3" text="phenytoin" type="active-ingredient" /><pair ddi="true" e1="quantitative.s170.e0" e2="quantitative.s170.e3" id="quantitative.s170.p0" /></sentence><sentence id="quantitative.s171" text="In a study assessing disposition of sertraline (100 mg) on the second of 8 days of cimetidine administration (800 mg daily), there were significant increases in sertraline mean AUC (50%), C max (24%) and half-life (26%) compared to the placebo group. "><entity charOffset="83-92" id="quantitative.s171.e0" text="cimetidine" type="active-ingredient" /><entity charOffset="36-45" id="quantitative.s171.e1" text="sertraline" type="active-ingredient" /><entity charOffset="161-170" id="quantitative.s171.e2" text="sertraline" type="active-ingredient" /><pair ddi="true" e1="quantitative.s171.e0" e2="quantitative.s171.e2" id="quantitative.s171.p0" /></sentence><sentence id="quantitative.s172" text="In a study comparing the disposition of intravenously administered diazepam before and after 21 days of dosing with either sertraline (50 to 200 mg/day escalating dose) or placebo, there was a 32% decrease relative to baseline in diazepam clearance for the sertraline group compared to a 19% decrease relative to baseline for the placebo group (p &lt; 0.03). "><entity charOffset="67-74" id="quantitative.s172.e0" text="diazepam" type="active-ingredient" /><entity charOffset="230-237" id="quantitative.s172.e1" text="diazepam" type="active-ingredient" /><entity charOffset="123-132" id="quantitative.s172.e2" text="sertraline" type="active-ingredient" /><entity charOffset="257-266" id="quantitative.s172.e3" text="sertraline" type="active-ingredient" /><pair ddi="true" e1="quantitative.s172.e1" e2="quantitative.s172.e3" id="quantitative.s172.p0" /></sentence><sentence id="quantitative.s173" text="In a study comparing the disposition of intravenously administered diazepam before and after 21 days of dosing with either sertraline (50 to 200 mg/day escalating dose) or placebo, there was a 32% decrease relative to baseline in diazepam clearance for the sertraline group compared to a 19% decrease relative to baseline for the placebo group (p &lt; 0.03). There was a 23% increase in T max for desmethyldiazepam in the sertraline group compared to a 20% decrease in the placebo group (p &lt; 0.03). "><entity charOffset="123-132" id="quantitative.s173.e0" text="sertraline" type="active-ingredient" /><entity charOffset="257-266" id="quantitative.s173.e1" text="sertraline" type="active-ingredient" /><entity charOffset="419-428" id="quantitative.s173.e2" text="sertraline" type="active-ingredient" /><entity charOffset="394-410" id="quantitative.s173.e3" text="desmethyldiazepam" type="active-ingredient" /><pair ddi="true" e1="quantitative.s173.e2" e2="quantitative.s173.e3" id="quantitative.s173.p0" /></sentence><sentence id="quantitative.s174" text="In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin."><entity charOffset="37-47" id="quantitative.s174.e0" text="simvastatin" type="active-ingredient" /><entity charOffset="160-168" id="quantitative.s174.e1" text="midazolam" type="active-ingredient" /><pair ddi="false" e1="quantitative.s174.e0" e2="quantitative.s174.e1" id="quantitative.s174.p0" /></sentence><sentence id="quantitative.s175" text="In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin."><entity charOffset="37-47" id="quantitative.s175.e0" text="simvastatin" type="active-ingredient" /><entity charOffset="174-185" id="quantitative.s175.e1" text="erythromycin" type="active-ingredient" /><pair ddi="false" e1="quantitative.s175.e0" e2="quantitative.s175.e1" id="quantitative.s175.p0" /></sentence><sentence id="quantitative.s176" text="In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone. Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine."><entity charOffset="83-93" id="quantitative.s176.e0" text="fluvoxamine" type="active-ingredient" /><entity charOffset="66-72" id="quantitative.s176.e1" text="tacrine" type="active-ingredient" /><entity charOffset="189-195" id="quantitative.s176.e2" text="tacrine" type="active-ingredient" /><entity charOffset="259-265" id="quantitative.s176.e3" text="tacrine" type="active-ingredient" /><entity charOffset="412-418" id="quantitative.s176.e4" text="tacrine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s176.e0" e2="quantitative.s176.e4" id="quantitative.s176.p0" /></sentence><sentence id="quantitative.s177" text="In a study of 6 normal volunteers, a significant decrease in tacrolimus oral bioavailability (14±6% vs. 7±3%) was observed with concomitant rifampin administration (600 mg). In addition, there was a significant increase in tacrolimus clearance (0.036±0.008 L/hr/kg vs. 0.053±0.010 L/hr/kg) with concomitant rifampin administration."><entity charOffset="142-149" id="quantitative.s177.e0" text="rifampin" type="active-ingredient" /><entity charOffset="311-318" id="quantitative.s177.e1" text="rifampin" type="active-ingredient" /><entity charOffset="61-70" id="quantitative.s177.e2" text="tacrolimus" type="active-ingredient" /><entity charOffset="225-234" id="quantitative.s177.e3" text="tacrolimus" type="active-ingredient" /><pair ddi="true" e1="quantitative.s177.e1" e2="quantitative.s177.e3" id="quantitative.s177.p0" /></sentence><sentence id="quantitative.s178" text="In a study of healthy male volunteers, co-administration of sildenafil at steady state (80 mg TID) with bosentan (a moderate inducer of CYP3A, CYP2C9 and possibly of cytochrome P450 2C19) at steady state (125 mg BID) resulted in a 63% decrease of sildenafil AUC and a 55% decrease in sildenafil Cmax. Co-administration resulted in a 50% increase in AUC of bosentan. The combination of both drugs did not lead to clinically significant changes in blood pressure (supine or standing). Concomitant administration of potent CYP3A inducers is expected to cause greater decreases in plasma levels of sildenafil."><entity charOffset="60-69" id="quantitative.s178.e0" text="sildenafil" type="active-ingredient" /><entity charOffset="247-256" id="quantitative.s178.e1" text="sildenafil" type="active-ingredient" /><entity charOffset="284-293" id="quantitative.s178.e2" text="sildenafil" type="active-ingredient" /><entity charOffset="594-603" id="quantitative.s178.e3" text="sildenafil" type="active-ingredient" /><entity charOffset="104-111" id="quantitative.s178.e4" text="bosentan" type="active-ingredient" /><entity charOffset="356-363" id="quantitative.s178.e5" text="bosentan" type="active-ingredient" /><pair ddi="true" e1="quantitative.s178.e3" e2="quantitative.s178.e5" id="quantitative.s178.p0" /></sentence><sentence id="quantitative.s179" text="In a study of healthy male volunteers, co-administration of sildenafil at steady state (80 mg TID) with bosentan (a moderate inducer of CYP3A, CYP2C9 and possibly of cytochrome P450 2C19) at steady state (125 mg BID) resulted in a 63% decrease of sildenafil AUC and a 55% decrease in sildenafil Cmax. Co-administration resulted in a 50% increase in AUC of bosentan. The combination of both drugs did not lead to clinically significant changes in blood pressure (supine or standing). Concomitant administration of potent CYP3A inducers is expected to cause greater decreases in plasma levels of sildenafil."><entity charOffset="60-69" id="quantitative.s179.e0" text="sildenafil" type="active-ingredient" /><entity charOffset="247-256" id="quantitative.s179.e1" text="sildenafil" type="active-ingredient" /><entity charOffset="284-293" id="quantitative.s179.e2" text="sildenafil" type="active-ingredient" /><entity charOffset="594-603" id="quantitative.s179.e3" text="sildenafil" type="active-ingredient" /><entity charOffset="104-111" id="quantitative.s179.e4" text="bosentan" type="active-ingredient" /><entity charOffset="356-363" id="quantitative.s179.e5" text="bosentan" type="active-ingredient" /><pair ddi="true" e1="quantitative.s179.e3" e2="quantitative.s179.e5" id="quantitative.s179.p0" /></sentence><sentence id="quantitative.s180" text="In another formal study (n = 8 extensive and n = 7 poor metabolizers of CYP2D6), coadministration of propafenone did not alter the kinetics of mexiletine in the poor CYP2D6 metabolizer group."><entity charOffset="101-111" id="quantitative.s180.e0" text="propafenone" type="active-ingredient" /><entity charOffset="143-152" id="quantitative.s180.e1" text="mexiletine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s180.e0" e2="quantitative.s180.e1" id="quantitative.s180.p0" /></sentence><sentence id="quantitative.s181" text="In four patients with cardiovascular disease, coadministration of propafenone 150 mg t.i.d. with immediate-release metoprolol 50 mg t.i.d. resulted in two- to five-fold increases in the steady-state concentration of metoprolol."><entity charOffset="115-124" id="quantitative.s181.e0" text="metoprolol" type="active-ingredient" /><entity charOffset="216-225" id="quantitative.s181.e1" text="metoprolol" type="active-ingredient" /><entity charOffset="66-76" id="quantitative.s181.e2" text="propafenone" type="active-ingredient" /><pair ddi="true" e1="quantitative.s181.e1" e2="quantitative.s181.e2" id="quantitative.s181.p0" /></sentence><sentence id="quantitative.s182" text="In healthy subjects with CYP2D6 extensive metabolizer phenotype, coadministration of quinidine 100 mg and immediate-release metoprolol 200 mg tripled the concentration of S-metoprolol and doubled the metoprolol elimination half-life."><entity charOffset="124-133" id="quantitative.s182.e0" text="metoprolol" type="active-ingredient" /><entity charOffset="173-182" id="quantitative.s182.e1" text="metoprolol" type="active-ingredient" /><entity charOffset="200-209" id="quantitative.s182.e2" text="metoprolol" type="active-ingredient" /><entity charOffset="85-93" id="quantitative.s182.e3" text="quinidine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s182.e2" e2="quantitative.s182.e3" id="quantitative.s182.p0" /></sentence><sentence id="quantitative.s183" text="In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin"><entity charOffset="97-103" id="quantitative.s183.e0" text="digoxin" type="active-ingredient" /><entity charOffset="239-245" id="quantitative.s183.e1" text="digoxin" type="active-ingredient" /><entity charOffset="106-115" id="quantitative.s183.e2" text="irbesartan" type="active-ingredient" /><pair ddi="false" e1="quantitative.s183.e1" e2="quantitative.s183.e2" id="quantitative.s183.p0" /></sentence><sentence id="quantitative.s184" text="In study in healthy volunteers, co-administration with ritonavir, a potent CYP3A inhibitor, at steady state (500 mg BID) with sildenafil (100 mg single dose) resulted in a 300% (4-fold) increase in sildenafil Cmax and a 1000% (11-fold) increase in sildenafil plasma AUC. At 24 hours, the plasma levels of sildenafil were still approximately 200 ng/mL, compared to approximately 5 ng/mL when sildenafil was dosed alone. This is consistent with ritonavir's marked effects on a broad range of P450 substrates. "><entity charOffset="55-63" id="quantitative.s184.e0" text="ritonavir" type="active-ingredient" /><entity charOffset="443-451" id="quantitative.s184.e1" text="ritonavir" type="active-ingredient" /><entity charOffset="126-135" id="quantitative.s184.e2" text="sildenafil" type="active-ingredient" /><entity charOffset="198-207" id="quantitative.s184.e3" text="sildenafil" type="active-ingredient" /><entity charOffset="248-257" id="quantitative.s184.e4" text="sildenafil" type="active-ingredient" /><entity charOffset="305-314" id="quantitative.s184.e5" text="sildenafil" type="active-ingredient" /><entity charOffset="391-400" id="quantitative.s184.e6" text="sildenafil" type="active-ingredient" /><pair ddi="true" e1="quantitative.s184.e1" e2="quantitative.s184.e6" id="quantitative.s184.p0" /></sentence><sentence id="quantitative.s185" text="In subjects who had received 21 days of 40 mg/day citalopram, combined administration of 400 mg/day cimetidine for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively."><entity charOffset="100-109" id="quantitative.s185.e0" text="cimetidine" type="active-ingredient" /><entity charOffset="50-59" id="quantitative.s185.e1" text="citalopram" type="active-ingredient" /><entity charOffset="149-158" id="quantitative.s185.e2" text="citalopram" type="active-ingredient" /><pair ddi="true" e1="quantitative.s185.e0" e2="quantitative.s185.e2" id="quantitative.s185.p0" /></sentence><sentence id="quantitative.s186" text="In subjects who had received 21 days of 40 mg/day citalopram, combined administration of citalopram and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin."><entity charOffset="50-59" id="quantitative.s186.e0" text="citalopram" type="active-ingredient" /><entity charOffset="89-98" id="quantitative.s186.e1" text="citalopram" type="active-ingredient" /><entity charOffset="194-203" id="quantitative.s186.e2" text="citalopram" type="active-ingredient" /><entity charOffset="104-110" id="quantitative.s186.e3" text="digoxin" type="active-ingredient" /><entity charOffset="208-214" id="quantitative.s186.e4" text="digoxin" type="active-ingredient" /><pair ddi="false" e1="quantitative.s186.e2" e2="quantitative.s186.e4" id="quantitative.s186.p0" /></sentence><sentence id="quantitative.s187" text="In subjects who had received 21 days of 40 mg/day citalopram, combined administration of citalopram and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin."><entity charOffset="104-110" id="quantitative.s187.e0" text="digoxin" type="active-ingredient" /><entity charOffset="208-214" id="quantitative.s187.e1" text="digoxin" type="active-ingredient" /><entity charOffset="50-59" id="quantitative.s187.e2" text="citalopram" type="active-ingredient" /><entity charOffset="89-98" id="quantitative.s187.e3" text="citalopram" type="active-ingredient" /><entity charOffset="194-203" id="quantitative.s187.e4" text="citalopram" type="active-ingredient" /><pair ddi="false" e1="quantitative.s187.e1" e2="quantitative.s187.e4" id="quantitative.s187.p0" /></sentence><sentence id="quantitative.s188" text="In this crossover steady state study, the pharmacokinetics of propafenone were unaffected in either phenotype by the coadministration of mexiletine."><entity charOffset="137-146" id="quantitative.s188.e0" text="mexiletine" type="active-ingredient" /><entity charOffset="62-72" id="quantitative.s188.e1" text="propafenone" type="active-ingredient" /><pair ddi="false" e1="quantitative.s188.e0" e2="quantitative.s188.e1" id="quantitative.s188.p0" /></sentence><sentence id="quantitative.s189" text="In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions. The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride. These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance. Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%)."><entity charOffset="128-140" id="quantitative.s189.e0" text="carbamazepine" type="active-ingredient" /><entity charOffset="297-309" id="quantitative.s189.e1" text="carbamazepine" type="active-ingredient" /><entity charOffset="47-56" id="quantitative.s189.e2" text="sertraline" type="active-ingredient" /><entity charOffset="231-240" id="quantitative.s189.e3" text="sertraline" type="active-ingredient" /><entity charOffset="351-360" id="quantitative.s189.e4" text="sertraline" type="active-ingredient" /><entity charOffset="516-525" id="quantitative.s189.e5" text="sertraline" type="active-ingredient" /><pair ddi="false" e1="quantitative.s189.e1" e2="quantitative.s189.e5" id="quantitative.s189.p0" /></sentence><sentence id="quantitative.s190" text="In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions. The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride. These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance. Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%)."><entity charOffset="47-56" id="quantitative.s190.e0" text="sertraline" type="active-ingredient" /><entity charOffset="231-240" id="quantitative.s190.e1" text="sertraline" type="active-ingredient" /><entity charOffset="351-360" id="quantitative.s190.e2" text="sertraline" type="active-ingredient" /><entity charOffset="516-525" id="quantitative.s190.e3" text="sertraline" type="active-ingredient" /><entity charOffset="115-125" id="quantitative.s190.e4" text="terfenadine" type="active-ingredient" /><entity charOffset="284-294" id="quantitative.s190.e5" text="terfenadine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s190.e3" e2="quantitative.s190.e5" id="quantitative.s190.p0" /></sentence><sentence id="quantitative.s191" text="In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions. The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride. These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance. Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%)."><entity charOffset="47-56" id="quantitative.s191.e0" text="sertraline" type="active-ingredient" /><entity charOffset="231-240" id="quantitative.s191.e1" text="sertraline" type="active-ingredient" /><entity charOffset="351-360" id="quantitative.s191.e2" text="sertraline" type="active-ingredient" /><entity charOffset="516-525" id="quantitative.s191.e3" text="sertraline" type="active-ingredient" /><entity charOffset="146-154" id="quantitative.s191.e4" text="cisapride" type="active-ingredient" /><entity charOffset="315-323" id="quantitative.s191.e5" text="cisapride" type="active-ingredient" /><entity charOffset="492-500" id="quantitative.s191.e6" text="cisapride" type="active-ingredient" /><entity charOffset="567-575" id="quantitative.s191.e7" text="cisapride" type="active-ingredient" /><entity charOffset="578-586" id="quantitative.s191.e8" text="cisapride" type="active-ingredient" /><pair ddi="false" e1="quantitative.s191.e3" e2="quantitative.s191.e8" id="quantitative.s191.p0" /></sentence><sentence id="quantitative.s192" text="In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6. Therefore, risperidone is not expected to substantially inhibit the clearance of drugs that are metabolized by this enzymatic pathway. In drug interaction studies, risperidone did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6"><entity charOffset="315-323" id="quantitative.s192.e0" text="donepezil" type="active-ingredient" /><entity charOffset="31-41" id="quantitative.s192.e1" text="risperidone" type="active-ingredient" /><entity charOffset="97-107" id="quantitative.s192.e2" text="risperidone" type="active-ingredient" /><entity charOffset="250-260" id="quantitative.s192.e3" text="risperidone" type="active-ingredient" /><pair ddi="false" e1="quantitative.s192.e0" e2="quantitative.s192.e3" id="quantitative.s192.p0" /></sentence><sentence id="quantitative.s193" text="In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6. Therefore, risperidone is not expected to substantially inhibit the clearance of drugs that are metabolized by this enzymatic pathway. In drug interaction studies, risperidone did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6"><entity charOffset="31-41" id="quantitative.s193.e0" text="risperidone" type="active-ingredient" /><entity charOffset="97-107" id="quantitative.s193.e1" text="risperidone" type="active-ingredient" /><entity charOffset="250-260" id="quantitative.s193.e2" text="risperidone" type="active-ingredient" /><entity charOffset="329-339" id="quantitative.s193.e3" text="galantamine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s193.e2" e2="quantitative.s193.e3" id="quantitative.s193.p0" /></sentence><sentence id="quantitative.s194" text="Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax. Indinavir did not affect the pharmacokinetics of venlafaxine and ODV. The clinical significance of this finding is unknown."><entity charOffset="0-8" id="quantitative.s194.e0" text="indinavir" type="active-ingredient" /><entity charOffset="187-195" id="quantitative.s194.e1" text="indinavir" type="active-ingredient" /><entity charOffset="219-227" id="quantitative.s194.e2" text="indinavir" type="active-ingredient" /><entity charOffset="235-243" id="quantitative.s194.e3" text="indinavir" type="active-ingredient" /><entity charOffset="48-58" id="quantitative.s194.e4" text="venlafaxine" type="active-ingredient" /><entity charOffset="284-294" id="quantitative.s194.e5" text="venlafaxine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s194.e3" e2="quantitative.s194.e5" id="quantitative.s194.p0" /></sentence><sentence id="quantitative.s195" text="Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax. Indinavir did not affect the pharmacokinetics of venlafaxine and ODV. The clinical significance of this finding is unknown."><entity charOffset="0-8" id="quantitative.s195.e0" text="indinavir" type="active-ingredient" /><entity charOffset="187-195" id="quantitative.s195.e1" text="indinavir" type="active-ingredient" /><entity charOffset="219-227" id="quantitative.s195.e2" text="indinavir" type="active-ingredient" /><entity charOffset="235-243" id="quantitative.s195.e3" text="indinavir" type="active-ingredient" /><entity charOffset="300-302" id="quantitative.s195.e4" text="ODV" type="metabolite" /><pair ddi="false" e1="quantitative.s195.e3" e2="quantitative.s195.e4" id="quantitative.s195.p0" /></sentence><sentence id="quantitative.s196" text="Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax. Indinavir did not affect the pharmacokinetics of venlafaxine and ODV. The clinical significance of this finding is unknown."><entity charOffset="48-58" id="quantitative.s196.e0" text="venlafaxine" type="active-ingredient" /><entity charOffset="284-294" id="quantitative.s196.e1" text="venlafaxine" type="active-ingredient" /><entity charOffset="0-8" id="quantitative.s196.e2" text="indinavir" type="active-ingredient" /><entity charOffset="187-195" id="quantitative.s196.e3" text="indinavir" type="active-ingredient" /><entity charOffset="219-227" id="quantitative.s196.e4" text="indinavir" type="active-ingredient" /><entity charOffset="235-243" id="quantitative.s196.e5" text="indinavir" type="active-ingredient" /><pair ddi="true" e1="quantitative.s196.e1" e2="quantitative.s196.e5" id="quantitative.s196.p0" /></sentence><sentence id="quantitative.s197" text="Irbesartan: Coadministration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing."><entity charOffset="51-59" id="quantitative.s197.e0" text="aliskiren" type="active-ingredient" /><entity charOffset="0-9" id="quantitative.s197.e1" text="irbesartan" type="active-ingredient" /><entity charOffset="32-41" id="quantitative.s197.e2" text="irbesartan" type="active-ingredient" /><pair ddi="true" e1="quantitative.s197.e0" e2="quantitative.s197.e2" id="quantitative.s197.p0" /></sentence><sentence id="quantitative.s198" text="Irbesartan: In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites by nifedipine. However, in clinical studies, concomitant nifedipine had no effect on irbesartan pharmacokinetics."><entity charOffset="0-9" id="quantitative.s198.e0" text="irbesartan" type="active-ingredient" /><entity charOffset="86-95" id="quantitative.s198.e1" text="irbesartan" type="active-ingredient" /><entity charOffset="194-203" id="quantitative.s198.e2" text="irbesartan" type="active-ingredient" /><entity charOffset="112-121" id="quantitative.s198.e3" text="nifedipine" type="active-ingredient" /><entity charOffset="166-175" id="quantitative.s198.e4" text="nifedipine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s198.e2" e2="quantitative.s198.e4" id="quantitative.s198.p0" /></sentence><sentence id="quantitative.s199" text="Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren"><entity charOffset="0-11" id="quantitative.s199.e0" text="itraconazole" type="active-ingredient" /><entity charOffset="41-52" id="quantitative.s199.e1" text="itraconazole" type="active-ingredient" /><entity charOffset="66-74" id="quantitative.s199.e2" text="aliskiren" type="active-ingredient" /><entity charOffset="160-168" id="quantitative.s199.e3" text="aliskiren" type="active-ingredient" /><pair ddi="true" e1="quantitative.s199.e1" e2="quantitative.s199.e3" id="quantitative.s199.p0" /></sentence><sentence id="quantitative.s200" text="Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole. Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects. Cmax values for ODV increased by 14% and 29% in EM and PM subjects, respectively.\n\nVenlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PM's -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PM's -38% to 105%) subjects, respectively. Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%)."><entity charOffset="0-11" id="quantitative.s200.e0" text="ketoconazole" type="active-ingredient" /><entity charOffset="43-54" id="quantitative.s200.e1" text="ketoconazole" type="active-ingredient" /><entity charOffset="336-347" id="quantitative.s200.e2" text="ketoconazole" type="active-ingredient" /><entity charOffset="286-288" id="quantitative.s200.e3" text="ODV" type="metabolite" /><entity charOffset="439-441" id="quantitative.s200.e4" text="ODV" type="metabolite" /><entity charOffset="627-629" id="quantitative.s200.e5" text="ODV" type="metabolite" /><entity charOffset="756-758" id="quantitative.s200.e6" text="ODV" type="metabolite" /><pair ddi="true" e1="quantitative.s200.e2" e2="quantitative.s200.e6" id="quantitative.s200.p0" /></sentence><sentence id="quantitative.s201" text="Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole. Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects. Cmax values for ODV increased by 14% and 29% in EM and PM subjects, respectively.\n\nVenlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PM's -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PM's -38% to 105%) subjects, respectively. Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%)."><entity charOffset="92-102" id="quantitative.s201.e0" text="venlafaxine" type="active-ingredient" /><entity charOffset="246-256" id="quantitative.s201.e1" text="venlafaxine" type="active-ingredient" /><entity charOffset="273-283" id="quantitative.s201.e2" text="venlafaxine" type="active-ingredient" /><entity charOffset="350-360" id="quantitative.s201.e3" text="venlafaxine" type="active-ingredient" /><entity charOffset="508-518" id="quantitative.s201.e4" text="venlafaxine" type="active-ingredient" /><entity charOffset="740-750" id="quantitative.s201.e5" text="venlafaxine" type="active-ingredient" /><entity charOffset="0-11" id="quantitative.s201.e6" text="ketoconazole" type="active-ingredient" /><entity charOffset="43-54" id="quantitative.s201.e7" text="ketoconazole" type="active-ingredient" /><entity charOffset="336-347" id="quantitative.s201.e8" text="ketoconazole" type="active-ingredient" /><pair ddi="true" e1="quantitative.s201.e5" e2="quantitative.s201.e8" id="quantitative.s201.p0" /></sentence><sentence id="quantitative.s202" text="Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren"><entity charOffset="71-79" id="quantitative.s202.e0" text="aliskiren" type="active-ingredient" /><entity charOffset="141-149" id="quantitative.s202.e1" text="aliskiren" type="active-ingredient" /><entity charOffset="0-11" id="quantitative.s202.e2" text="ketoconazole" type="active-ingredient" /><entity charOffset="53-64" id="quantitative.s202.e3" text="ketoconazole" type="active-ingredient" /><pair ddi="true" e1="quantitative.s202.e1" e2="quantitative.s202.e3" id="quantitative.s202.p0" /></sentence><sentence id="quantitative.s203" text="Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction."><entity charOffset="0-8" id="quantitative.s203.e0" text="lorazepam" type="active-ingredient" /><entity charOffset="132-140" id="quantitative.s203.e1" text="lorazepam" type="active-ingredient" /><entity charOffset="40-58" id="quantitative.s203.e2" text="fluvoxamine maleate" type="active-ingredient" /><pair ddi="false" e1="quantitative.s203.e1" e2="quantitative.s203.e2" id="quantitative.s203.p0" /></sentence><sentence id="quantitative.s204" text="Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction."><entity charOffset="0-8" id="quantitative.s204.e0" text="lorazepam" type="active-ingredient" /><entity charOffset="132-140" id="quantitative.s204.e1" text="lorazepam" type="active-ingredient" /><entity charOffset="40-58" id="quantitative.s204.e2" text="fluvoxamine maleate" type="active-ingredient" /><pair ddi="false" e1="quantitative.s204.e1" e2="quantitative.s204.e2" id="quantitative.s204.p0" /></sentence><sentence id="quantitative.s205" text="Methotrexate and 7-hydromethotrexate: In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and lansoprazole delayed-release capsules 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate. "><entity charOffset="388-408" id="quantitative.s205.e0" text="7-hydroxymethotrexate" type="metabolite" /><entity charOffset="248-255" id="quantitative.s205.e1" text="naproxen" type="active-ingredient" /><pair ddi="false" e1="quantitative.s205.e0" e2="quantitative.s205.e1" id="quantitative.s205.p0" /></sentence><sentence id="quantitative.s206" text="Methotrexate and 7-hydromethotrexate: In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and lansoprazole delayed-release capsules 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate. "><entity charOffset="280-291" id="quantitative.s206.e0" text="lansoprazole" type="active-ingredient" /><entity charOffset="388-408" id="quantitative.s206.e1" text="7-hydroxymethotrexate" type="metabolite" /><pair ddi="false" e1="quantitative.s206.e0" e2="quantitative.s206.e1" id="quantitative.s206.p0" /></sentence><sentence id="quantitative.s207" text="Methotrexate and 7-hydromethotrexate: In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and lansoprazole delayed-release capsules 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate. "><entity charOffset="280-291" id="quantitative.s207.e0" text="lansoprazole" type="active-ingredient" /><entity charOffset="0-11" id="quantitative.s207.e1" text="Methotrexate" type="active-ingredient" /><entity charOffset="24-35" id="quantitative.s207.e2" text="Methotrexate" type="active-ingredient" /><entity charOffset="192-203" id="quantitative.s207.e3" text="Methotrexate" type="active-ingredient" /><entity charOffset="371-382" id="quantitative.s207.e4" text="Methotrexate" type="active-ingredient" /><entity charOffset="397-408" id="quantitative.s207.e5" text="Methotrexate" type="active-ingredient" /><pair ddi="false" e1="quantitative.s207.e0" e2="quantitative.s207.e5" id="quantitative.s207.p0" /></sentence><sentence id="quantitative.s208" text="Methotrexate and 7-hydromethotrexate: In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and lansoprazole delayed-release capsules 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate. "><entity charOffset="0-11" id="quantitative.s208.e0" text="Methotrexate" type="active-ingredient" /><entity charOffset="24-35" id="quantitative.s208.e1" text="Methotrexate" type="active-ingredient" /><entity charOffset="192-203" id="quantitative.s208.e2" text="Methotrexate" type="active-ingredient" /><entity charOffset="371-382" id="quantitative.s208.e3" text="Methotrexate" type="active-ingredient" /><entity charOffset="397-408" id="quantitative.s208.e4" text="Methotrexate" type="active-ingredient" /><entity charOffset="248-255" id="quantitative.s208.e5" text="naproxen" type="active-ingredient" /><pair ddi="false" e1="quantitative.s208.e4" e2="quantitative.s208.e5" id="quantitative.s208.p0" /></sentence><sentence id="quantitative.s209" text="Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, α-hydroxymetoprolol. Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine."><entity charOffset="495-516" id="quantitative.s209.e0" text="O-desmethylvenlafaxine" type="metabolite" /><entity charOffset="0-9" id="quantitative.s209.e1" text="metoprolol" type="active-ingredient" /><entity charOffset="92-101" id="quantitative.s209.e2" text="metoprolol" type="active-ingredient" /><entity charOffset="272-281" id="quantitative.s209.e3" text="metoprolol" type="active-ingredient" /><entity charOffset="389-398" id="quantitative.s209.e4" text="metoprolol" type="active-ingredient" /><entity charOffset="401-410" id="quantitative.s209.e5" text="metoprolol" type="active-ingredient" /><pair ddi="false" e1="quantitative.s209.e0" e2="quantitative.s209.e5" id="quantitative.s209.p0" /></sentence><sentence id="quantitative.s210" text="Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, α-hydroxymetoprolol. Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine."><entity charOffset="43-53" id="quantitative.s210.e0" text="venlafaxine" type="active-ingredient" /><entity charOffset="457-467" id="quantitative.s210.e1" text="venlafaxine" type="active-ingredient" /><entity charOffset="506-516" id="quantitative.s210.e2" text="venlafaxine" type="active-ingredient" /><entity charOffset="0-9" id="quantitative.s210.e3" text="metoprolol" type="active-ingredient" /><entity charOffset="92-101" id="quantitative.s210.e4" text="metoprolol" type="active-ingredient" /><entity charOffset="272-281" id="quantitative.s210.e5" text="metoprolol" type="active-ingredient" /><entity charOffset="389-398" id="quantitative.s210.e6" text="metoprolol" type="active-ingredient" /><entity charOffset="401-410" id="quantitative.s210.e7" text="metoprolol" type="active-ingredient" /><pair ddi="true" e1="quantitative.s210.e2" e2="quantitative.s210.e7" id="quantitative.s210.p0" /></sentence><sentence id="quantitative.s211" text="Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, α-hydroxymetoprolol. Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine."><entity charOffset="43-53" id="quantitative.s211.e0" text="venlafaxine" type="active-ingredient" /><entity charOffset="457-467" id="quantitative.s211.e1" text="venlafaxine" type="active-ingredient" /><entity charOffset="506-516" id="quantitative.s211.e2" text="venlafaxine" type="active-ingredient" /><entity charOffset="0-9" id="quantitative.s211.e3" text="metoprolol" type="active-ingredient" /><entity charOffset="92-101" id="quantitative.s211.e4" text="metoprolol" type="active-ingredient" /><entity charOffset="272-281" id="quantitative.s211.e5" text="metoprolol" type="active-ingredient" /><entity charOffset="389-398" id="quantitative.s211.e6" text="metoprolol" type="active-ingredient" /><entity charOffset="401-410" id="quantitative.s211.e7" text="metoprolol" type="active-ingredient" /><pair ddi="false" e1="quantitative.s211.e2" e2="quantitative.s211.e7" id="quantitative.s211.p0" /></sentence><sentence id="quantitative.s212" text="Nefazodone plasma concentrations were unaffected by alprazolam."><entity charOffset="0-9" id="quantitative.s212.e0" text="Nefazodone" type="active-ingredient" /><entity charOffset="52-61" id="quantitative.s212.e1" text="alprazolam" type="active-ingredient" /><pair ddi="false" e1="quantitative.s212.e0" e2="quantitative.s212.e1" id="quantitative.s212.p0" /></sentence><sentence id="quantitative.s213" text="Nefazodone plasma concentrations were unaffected by triazolam."><entity charOffset="0-9" id="quantitative.s213.e0" text="Nefazodone" type="active-ingredient" /><entity charOffset="52-60" id="quantitative.s213.e1" text="triazolam" type="active-ingredient" /><pair ddi="false" e1="quantitative.s213.e0" e2="quantitative.s213.e1" id="quantitative.s213.p0" /></sentence><sentence id="quantitative.s214" text="No significant effects on the pharmacokinetics of propafenone or lidocaine have been seen following their concomitant use in patients."><entity charOffset="50-60" id="quantitative.s214.e0" text="propafenone" type="active-ingredient" /><entity charOffset="65-73" id="quantitative.s214.e1" text="lidocaine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s214.e0" e2="quantitative.s214.e1" id="quantitative.s214.p0" /></sentence><sentence id="quantitative.s215" text="No significant effects on the pharmacokinetics of propafenone or lidocaine have been seen following their concomitant use in patients."><entity charOffset="50-60" id="quantitative.s215.e0" text="propafenone" type="active-ingredient" /><entity charOffset="65-73" id="quantitative.s215.e1" text="lidocaine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s215.e0" e2="quantitative.s215.e1" id="quantitative.s215.p0" /></sentence><sentence id="quantitative.s216" text="No significant interactions were found between nisoldipine and warfarin or digoxin."><entity charOffset="75-81" id="quantitative.s216.e0" text="digoxin" type="active-ingredient" /><entity charOffset="47-57" id="quantitative.s216.e1" text="nisoldipine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s216.e0" e2="quantitative.s216.e1" id="quantitative.s216.p0" /></sentence><sentence id="quantitative.s217" text="No significant interactions were found between nisoldipine and warfarin or digoxin."><entity charOffset="75-81" id="quantitative.s217.e0" text="digoxin" type="active-ingredient" /><entity charOffset="47-57" id="quantitative.s217.e1" text="nisoldipine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s217.e0" e2="quantitative.s217.e1" id="quantitative.s217.p0" /></sentence><sentence id="quantitative.s218" text="No significant interactions were found between nisoldipine and warfarin or digoxin."><entity charOffset="63-70" id="quantitative.s218.e0" text="warfarin" type="active-ingredient" /><entity charOffset="47-57" id="quantitative.s218.e1" text="nisoldipine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s218.e0" e2="quantitative.s218.e1" id="quantitative.s218.p0" /></sentence><sentence id="quantitative.s219" text="No significant interactions were found between nisoldipine and warfarin or digoxin."><entity charOffset="63-70" id="quantitative.s219.e0" text="warfarin" type="active-ingredient" /><entity charOffset="47-57" id="quantitative.s219.e1" text="nisoldipine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s219.e0" e2="quantitative.s219.e1" id="quantitative.s219.p0" /></sentence><sentence id="quantitative.s220" text="Omeprazole 40 mg daily was given in combination with clarithromycin 500 mg every 8 hours to healthy adult male subjects. The steady state plasma concentrations of omeprazole were increased (Cmax, AUC0-24, and T1/2 increases of 30%, 89% and 34% respectively) by the concomitant administration of clarithromycin."><entity charOffset="53-66" id="quantitative.s220.e0" text="clarithromycin" type="active-ingredient" /><entity charOffset="295-308" id="quantitative.s220.e1" text="clarithromycin" type="active-ingredient" /><entity charOffset="0-9" id="quantitative.s220.e2" text="Omeprazole" type="active-ingredient" /><entity charOffset="163-172" id="quantitative.s220.e3" text="Omeprazole" type="active-ingredient" /><pair ddi="true" e1="quantitative.s220.e1" e2="quantitative.s220.e3" id="quantitative.s220.p0" /></sentence><sentence id="quantitative.s221" text="Omeprazole has been reported to interact with some antiretroviral drugs. The clinical importance and the mechanisms behind these interactions are not always known. Increased gastric pH during omeprazole treatment may change the absorption of the antiretroviral drug. Other possible interaction mechanisms are via CYP2C19. For some antiretroviral drugs, such as atazanavir and nelfinavir, decreased serum levels have been reported when given together with omeprazole. Following multiple doses of nelfinavir (1250 mg, bid) and omeprazole (40 mg, qd), AUC was decreased by 36% and 92%, Cmax by 37% and 89% and Cmin by 39% and 75% respectively for nelfinavir and M8. Following multiple doses of atazanavir (400 mg, qd) and omeprazole (40 mg, qd, 2 hr before atazanavir), AUC was decreased by 94%, Cmax by 96%, and Cmin by 95%."><entity charOffset="376-385" id="quantitative.s221.e0" text="nelfinavir" type="active-ingredient" /><entity charOffset="495-504" id="quantitative.s221.e1" text="nelfinavir" type="active-ingredient" /><entity charOffset="644-653" id="quantitative.s221.e2" text="nelfinavir" type="active-ingredient" /><entity charOffset="0-9" id="quantitative.s221.e3" text="omeprazole" type="active-ingredient" /><entity charOffset="192-201" id="quantitative.s221.e4" text="omeprazole" type="active-ingredient" /><entity charOffset="455-464" id="quantitative.s221.e5" text="omeprazole" type="active-ingredient" /><entity charOffset="525-534" id="quantitative.s221.e6" text="omeprazole" type="active-ingredient" /><entity charOffset="719-728" id="quantitative.s221.e7" text="omeprazole" type="active-ingredient" /><pair ddi="true" e1="quantitative.s221.e2" e2="quantitative.s221.e7" id="quantitative.s221.p0" /></sentence><sentence id="quantitative.s222" text="Omeprazole has been reported to interact with some antiretroviral drugs. The clinical importance and the mechanisms behind these interactions are not always known. Increased gastric pH during omeprazole treatment may change the absorption of the antiretroviral drug. Other possible interaction mechanisms are via CYP2C19. For some antiretroviral drugs, such as atazanavir and nelfinavir, decreased serum levels have been reported when given together with omeprazole. Following multiple doses of nelfinavir (1250 mg, bid) and omeprazole (40 mg, qd), AUC was decreased by 36% and 92%, Cmax by 37% and 89% and Cmin by 39% and 75% respectively for nelfinavir and M8. Following multiple doses of atazanavir (400 mg, qd) and omeprazole (40 mg, qd, 2 hr before atazanavir), AUC was decreased by 94%, Cmax by 96%, and Cmin by 95%."><entity charOffset="0-9" id="quantitative.s222.e0" text="omeprazole" type="active-ingredient" /><entity charOffset="192-201" id="quantitative.s222.e1" text="omeprazole" type="active-ingredient" /><entity charOffset="455-464" id="quantitative.s222.e2" text="omeprazole" type="active-ingredient" /><entity charOffset="525-534" id="quantitative.s222.e3" text="omeprazole" type="active-ingredient" /><entity charOffset="719-728" id="quantitative.s222.e4" text="omeprazole" type="active-ingredient" /><entity charOffset="361-370" id="quantitative.s222.e5" text="atazanavir" type="active-ingredient" /><entity charOffset="691-700" id="quantitative.s222.e6" text="atazanavir" type="active-ingredient" /><entity charOffset="754-763" id="quantitative.s222.e7" text="atazanavir" type="active-ingredient" /><pair ddi="true" e1="quantitative.s222.e4" e2="quantitative.s222.e7" id="quantitative.s222.p0" /></sentence><sentence id="quantitative.s223" text="Oral conivaptan hydrochloride 40 mg twice daily resulted in a 2-fold increase in the AUC and half-life of amlodipine"><entity charOffset="106-115" id="quantitative.s223.e0" text="amlodipine" type="active-ingredient" /><entity charOffset="5-14" id="quantitative.s223.e1" text="conivaptan" type="active-ingredient" /><pair ddi="true" e1="quantitative.s223.e0" e2="quantitative.s223.e1" id="quantitative.s223.p0" /></sentence><sentence id="quantitative.s224" text="Oral contraceptives were administered as a single dose both before and after the oral administration of fluconazole 50 mg once daily for 10 days in 10 healthy women. There was no significant difference in ethinyl estradiol or levonorgestrel AUC after the administration of 50 mg of fluconazole. The mean increase in ethinyl estradiol AUC was 6% (range: -47 to 108%) and levonorgestrel AUC increased 17% (range: -33 to 141%)."><entity charOffset="104-114" id="quantitative.s224.e0" text="fluconazole" type="active-ingredient" /><entity charOffset="282-292" id="quantitative.s224.e1" text="fluconazole" type="active-ingredient" /><entity charOffset="226-239" id="quantitative.s224.e2" text="levonorgestrel" type="active-ingredient" /><entity charOffset="370-383" id="quantitative.s224.e3" text="levonorgestrel" type="active-ingredient" /><pair ddi="true" e1="quantitative.s224.e1" e2="quantitative.s224.e3" id="quantitative.s224.p0" /></sentence><sentence id="quantitative.s225" text="Oral contraceptives were administered as a single dose both before and after the oral administration of fluconazole 50 mg once daily for 10 days in 10 healthy women. There was no significant difference in ethinyl estradiol or levonorgestrel AUC after the administration of 50 mg of fluconazole. The mean increase in ethinyl estradiol AUC was 6% (range: -47 to 108%) and levonorgestrel AUC increased 17% (range: -33 to 141%)."><entity charOffset="104-114" id="quantitative.s225.e0" text="fluconazole" type="active-ingredient" /><entity charOffset="282-292" id="quantitative.s225.e1" text="fluconazole" type="active-ingredient" /><entity charOffset="205-221" id="quantitative.s225.e2" text="ethinyl estradiol" type="active-ingredient" /><entity charOffset="316-332" id="quantitative.s225.e3" text="ethinyl estradiol" type="active-ingredient" /><pair ddi="true" e1="quantitative.s225.e1" e2="quantitative.s225.e3" id="quantitative.s225.p0" /></sentence><sentence id="quantitative.s226" text="Phenobarbital induces many cytochrome P450 (oxidative) enzymes. When a single oral 30-mg dose of immediate-release paroxetine was administered at phenobarbital steady state (100 mg once daily for 14 days), paroxetine AUC and T½ were reduced (by an average of 25% and 38%, respectively) compared to paroxetine administered alone. The effect of paroxetine on phenobarbital pharmacokinetics was not studied. Since paroxetine exhibits nonlinear pharmacokinetics, the results of this study may not address the case where the 2 drugs are both being chronically dosed. No initial dosage adjustment with Paroxetine Hydrochloride Controlled-Release Tablets is considered necessary when coadministered with phenobarbital; any subsequent adjustment should be guided by clinical effect."><entity charOffset="0-12" id="quantitative.s226.e0" text="phenobarbital" type="active-ingredient" /><entity charOffset="146-158" id="quantitative.s226.e1" text="phenobarbital" type="active-ingredient" /><entity charOffset="358-370" id="quantitative.s226.e2" text="phenobarbital" type="active-ingredient" /><entity charOffset="698-710" id="quantitative.s226.e3" text="phenobarbital" type="active-ingredient" /><entity charOffset="597-620" id="quantitative.s226.e4" text="Paroxetine Hydrochloride" type="active-ingredient" /><pair ddi="true" e1="quantitative.s226.e3" e2="quantitative.s226.e4" id="quantitative.s226.p0" /></sentence><sentence id="quantitative.s227" text="Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations. In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL. The steady-state Cmin concentration increased to 17.8 micrograms/mL when 2400 mg/day of felbamate was coadministered for one week."><entity charOffset="35-43" id="quantitative.s227.e0" text="felbamate" type="active-ingredient" /><entity charOffset="359-367" id="quantitative.s227.e1" text="felbamate" type="active-ingredient" /><entity charOffset="0-12" id="quantitative.s227.e2" text="phenobarbital" type="active-ingredient" /><entity charOffset="50-62" id="quantitative.s227.e3" text="phenobarbital" type="active-ingredient" /><entity charOffset="86-98" id="quantitative.s227.e4" text="phenobarbital" type="active-ingredient" /><entity charOffset="173-185" id="quantitative.s227.e5" text="phenobarbital" type="active-ingredient" /><entity charOffset="219-231" id="quantitative.s227.e6" text="phenobarbital" type="active-ingredient" /><pair ddi="true" e1="quantitative.s227.e1" e2="quantitative.s227.e6" id="quantitative.s227.p0" /></sentence><sentence id="quantitative.s228" text="Phenytoin AUC was determined after 4 days of phenytoin dosing (200 mg daily, orally for 3 days followed by 250 mg intravenously for one dose) both with and without the administration of fluconazole (oral fluconazole 200 mg daily for 16 days) in 10 normal male volunteers. There was a significant increase in phenytoin AUC. The mean ± SD increase in phenytoin AUC was 88% ± 68% (range: 16 to 247%). The absolute magnitude of this interaction is unknown because of the intrinsically nonlinear disposition of phenytoin."><entity charOffset="0-8" id="quantitative.s228.e0" text="phenytoin" type="active-ingredient" /><entity charOffset="45-53" id="quantitative.s228.e1" text="phenytoin" type="active-ingredient" /><entity charOffset="308-316" id="quantitative.s228.e2" text="phenytoin" type="active-ingredient" /><entity charOffset="350-358" id="quantitative.s228.e3" text="phenytoin" type="active-ingredient" /><entity charOffset="508-516" id="quantitative.s228.e4" text="phenytoin" type="active-ingredient" /><entity charOffset="186-196" id="quantitative.s228.e5" text="fluconazole" type="active-ingredient" /><entity charOffset="204-214" id="quantitative.s228.e6" text="fluconazole" type="active-ingredient" /><pair ddi="true" e1="quantitative.s228.e4" e2="quantitative.s228.e6" id="quantitative.s228.p0" /></sentence><sentence id="quantitative.s229" text="Phenytoin: Felbatol® causes an increase in steady-state phenytoin plasma concentrations. In 10 otherwise healthy subjects with epilepsy ingesting phenytoin, the steady-state trough (Cmin) phenytoin plasma concentration was 17±5 micrograms/mL. The steady-state Cmin increased to 21±5 micrograms/mL when 1200 mg/day of felbamate was coadministered. Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25±7 micrograms/mL. In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.\n\nIn a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol® therapy resulted in phenytoin levels comparable to those prior to Felbatol® administration."><entity charOffset="11-18" id="quantitative.s229.e0" text="Felbatol" type="drug-product" /><entity charOffset="787-794" id="quantitative.s229.e1" text="Felbatol" type="drug-product" /><entity charOffset="864-871" id="quantitative.s229.e2" text="Felbatol" type="drug-product" /><entity charOffset="0-8" id="quantitative.s229.e3" text="phenytoin" type="active-ingredient" /><entity charOffset="57-65" id="quantitative.s229.e4" text="phenytoin" type="active-ingredient" /><entity charOffset="147-155" id="quantitative.s229.e5" text="phenytoin" type="active-ingredient" /><entity charOffset="189-197" id="quantitative.s229.e6" text="phenytoin" type="active-ingredient" /><entity charOffset="447-455" id="quantitative.s229.e7" text="phenytoin" type="active-ingredient" /><entity charOffset="507-515" id="quantitative.s229.e8" text="phenytoin" type="active-ingredient" /><entity charOffset="601-609" id="quantitative.s229.e9" text="phenytoin" type="active-ingredient" /><entity charOffset="751-759" id="quantitative.s229.e10" text="phenytoin" type="active-ingredient" /><entity charOffset="818-826" id="quantitative.s229.e11" text="phenytoin" type="active-ingredient" /><pair ddi="true" e1="quantitative.s229.e2" e2="quantitative.s229.e11" id="quantitative.s229.p0" /></sentence><sentence id="quantitative.s230" text="Phenytoin: Nifedipine is metabolized by CYP3A4. Coadministration of nifedipine 10 mg capsule and 60 mg nifedipine coat-core tablet with phenytoin, an inducer of CYP3A4, lowered the AUC and Cmax of nifedipine by approximately 70%. When using nifedipine with phenytoin, the clinical response to nifedipine should be monitored and its dose adjusted if necessary."><entity charOffset="11-20" id="quantitative.s230.e0" text="nifedipine" type="active-ingredient" /><entity charOffset="68-77" id="quantitative.s230.e1" text="nifedipine" type="active-ingredient" /><entity charOffset="103-112" id="quantitative.s230.e2" text="nifedipine" type="active-ingredient" /><entity charOffset="197-206" id="quantitative.s230.e3" text="nifedipine" type="active-ingredient" /><entity charOffset="241-250" id="quantitative.s230.e4" text="nifedipine" type="active-ingredient" /><entity charOffset="293-302" id="quantitative.s230.e5" text="nifedipine" type="active-ingredient" /><entity charOffset="0-8" id="quantitative.s230.e6" text="phenytoin" type="active-ingredient" /><entity charOffset="136-144" id="quantitative.s230.e7" text="phenytoin" type="active-ingredient" /><entity charOffset="257-265" id="quantitative.s230.e8" text="phenytoin" type="active-ingredient" /><pair ddi="true" e1="quantitative.s230.e5" e2="quantitative.s230.e8" id="quantitative.s230.p0" /></sentence><sentence id="quantitative.s231" text="Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol® (felbamate) at steady-state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol® as compared to the same dose of Felbatol® given as monotherapy."><entity charOffset="0-8" id="quantitative.s231.e0" text="phenytoin" type="active-ingredient" /><entity charOffset="11-19" id="quantitative.s231.e1" text="phenytoin" type="active-ingredient" /><entity charOffset="143-151" id="quantitative.s231.e2" text="phenytoin" type="active-ingredient" /><entity charOffset="72-79" id="quantitative.s231.e3" text="Felbatol" type="drug-product" /><entity charOffset="233-240" id="quantitative.s231.e4" text="Felbatol" type="drug-product" /><entity charOffset="276-283" id="quantitative.s231.e5" text="Felbatol" type="drug-product" /><pair ddi="true" e1="quantitative.s231.e2" e2="quantitative.s231.e5" id="quantitative.s231.p0" /></sentence><sentence id="quantitative.s232" text="Phenytoin: Phenytoin plasma levels have been reported to be low in some patients receiving zidovudine, while in one case a high level was documented. However, in a pharmacokinetic interaction study in which 12 HIV-1-positive volunteers received a single 300 mg phenytoin dose alone and during steady-state zidovudine conditions (200 mg every 4 hours), no change in phenytoin kinetics was observed. Although not designed to optimally assess the effect of phenytoin on zidovudine kinetics, a 30% decrease in oral zidovudine clearance was observed with phenytoin."><entity charOffset="0-8" id="quantitative.s232.e0" text="phenytoin" type="active-ingredient" /><entity charOffset="11-19" id="quantitative.s232.e1" text="phenytoin" type="active-ingredient" /><entity charOffset="261-269" id="quantitative.s232.e2" text="phenytoin" type="active-ingredient" /><entity charOffset="365-373" id="quantitative.s232.e3" text="phenytoin" type="active-ingredient" /><entity charOffset="454-462" id="quantitative.s232.e4" text="phenytoin" type="active-ingredient" /><entity charOffset="550-558" id="quantitative.s232.e5" text="phenytoin" type="active-ingredient" /><entity charOffset="91-100" id="quantitative.s232.e6" text="zidovudine" type="active-ingredient" /><entity charOffset="306-315" id="quantitative.s232.e7" text="zidovudine" type="active-ingredient" /><entity charOffset="467-476" id="quantitative.s232.e8" text="zidovudine" type="active-ingredient" /><entity charOffset="511-520" id="quantitative.s232.e9" text="zidovudine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s232.e5" e2="quantitative.s232.e9" id="quantitative.s232.p0" /></sentence><sentence id="quantitative.s233" text="Plasma zidovudine concentrations were determined on two occasions (before and following fluconazole 200 mg daily for 15 days) in 13 volunteers with AIDS or ARC who were on a stable zidovudine dose for at least two weeks. There was a significant increase in zidovudine AUC following the administration of fluconazole. The mean ± SD increase in AUC was 20% ± 32% (range: -27 to 104%). The metabolite, GZDV, to parent drug ratio significantly decreased after the administration of fluconazole, from 7.6 ± 3.6 to 5.7 ± 2.2."><entity charOffset="401-404" id="quantitative.s233.e0" text="gzdv" type="metabolite" /><entity charOffset="88-98" id="quantitative.s233.e1" text="fluconazole" type="active-ingredient" /><entity charOffset="304-314" id="quantitative.s233.e2" text="fluconazole" type="active-ingredient" /><entity charOffset="480-490" id="quantitative.s233.e3" text="fluconazole" type="active-ingredient" /><pair ddi="true" e1="quantitative.s233.e0" e2="quantitative.s233.e3" id="quantitative.s233.p0" /></sentence><sentence id="quantitative.s234" text="Plasma zidovudine concentrations were determined on two occasions (before and following fluconazole 200 mg daily for 15 days) in 13 volunteers with AIDS or ARC who were on a stable zidovudine dose for at least two weeks. There was a significant increase in zidovudine AUC following the administration of fluconazole. The mean ± SD increase in AUC was 20% ± 32% (range: -27 to 104%). The metabolite, GZDV, to parent drug ratio significantly decreased after the administration of fluconazole, from 7.6 ± 3.6 to 5.7 ± 2.2."><entity charOffset="7-16" id="quantitative.s234.e0" text="zidovudine" type="active-ingredient" /><entity charOffset="181-190" id="quantitative.s234.e1" text="zidovudine" type="active-ingredient" /><entity charOffset="257-266" id="quantitative.s234.e2" text="zidovudine" type="active-ingredient" /><entity charOffset="88-98" id="quantitative.s234.e3" text="fluconazole" type="active-ingredient" /><entity charOffset="304-314" id="quantitative.s234.e4" text="fluconazole" type="active-ingredient" /><entity charOffset="480-490" id="quantitative.s234.e5" text="fluconazole" type="active-ingredient" /><pair ddi="true" e1="quantitative.s234.e2" e2="quantitative.s234.e5" id="quantitative.s234.p0" /></sentence><sentence id="quantitative.s235" text="Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers. These results suggest that the absorption of oral rosiglitazone is not altered in conditions accompanied by increases in gastrointestinal pH"><entity charOffset="18-27" id="quantitative.s235.e0" text="ranitidine" type="active-ingredient" /><entity charOffset="142-154" id="quantitative.s235.e1" text="rosiglitazone" type="active-ingredient" /><entity charOffset="229-241" id="quantitative.s235.e2" text="rosiglitazone" type="active-ingredient" /><pair ddi="false" e1="quantitative.s235.e0" e2="quantitative.s235.e2" id="quantitative.s235.p0" /></sentence><sentence id="quantitative.s236" text="Propranolol does not affect the pharmacokinetics of verapamil and norverapamil. Verapamil does not affect the pharmacokinetics of propranolol"><entity charOffset="0-10" id="quantitative.s236.e0" text="propranolol" type="active-ingredient" /><entity charOffset="130-140" id="quantitative.s236.e1" text="propranolol" type="active-ingredient" /><entity charOffset="52-60" id="quantitative.s236.e2" text="verapamil" type="active-ingredient" /><entity charOffset="69-77" id="quantitative.s236.e3" text="verapamil" type="active-ingredient" /><entity charOffset="80-88" id="quantitative.s236.e4" text="verapamil" type="active-ingredient" /><pair ddi="false" e1="quantitative.s236.e1" e2="quantitative.s236.e4" id="quantitative.s236.p0" /></sentence><sentence id="quantitative.s237" text="Propranolol does not affect the pharmacokinetics of verapamil and norverapamil. Verapamil does not affect the pharmacokinetics of propranolol"><entity charOffset="0-10" id="quantitative.s237.e0" text="propranolol" type="active-ingredient" /><entity charOffset="130-140" id="quantitative.s237.e1" text="propranolol" type="active-ingredient" /><entity charOffset="66-77" id="quantitative.s237.e2" text="norverapamil" type="active-ingredient" /><pair ddi="false" e1="quantitative.s237.e1" e2="quantitative.s237.e2" id="quantitative.s237.p0" /></sentence><sentence id="quantitative.s238" text="Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration."><entity charOffset="63-73" id="quantitative.s238.e0" text="nisoldipine" type="active-ingredient" /><entity charOffset="0-8" id="quantitative.s238.e1" text="Quinidine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s238.e0" e2="quantitative.s238.e1" id="quantitative.s238.p0" /></sentence><sentence id="quantitative.s239" text="Quinupristin/Dalfopristin:In vitro drug interaction studies have demonstrated that quinupristin/dalfopristin significantly inhibits the CYP3A metabolism of nifedipine. Concomitant administration of quinupristin/dalfopristin and nifedipine (repeated oral dose) in healthy volunteers increased AUC and Cmax for nifedipine by factors of 1.44 and 1.18, respectively, compared to nifedipine monotherapy. Upon coadministration of quinupristin/dalfopristin with nifedipine, blood pressure should be monitored and a reduction of the dose of nifedipine considered"><entity charOffset="156-165" id="quantitative.s239.e0" text="nifedipine" type="active-ingredient" /><entity charOffset="228-237" id="quantitative.s239.e1" text="nifedipine" type="active-ingredient" /><entity charOffset="309-318" id="quantitative.s239.e2" text="nifedipine" type="active-ingredient" /><entity charOffset="375-384" id="quantitative.s239.e3" text="nifedipine" type="active-ingredient" /><entity charOffset="455-464" id="quantitative.s239.e4" text="nifedipine" type="active-ingredient" /><entity charOffset="533-542" id="quantitative.s239.e5" text="nifedipine" type="active-ingredient" /><entity charOffset="13-24" id="quantitative.s239.e6" text="dalfopristin" type="active-ingredient" /><entity charOffset="96-107" id="quantitative.s239.e7" text="dalfopristin" type="active-ingredient" /><entity charOffset="211-222" id="quantitative.s239.e8" text="dalfopristin" type="active-ingredient" /><entity charOffset="437-448" id="quantitative.s239.e9" text="dalfopristin" type="active-ingredient" /><pair ddi="true" e1="quantitative.s239.e5" e2="quantitative.s239.e9" id="quantitative.s239.p0" /></sentence><sentence id="quantitative.s240" text="Quinupristin/Dalfopristin:In vitro drug interaction studies have demonstrated that quinupristin/dalfopristin significantly inhibits the CYP3A metabolism of nifedipine. Concomitant administration of quinupristin/dalfopristin and nifedipine (repeated oral dose) in healthy volunteers increased AUC and Cmax for nifedipine by factors of 1.44 and 1.18, respectively, compared to nifedipine monotherapy. Upon coadministration of quinupristin/dalfopristin with nifedipine, blood pressure should be monitored and a reduction of the dose of nifedipine considered."><entity charOffset="0-11" id="quantitative.s240.e0" text="quinupristin" type="active-ingredient" /><entity charOffset="83-94" id="quantitative.s240.e1" text="quinupristin" type="active-ingredient" /><entity charOffset="198-209" id="quantitative.s240.e2" text="quinupristin" type="active-ingredient" /><entity charOffset="424-435" id="quantitative.s240.e3" text="quinupristin" type="active-ingredient" /><entity charOffset="156-165" id="quantitative.s240.e4" text="nifedipine" type="active-ingredient" /><entity charOffset="228-237" id="quantitative.s240.e5" text="nifedipine" type="active-ingredient" /><entity charOffset="309-318" id="quantitative.s240.e6" text="nifedipine" type="active-ingredient" /><entity charOffset="375-384" id="quantitative.s240.e7" text="nifedipine" type="active-ingredient" /><entity charOffset="455-464" id="quantitative.s240.e8" text="nifedipine" type="active-ingredient" /><entity charOffset="533-542" id="quantitative.s240.e9" text="nifedipine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s240.e3" e2="quantitative.s240.e9" id="quantitative.s240.p0" /></sentence><sentence id="quantitative.s241" text="ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%"><entity charOffset="48-67" id="quantitative.s241.e0" text="9-hydroxyrisperidone" type="metabolite" /><entity charOffset="0-9" id="quantitative.s241.e1" text="ranitidine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s241.e0" e2="quantitative.s241.e1" id="quantitative.s241.p0" /></sentence><sentence id="quantitative.s242" text="ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%"><entity charOffset="32-42" id="quantitative.s242.e0" text="risperidone" type="active-ingredient" /><entity charOffset="57-67" id="quantitative.s242.e1" text="risperidone" type="active-ingredient" /><entity charOffset="0-9" id="quantitative.s242.e2" text="ranitidine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s242.e1" e2="quantitative.s242.e2" id="quantitative.s242.p0" /></sentence><sentence id="quantitative.s243" text="Repeat dose administration of oral voriconazole (400mg Q12h for 1 day, then 200mg Q12h for 4 days) increased the Cmax and AUC of (R)-methadone by 31% and 47%, respectively, in subjects receiving a methadone maintenance dose (30 to 100 mg QD). The Cmax and AUC of (S)-methadone increased by 65% and 103%, respectively."><entity charOffset="35-46" id="quantitative.s243.e0" text="voriconazole" type="active-ingredient" /><entity charOffset="133-141" id="quantitative.s243.e1" text="methadone" type="active-ingredient" /><entity charOffset="197-205" id="quantitative.s243.e2" text="methadone" type="active-ingredient" /><entity charOffset="267-275" id="quantitative.s243.e3" text="methadone" type="active-ingredient" /><pair ddi="true" e1="quantitative.s243.e0" e2="quantitative.s243.e3" id="quantitative.s243.p0" /></sentence><sentence id="quantitative.s244" text="Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers."><entity charOffset="19-25" id="quantitative.s244.e0" text="avandia" type="drug-product" /><entity charOffset="101-108" id="quantitative.s244.e1" text="warfarin" type="active-ingredient" /><pair ddi="false" e1="quantitative.s244.e0" e2="quantitative.s244.e1" id="quantitative.s244.p0" /></sentence><sentence id="quantitative.s245" text="Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers"><entity charOffset="111-117" id="quantitative.s245.e0" text="digoxin" type="active-ingredient" /><entity charOffset="22-28" id="quantitative.s245.e1" text="avandia" type="drug-product" /><pair ddi="false" e1="quantitative.s245.e0" e2="quantitative.s245.e1" id="quantitative.s245.p0" /></sentence><sentence id="quantitative.s246" text="Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13)"><entity charOffset="23-33" id="quantitative.s246.e0" text="risperidone" type="active-ingredient" /><entity charOffset="128-134" id="quantitative.s246.e1" text="lithium" type="active-ingredient" /><pair ddi="false" e1="quantitative.s246.e0" e2="quantitative.s246.e1" id="quantitative.s246.p0" /></sentence><sentence id="quantitative.s247" text="Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21). However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone"><entity charOffset="136-144" id="quantitative.s247.e0" text="valproate" type="active-ingredient" /><entity charOffset="248-256" id="quantitative.s247.e1" text="valproate" type="active-ingredient" /><entity charOffset="23-33" id="quantitative.s247.e2" text="risperidone" type="active-ingredient" /><entity charOffset="327-337" id="quantitative.s247.e3" text="risperidone" type="active-ingredient" /><pair ddi="true" e1="quantitative.s247.e1" e2="quantitative.s247.e3" id="quantitative.s247.p0" /></sentence><sentence id="quantitative.s248" text="Results of a placebo-controlled trial in normal volunteers suggest that chronic administration of sertraline 200 mg/day does not produce clinically important inhibition of phenytoin metabolism. "><entity charOffset="98-107" id="quantitative.s248.e0" text="sertraline" type="active-ingredient" /><entity charOffset="172-180" id="quantitative.s248.e1" text="phenytoin" type="active-ingredient" /><pair ddi="false" e1="quantitative.s248.e0" e2="quantitative.s248.e1" id="quantitative.s248.p0" /></sentence><sentence id="quantitative.s249" text="Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone"><entity charOffset="0-7" id="quantitative.s249.e0" text="rifampin" type="active-ingredient" /><entity charOffset="102-114" id="quantitative.s249.e1" text="rosiglitazone" type="active-ingredient" /><entity charOffset="162-174" id="quantitative.s249.e2" text="rosiglitazone" type="active-ingredient" /><pair ddi="true" e1="quantitative.s249.e0" e2="quantitative.s249.e2" id="quantitative.s249.p0" /></sentence><sentence id="quantitative.s250" text="Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin"><entity charOffset="103-109" id="quantitative.s250.e0" text="digoxin" type="active-ingredient" /><entity charOffset="0-10" id="quantitative.s250.e1" text="risperidone" type="active-ingredient" /><pair ddi="false" e1="quantitative.s250.e0" e2="quantitative.s250.e1" id="quantitative.s250.p0" /></sentence><sentence id="quantitative.s251" text="Rosiglitazone: Coadministration of rosiglitazone (4 mg b.i.d.) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine."><entity charOffset="0-12" id="quantitative.s251.e0" text="rosiglitazone" type="active-ingredient" /><entity charOffset="35-47" id="quantitative.s251.e1" text="rosiglitazone" type="active-ingredient" /><entity charOffset="138-147" id="quantitative.s251.e2" text="nifedipine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s251.e1" e2="quantitative.s251.e2" id="quantitative.s251.p0" /></sentence><sentence id="quantitative.s252" text="SEPTRA may inhibit the hepatic metabolism of phenytoin. SEPTRA, given at a common clinical dosage, increased the phenytoin half-life by 39% and decreased the phenytoin metabolic clearance rate by 27%. When administering these drugs concurrently, one should be alert for possible excessive phenytoin effect."><entity charOffset="45-53" id="quantitative.s252.e0" text="phenytoin" type="active-ingredient" /><entity charOffset="113-121" id="quantitative.s252.e1" text="phenytoin" type="active-ingredient" /><entity charOffset="158-166" id="quantitative.s252.e2" text="phenytoin" type="active-ingredient" /><entity charOffset="289-297" id="quantitative.s252.e3" text="phenytoin" type="active-ingredient" /><entity charOffset="0-5" id="quantitative.s252.e4" text="septra" type="drug-product" /><entity charOffset="56-61" id="quantitative.s252.e5" text="septra" type="drug-product" /><pair ddi="true" e1="quantitative.s252.e3" e2="quantitative.s252.e5" id="quantitative.s252.p0" /></sentence><sentence id="quantitative.s253" text="Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA. No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects"><entity charOffset="21-31" id="quantitative.s253.e0" text="glimepiride" type="active-ingredient" /><entity charOffset="188-198" id="quantitative.s253.e1" text="glimepiride" type="active-ingredient" /><entity charOffset="139-145" id="quantitative.s253.e2" text="avandia" type="drug-product" /><entity charOffset="249-255" id="quantitative.s253.e3" text="avandia" type="drug-product" /><pair ddi="false" e1="quantitative.s253.e1" e2="quantitative.s253.e3" id="quantitative.s253.p0" /></sentence><sentence id="quantitative.s254" text="Sirolimus (CYP3A4 substrate): Repeat dose administration of oral voriconazole (400 mg Q12h for 1 day, then 200 mg Q12h for 8 days) increased the Cmax and AUC of sirolimus (2 mg single dose) an average of 7-fold (90% CI: 5.7, 7.5) and 11-fold (90% CI: 9.9, 12.6), respectively, in healthy male subjects. "><entity charOffset="0-8" id="quantitative.s254.e0" text="sirolimus" type="active-ingredient" /><entity charOffset="161-169" id="quantitative.s254.e1" text="sirolimus" type="active-ingredient" /><entity charOffset="65-76" id="quantitative.s254.e2" text="voriconazole" type="active-ingredient" /><pair ddi="true" e1="quantitative.s254.e1" e2="quantitative.s254.e2" id="quantitative.s254.p0" /></sentence><sentence id="quantitative.s255" text="Small doses of quinidine completely inhibit the CYP2D6 hydroxylation metabolic pathway, making all patients, in effect, slow metabolizers [see Clinical Pharmacology (12)]. Concomitant administration of quinidine (50 mg three times daily) with 150 mg immediate-release propafenone three times daily decreased the clearance of propafenone by 60% in EM, making them PM. Steady-state plasma concentrations increased by more that 2-fold for propafenone, and decreased 50% for 5OH-propafenone. A 100 mg dose of quinidine increased steady state concentrations of propafenone 3-fold. Avoid concomitant use of propafenone and quinidine."><entity charOffset="268-278" id="quantitative.s255.e0" text="propafenone" type="active-ingredient" /><entity charOffset="325-335" id="quantitative.s255.e1" text="propafenone" type="active-ingredient" /><entity charOffset="436-446" id="quantitative.s255.e2" text="propafenone" type="active-ingredient" /><entity charOffset="475-485" id="quantitative.s255.e3" text="propafenone" type="active-ingredient" /><entity charOffset="556-566" id="quantitative.s255.e4" text="propafenone" type="active-ingredient" /><entity charOffset="601-611" id="quantitative.s255.e5" text="propafenone" type="active-ingredient" /><entity charOffset="15-23" id="quantitative.s255.e6" text="quinidine" type="active-ingredient" /><entity charOffset="202-210" id="quantitative.s255.e7" text="quinidine" type="active-ingredient" /><entity charOffset="505-513" id="quantitative.s255.e8" text="quinidine" type="active-ingredient" /><entity charOffset="617-625" id="quantitative.s255.e9" text="quinidine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s255.e5" e2="quantitative.s255.e9" id="quantitative.s255.p0" /></sentence><sentence id="quantitative.s256" text="Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, or clarithromycin in healthy subjects"><entity charOffset="165-174" id="quantitative.s256.e0" text="antipyrine" type="active-ingredient" /><entity charOffset="24-35" id="quantitative.s256.e1" text="lansoprazole" type="active-ingredient" /><pair ddi="false" e1="quantitative.s256.e0" e2="quantitative.s256.e1" id="quantitative.s256.p0" /></sentence><sentence id="quantitative.s257" text="Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, or clarithromycin in healthy subjects"><entity charOffset="238-245" id="quantitative.s257.e0" text="diazepam" type="active-ingredient" /><entity charOffset="24-35" id="quantitative.s257.e1" text="lansoprazole" type="active-ingredient" /><pair ddi="false" e1="quantitative.s257.e0" e2="quantitative.s257.e1" id="quantitative.s257.p0" /></sentence><sentence id="quantitative.s258" text="Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, or clarithromycin in healthy subjects"><entity charOffset="191-199" id="quantitative.s258.e0" text="ibuprofen" type="active-ingredient" /><entity charOffset="24-35" id="quantitative.s258.e1" text="lansoprazole" type="active-ingredient" /><pair ddi="false" e1="quantitative.s258.e0" e2="quantitative.s258.e1" id="quantitative.s258.p0" /></sentence><sentence id="quantitative.s259" text="Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, or clarithromycin in healthy subjects"><entity charOffset="24-35" id="quantitative.s259.e0" text="lansoprazole" type="active-ingredient" /><entity charOffset="251-264" id="quantitative.s259.e1" text="clarithromycin" type="active-ingredient" /><pair ddi="false" e1="quantitative.s259.e0" e2="quantitative.s259.e1" id="quantitative.s259.p0" /></sentence><sentence id="quantitative.s260" text="Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, or clarithromycin in healthy subjects"><entity charOffset="24-35" id="quantitative.s260.e0" text="lansoprazole" type="active-ingredient" /><entity charOffset="226-235" id="quantitative.s260.e1" text="prednisone" type="active-ingredient" /><pair ddi="false" e1="quantitative.s260.e0" e2="quantitative.s260.e1" id="quantitative.s260.p0" /></sentence><sentence id="quantitative.s261" text="Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, or clarithromycin in healthy subjects"><entity charOffset="24-35" id="quantitative.s261.e0" text="lansoprazole" type="active-ingredient" /><entity charOffset="177-188" id="quantitative.s261.e1" text="indomethacin" type="active-ingredient" /><pair ddi="false" e1="quantitative.s261.e0" e2="quantitative.s261.e1" id="quantitative.s261.p0" /></sentence><sentence id="quantitative.s262" text="Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, or clarithromycin in healthy subjects"><entity charOffset="24-35" id="quantitative.s262.e0" text="lansoprazole" type="active-ingredient" /><entity charOffset="213-223" id="quantitative.s262.e1" text="propranolol" type="active-ingredient" /><pair ddi="false" e1="quantitative.s262.e0" e2="quantitative.s262.e1" id="quantitative.s262.p0" /></sentence><sentence id="quantitative.s263" text="Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, or clarithromycin in healthy subjects"><entity charOffset="202-210" id="quantitative.s263.e0" text="phenytoin" type="active-ingredient" /><entity charOffset="24-35" id="quantitative.s263.e1" text="lansoprazole" type="active-ingredient" /><pair ddi="false" e1="quantitative.s263.e0" e2="quantitative.s263.e1" id="quantitative.s263.p0" /></sentence><sentence id="quantitative.s264" text="Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, or clarithromycin in healthy subjects"><entity charOffset="155-162" id="quantitative.s264.e0" text="warfarin" type="active-ingredient" /><entity charOffset="24-35" id="quantitative.s264.e1" text="lansoprazole" type="active-ingredient" /><pair ddi="false" e1="quantitative.s264.e0" e2="quantitative.s264.e1" id="quantitative.s264.p0" /></sentence><sentence id="quantitative.s265" text="Sucralfate: In a single-dose crossover study examining lansoprazole delayed-release capsules 30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate."><entity charOffset="55-66" id="quantitative.s265.e0" text="lansoprazole" type="active-ingredient" /><entity charOffset="0-9" id="quantitative.s265.e1" text="sucralfate" type="active-ingredient" /><entity charOffset="167-176" id="quantitative.s265.e2" text="sucralfate" type="active-ingredient" /><entity charOffset="344-353" id="quantitative.s265.e3" text="sucralfate" type="active-ingredient" /><pair ddi="true" e1="quantitative.s265.e0" e2="quantitative.s265.e3" id="quantitative.s265.p0" /></sentence><sentence id="quantitative.s266" text="Sucralfate: In a single-dose crossover study examining lansoprazole delayed-release capsules 30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate."><entity charOffset="0-9" id="quantitative.s266.e0" text="sucralfate" type="active-ingredient" /><entity charOffset="167-176" id="quantitative.s266.e1" text="sucralfate" type="active-ingredient" /><entity charOffset="344-353" id="quantitative.s266.e2" text="sucralfate" type="active-ingredient" /><entity charOffset="103-112" id="quantitative.s266.e3" text="omeprazole" type="active-ingredient" /><pair ddi="true" e1="quantitative.s266.e2" e2="quantitative.s266.e3" id="quantitative.s266.p0" /></sentence><sentence id="quantitative.s267" text="The AUC and Cmax of glipizide (2.5 mg single dose) were significantly increased following the administration of fluconazole in 13 normal male volunteers. There was a mean ± SD increase in AUC of 49% ± 13% (range: 27 to 73%) and an increase in Cmax of 19% ± 23% (range: -11 to 79%)"><entity charOffset="20-28" id="quantitative.s267.e0" text="glipizide" type="active-ingredient" /><entity charOffset="112-122" id="quantitative.s267.e1" text="fluconazole" type="active-ingredient" /><pair ddi="true" e1="quantitative.s267.e0" e2="quantitative.s267.e1" id="quantitative.s267.p0" /></sentence><sentence id="quantitative.s268" text="The AUC and Cmax of glyburide (5 mg single dose) were significantly increased following the administration of fluconazole in 20 normal male volunteers. There was a mean ± SD increase in AUC of 44% ± 29% (range: -13 to 115%) and Cmax increased 19% ± 19% (range: -23 to 62%). Five subjects required oral glucose following the ingestion of glyburide after 7 days of fluconazole administration. "><entity charOffset="20-28" id="quantitative.s268.e0" text="glyburide" type="active-ingredient" /><entity charOffset="340-348" id="quantitative.s268.e1" text="glyburide" type="active-ingredient" /><entity charOffset="110-120" id="quantitative.s268.e2" text="fluconazole" type="active-ingredient" /><entity charOffset="366-376" id="quantitative.s268.e3" text="fluconazole" type="active-ingredient" /><pair ddi="true" e1="quantitative.s268.e1" e2="quantitative.s268.e3" id="quantitative.s268.p0" /></sentence><sentence id="quantitative.s269" text="The AUC of propafenone is increased by more than 200% by co-administration of propranolol."><entity charOffset="78-88" id="quantitative.s269.e0" text="propranolol" type="active-ingredient" /><entity charOffset="11-21" id="quantitative.s269.e1" text="propafenone" type="active-ingredient" /><pair ddi="true" e1="quantitative.s269.e0" e2="quantitative.s269.e1" id="quantitative.s269.p0" /></sentence><sentence id="quantitative.s270" text="The concomitant administration of propafenone and warfarin increased warfarin plasma concentrations at steady state by 39% in healthy volunteers and prolonged the prothrombin time (PT) in patients taking warfarin. Adjust the warfarin dose as needed by monitoring INR (international normalized ratio)"><entity charOffset="34-44" id="quantitative.s270.e0" text="propafenone" type="active-ingredient" /><entity charOffset="50-57" id="quantitative.s270.e1" text="warfarin" type="active-ingredient" /><entity charOffset="69-76" id="quantitative.s270.e2" text="warfarin" type="active-ingredient" /><entity charOffset="204-211" id="quantitative.s270.e3" text="warfarin" type="active-ingredient" /><entity charOffset="225-232" id="quantitative.s270.e4" text="warfarin" type="active-ingredient" /><pair ddi="true" e1="quantitative.s270.e0" e2="quantitative.s270.e4" id="quantitative.s270.p0" /></sentence><sentence id="quantitative.s271" text="The effect of fluconazole on the pharmacokinetics and pharmacodynamics of midazolam was examined in a randomized, cross-over study in 12 volunteers. In the study, subjects ingested placebo or 400 mg fluconazole on Day 1 followed by 200 mg daily from Day 2 to Day 6. In addition, a 7.5 mg dose of midazolam was orally ingested on the first day, 0.05 mg/kg was administered intravenously on the fourth day, and 7.5 mg orally on the sixth day. Fluconazole reduced the clearance of IV midazolam by 51%. On the first day of dosing, fluconazole increased the midazolam AUC and Cmax by 259% and 150%, respectively. On the sixth day of dosing, fluconazole increased the midazolam AUC and Cmax by 259% and 74%, respectively. The psychomotor effects of midazolam were significantly increased after oral administration of midazolam but not significantly affected following intravenous midazolam."><entity charOffset="14-24" id="quantitative.s271.e0" text="fluconazole" type="active-ingredient" /><entity charOffset="199-209" id="quantitative.s271.e1" text="fluconazole" type="active-ingredient" /><entity charOffset="441-451" id="quantitative.s271.e2" text="fluconazole" type="active-ingredient" /><entity charOffset="527-537" id="quantitative.s271.e3" text="fluconazole" type="active-ingredient" /><entity charOffset="636-646" id="quantitative.s271.e4" text="fluconazole" type="active-ingredient" /><entity charOffset="74-82" id="quantitative.s271.e5" text="midazolam" type="active-ingredient" /><entity charOffset="296-304" id="quantitative.s271.e6" text="midazolam" type="active-ingredient" /><entity charOffset="481-489" id="quantitative.s271.e7" text="midazolam" type="active-ingredient" /><entity charOffset="553-561" id="quantitative.s271.e8" text="midazolam" type="active-ingredient" /><entity charOffset="662-670" id="quantitative.s271.e9" text="midazolam" type="active-ingredient" /><entity charOffset="743-751" id="quantitative.s271.e10" text="midazolam" type="active-ingredient" /><entity charOffset="811-819" id="quantitative.s271.e11" text="midazolam" type="active-ingredient" /><entity charOffset="874-882" id="quantitative.s271.e12" text="midazolam" type="active-ingredient" /><pair ddi="true" e1="quantitative.s271.e4" e2="quantitative.s271.e12" id="quantitative.s271.p0" /></sentence><sentence id="quantitative.s272" text="The mean Cmax and AUC of nifedipine are increased by 64% and 79%, respectively, by co-administration of propranolol."><entity charOffset="104-114" id="quantitative.s272.e0" text="propranolol" type="active-ingredient" /><entity charOffset="25-34" id="quantitative.s272.e1" text="nifedipine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s272.e0" e2="quantitative.s272.e1" id="quantitative.s272.p0" /></sentence><sentence id="quantitative.s273" text="The mean reduction of sildenafil (80 mg tid) bioavailability due to co-administration of epoprostenol was 28%, resulting in about 22% lower mean average steady state concentrations. Therefore, the slight decrease of sildenafil exposure in the presence of epoprostenol is not considered clinically relevant. The effect of sildenafil on epoprostenol pharmacokinetics is not known."><entity charOffset="22-31" id="quantitative.s273.e0" text="sildenafil" type="active-ingredient" /><entity charOffset="216-225" id="quantitative.s273.e1" text="sildenafil" type="active-ingredient" /><entity charOffset="321-330" id="quantitative.s273.e2" text="sildenafil" type="active-ingredient" /><entity charOffset="89-100" id="quantitative.s273.e3" text="epoprostenol" type="active-ingredient" /><entity charOffset="255-266" id="quantitative.s273.e4" text="epoprostenol" type="active-ingredient" /><entity charOffset="335-346" id="quantitative.s273.e5" text="epoprostenol" type="active-ingredient" /><pair ddi="false" e1="quantitative.s273.e2" e2="quantitative.s273.e5" id="quantitative.s273.p0" /></sentence><sentence id="quantitative.s274" text="The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide."><entity charOffset="90-108" id="quantitative.s274.e0" text="hydrochlorothiazide" type="active-ingredient" /><entity charOffset="24-33" id="quantitative.s274.e1" text="irbesartan" type="active-ingredient" /><pair ddi="false" e1="quantitative.s274.e0" e2="quantitative.s274.e1" id="quantitative.s274.p0" /></sentence><sentence id="quantitative.s275" text="The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide."><entity charOffset="76-85" id="quantitative.s275.e0" text="nifedipine" type="active-ingredient" /><entity charOffset="24-33" id="quantitative.s275.e1" text="irbesartan" type="active-ingredient" /><pair ddi="false" e1="quantitative.s275.e0" e2="quantitative.s275.e1" id="quantitative.s275.p0" /></sentence><sentence id="quantitative.s276" text="The pharmacokinetics of oral conivaptan (20 - 40 mg/day) were unchanged with coadministration of either captopril 25 mg or furosemide up to 80 mg/day."><entity charOffset="29-38" id="quantitative.s276.e0" text="conivaptan" type="active-ingredient" /><entity charOffset="104-112" id="quantitative.s276.e1" text="captopril" type="active-ingredient" /><pair ddi="false" e1="quantitative.s276.e0" e2="quantitative.s276.e1" id="quantitative.s276.p0" /></sentence><sentence id="quantitative.s277" text="The pharmacokinetics of oral conivaptan (20 - 40 mg/day) were unchanged with coadministration of either captopril 25 mg or furosemide up to 80 mg/day."><entity charOffset="123-132" id="quantitative.s277.e0" text="furosemide" type="active-ingredient" /><entity charOffset="29-38" id="quantitative.s277.e1" text="conivaptan" type="active-ingredient" /><pair ddi="false" e1="quantitative.s277.e0" e2="quantitative.s277.e1" id="quantitative.s277.p0" /></sentence><sentence id="quantitative.s278" text="The pharmacokinetics of propafenone was not affected by the coadministration of either propranolol or metoprolol. "><entity charOffset="102-111" id="quantitative.s278.e0" text="metoprolol" type="active-ingredient" /><entity charOffset="24-34" id="quantitative.s278.e1" text="propafenone" type="active-ingredient" /><pair ddi="false" e1="quantitative.s278.e0" e2="quantitative.s278.e1" id="quantitative.s278.p0" /></sentence><sentence id="quantitative.s279" text="The pharmacokinetics of propafenone was not affected by the coadministration of either propranolol or metoprolol. "><entity charOffset="24-34" id="quantitative.s279.e0" text="propafenone" type="active-ingredient" /><entity charOffset="87-97" id="quantitative.s279.e1" text="propranolol" type="active-ingredient" /><pair ddi="false" e1="quantitative.s279.e0" e2="quantitative.s279.e1" id="quantitative.s279.p0" /></sentence><sentence id="quantitative.s280" text="The pharmacokinetics of theophylline were determined from a single intravenous dose of aminophylline (6 mg/kg) before and after the oral administration of fluconazole 200 mg daily for 14 days in 16 normal male volunteers. There were significant increases in theophylline AUC, Cmax, and half-life with a corresponding decrease in clearance. The mean ± SD theophylline AUC increased 21% ± 16% (range: -5 to 48%). The Cmax increased 13% ± 17% (range: -13 to 40%). Theophylline clearance decreased 16% ± 11 % (range: -32 to 5%). The half-life of theophylline increased from 6.6 ± 1.7 hours to 7.9 ± 1.5 hours."><entity charOffset="87-99" id="quantitative.s280.e0" text="aminophylline" type="metabolite" /><entity charOffset="155-165" id="quantitative.s280.e1" text="fluconazole" type="active-ingredient" /><pair ddi="true" e1="quantitative.s280.e0" e2="quantitative.s280.e1" id="quantitative.s280.p0" /></sentence><sentence id="quantitative.s281" text="The pharmacokinetics of theophylline were determined from a single intravenous dose of aminophylline (6 mg/kg) before and after the oral administration of fluconazole 200 mg daily for 14 days in 16 normal male volunteers. There were significant increases in theophylline AUC, Cmax, and half-life with a corresponding decrease in clearance. The mean ± SD theophylline AUC increased 21% ± 16% (range: -5 to 48%). The Cmax increased 13% ± 17% (range: -13 to 40%). Theophylline clearance decreased 16% ± 11 % (range: -32 to 5%). The half-life of theophylline increased from 6.6 ± 1.7 hours to 7.9 ± 1.5 hours. "><entity charOffset="155-165" id="quantitative.s281.e0" text="fluconazole" type="active-ingredient" /><entity charOffset="24-35" id="quantitative.s281.e1" text="theophylline" type="active-ingredient" /><entity charOffset="258-269" id="quantitative.s281.e2" text="theophylline" type="active-ingredient" /><entity charOffset="355-366" id="quantitative.s281.e3" text="theophylline" type="active-ingredient" /><entity charOffset="464-475" id="quantitative.s281.e4" text="theophylline" type="active-ingredient" /><entity charOffset="546-557" id="quantitative.s281.e5" text="theophylline" type="active-ingredient" /><pair ddi="true" e1="quantitative.s281.e0" e2="quantitative.s281.e5" id="quantitative.s281.p0" /></sentence><sentence id="quantitative.s282" text="The plasma levels of clarithromycin and 14-hydroxy-clarithromycin were increased by the concomitant administration of omeprazole. For clarithromycin, the mean Cmax was 10% greater, the mean Cmin was 27% greater, and the mean AUC0-8 was 15% greater when clarithromycin was administered with omeprazole than when clarithromycin was administered alone. "><entity charOffset="21-34" id="quantitative.s282.e0" text="clarithromycin" type="active-ingredient" /><entity charOffset="51-64" id="quantitative.s282.e1" text="clarithromycin" type="active-ingredient" /><entity charOffset="134-147" id="quantitative.s282.e2" text="clarithromycin" type="active-ingredient" /><entity charOffset="253-266" id="quantitative.s282.e3" text="clarithromycin" type="active-ingredient" /><entity charOffset="311-324" id="quantitative.s282.e4" text="clarithromycin" type="active-ingredient" /><entity charOffset="118-127" id="quantitative.s282.e5" text="omeprazole" type="active-ingredient" /><entity charOffset="290-299" id="quantitative.s282.e6" text="omeprazole" type="active-ingredient" /><pair ddi="true" e1="quantitative.s282.e4" e2="quantitative.s282.e6" id="quantitative.s282.p0" /></sentence><sentence id="quantitative.s283" text="The plasma levels of clarithromycin and 14-hydroxy-clarithromycin were increased by the concomitant administration of omeprazole. For clarithromycin, the mean Cmax was 10% greater, the mean Cmin was 27% greater, and the mean AUC0-8 was 15% greater when clarithromycin was administered with omeprazole than when clarithromycin was administered alone. Similar results were seen for 14-hydroxy-clarithromycin, the mean Cmax was 45% greater, the mean Cmin was 57% greater, and the mean AUC0-8 was 45% greater"><entity charOffset="118-127" id="quantitative.s283.e0" text="omeprazole" type="active-ingredient" /><entity charOffset="290-299" id="quantitative.s283.e1" text="omeprazole" type="active-ingredient" /><entity charOffset="40-64" id="quantitative.s283.e2" text="14-hydroxy-clarithromycin" type="metabolite" /><entity charOffset="380-404" id="quantitative.s283.e3" text="14-hydroxy-clarithromycin" type="metabolite" /><pair ddi="true" e1="quantitative.s283.e1" e2="quantitative.s283.e3" id="quantitative.s283.p0" /></sentence><sentence id="quantitative.s284" text="Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects. Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam."><entity charOffset="313-329" id="quantitative.s284.e0" text="desmethyldiazepam" type="active-ingredient" /><entity charOffset="34-44" id="quantitative.s284.e1" text="venlafaxine" type="active-ingredient" /><entity charOffset="162-172" id="quantitative.s284.e2" text="venlafaxine" type="active-ingredient" /><entity charOffset="210-220" id="quantitative.s284.e3" text="venlafaxine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s284.e0" e2="quantitative.s284.e3" id="quantitative.s284.p0" /></sentence><sentence id="quantitative.s285" text="Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects. Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam."><entity charOffset="97-104" id="quantitative.s285.e0" text="diazepam" type="active-ingredient" /><entity charOffset="278-285" id="quantitative.s285.e1" text="diazepam" type="active-ingredient" /><entity charOffset="322-329" id="quantitative.s285.e2" text="diazepam" type="active-ingredient" /><entity charOffset="394-401" id="quantitative.s285.e3" text="diazepam" type="active-ingredient" /><entity charOffset="34-44" id="quantitative.s285.e4" text="venlafaxine" type="active-ingredient" /><entity charOffset="162-172" id="quantitative.s285.e5" text="venlafaxine" type="active-ingredient" /><entity charOffset="210-220" id="quantitative.s285.e6" text="venlafaxine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s285.e3" e2="quantitative.s285.e6" id="quantitative.s285.p0" /></sentence><sentence id="quantitative.s286" text="Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects. Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam."><entity charOffset="97-104" id="quantitative.s286.e0" text="diazepam" type="active-ingredient" /><entity charOffset="278-285" id="quantitative.s286.e1" text="diazepam" type="active-ingredient" /><entity charOffset="322-329" id="quantitative.s286.e2" text="diazepam" type="active-ingredient" /><entity charOffset="394-401" id="quantitative.s286.e3" text="diazepam" type="active-ingredient" /><entity charOffset="34-44" id="quantitative.s286.e4" text="venlafaxine" type="active-ingredient" /><entity charOffset="162-172" id="quantitative.s286.e5" text="venlafaxine" type="active-ingredient" /><entity charOffset="210-220" id="quantitative.s286.e6" text="venlafaxine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s286.e3" e2="quantitative.s286.e6" id="quantitative.s286.p0" /></sentence><sentence id="quantitative.s287" text="Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects. Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam."><entity charOffset="34-44" id="quantitative.s287.e0" text="venlafaxine" type="active-ingredient" /><entity charOffset="162-172" id="quantitative.s287.e1" text="venlafaxine" type="active-ingredient" /><entity charOffset="210-220" id="quantitative.s287.e2" text="venlafaxine" type="active-ingredient" /><entity charOffset="177-179" id="quantitative.s287.e3" text="ODV" type="metabolite" /><pair ddi="false" e1="quantitative.s287.e2" e2="quantitative.s287.e3" id="quantitative.s287.p0" /></sentence><sentence id="quantitative.s288" text="Valproate: Available data suggest that there is no significant effect of valproate on the clearance of Felbatol® at steady-state."><entity charOffset="103-110" id="quantitative.s288.e0" text="Felbatol" type="drug-product" /><entity charOffset="0-8" id="quantitative.s288.e1" text="valproate" type="active-ingredient" /><entity charOffset="73-81" id="quantitative.s288.e2" text="valproate" type="active-ingredient" /><pair ddi="false" e1="quantitative.s288.e0" e2="quantitative.s288.e2" id="quantitative.s288.p0" /></sentence><sentence id="quantitative.s289" text="Valproate: Felbatol® causes an increase in steady-state valproate concentrations. In four subjects with epilepsy ingesting valproate, the steady-state trough (Cmin) valproate plasma concentration was 63±16 micrograms/mL. The steady-state Cmin increased to 78±14 micrograms/mL when 1200 mg/day of felbamate was coadministered. Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL. Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively. The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively. This indicates that the protein binding of valproate did not change appreciably with increasing doses of Felbatol®. "><entity charOffset="0-8" id="quantitative.s289.e0" text="valproate" type="active-ingredient" /><entity charOffset="57-65" id="quantitative.s289.e1" text="valproate" type="active-ingredient" /><entity charOffset="124-132" id="quantitative.s289.e2" text="valproate" type="active-ingredient" /><entity charOffset="166-174" id="quantitative.s289.e3" text="valproate" type="active-ingredient" /><entity charOffset="401-409" id="quantitative.s289.e4" text="valproate" type="active-ingredient" /><entity charOffset="471-479" id="quantitative.s289.e5" text="valproate" type="active-ingredient" /><entity charOffset="631-639" id="quantitative.s289.e6" text="valproate" type="active-ingredient" /><entity charOffset="666-674" id="quantitative.s289.e7" text="valproate" type="active-ingredient" /><entity charOffset="828-836" id="quantitative.s289.e8" text="valproate" type="active-ingredient" /><entity charOffset="11-18" id="quantitative.s289.e9" text="Felbatol" type="drug-product" /><entity charOffset="571-578" id="quantitative.s289.e10" text="Felbatol" type="drug-product" /><entity charOffset="759-766" id="quantitative.s289.e11" text="Felbatol" type="drug-product" /><entity charOffset="890-897" id="quantitative.s289.e12" text="Felbatol" type="drug-product" /><pair ddi="true" e1="quantitative.s289.e8" e2="quantitative.s289.e12" id="quantitative.s289.p0" /></sentence><sentence id="quantitative.s290" text="VAPRISOL (40 mg/day for 4 days) administered with a single 25 mg dose of warfarin, which undergoes major metabolism by CYP2C9 and minor metabolism by CYP3A, increased the mean S-warfarin AUC and S-warfarin Cmax by 14% and 17%, respectively. The corresponding prothrombin time and international normalized ratio values were unchanged."><entity charOffset="0-7" id="quantitative.s290.e0" text="vaprisol" type="drug-product" /><entity charOffset="73-80" id="quantitative.s290.e1" text="warfarin" type="active-ingredient" /><entity charOffset="178-185" id="quantitative.s290.e2" text="warfarin" type="active-ingredient" /><entity charOffset="197-204" id="quantitative.s290.e3" text="warfarin" type="active-ingredient" /><pair ddi="true" e1="quantitative.s290.e0" e2="quantitative.s290.e3" id="quantitative.s290.p0" /></sentence><sentence id="quantitative.s291" text="VAPRISOL 30 mg/day resulted in a 3-fold increase in the AUC of simvastatin."><entity charOffset="0-7" id="quantitative.s291.e0" text="vaprisol" type="drug-product" /><entity charOffset="63-73" id="quantitative.s291.e1" text="simvastatin" type="active-ingredient" /><pair ddi="true" e1="quantitative.s291.e0" e2="quantitative.s291.e1" id="quantitative.s291.p0" /></sentence><sentence id="quantitative.s292" text="Venlafaxine did not inhibit CYP1A2 in vitro. This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate."><entity charOffset="172-179" id="quantitative.s292.e0" text="caffeine" type="active-ingredient" /><entity charOffset="0-10" id="quantitative.s292.e1" text="venlafaxine" type="active-ingredient" /><entity charOffset="126-136" id="quantitative.s292.e2" text="venlafaxine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s292.e0" e2="quantitative.s292.e2" id="quantitative.s292.p0" /></sentence><sentence id="quantitative.s293" text="Verapamil does not affect the pharmacokinetics of propranolol"><entity charOffset="0-8" id="quantitative.s293.e0" text="verapamil" type="active-ingredient" /><entity charOffset="50-60" id="quantitative.s293.e1" text="propranolol" type="active-ingredient" /><pair ddi="false" e1="quantitative.s293.e0" e2="quantitative.s293.e1" id="quantitative.s293.p0" /></sentence><sentence id="quantitative.s294" text="Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren."><entity charOffset="0-8" id="quantitative.s294.e0" text="verapamil" type="active-ingredient" /><entity charOffset="41-49" id="quantitative.s294.e1" text="verapamil" type="active-ingredient" /><entity charOffset="63-71" id="quantitative.s294.e2" text="aliskiren" type="active-ingredient" /><entity charOffset="137-145" id="quantitative.s294.e3" text="aliskiren" type="active-ingredient" /><pair ddi="true" e1="quantitative.s294.e1" e2="quantitative.s294.e3" id="quantitative.s294.p0" /></sentence><sentence id="quantitative.s295" text="When a single oral 30-mg dose of immediate-release paroxetine was administered at phenytoin steady state (300 mg once daily for 14 days), paroxetine AUC and T½ were reduced (by an average of 50% and 35%, respectively) compared to immediate-release paroxetine administered alone."><entity charOffset="51-60" id="quantitative.s295.e0" text="paroxetine" type="active-ingredient" /><entity charOffset="138-147" id="quantitative.s295.e1" text="paroxetine" type="active-ingredient" /><entity charOffset="249-258" id="quantitative.s295.e2" text="paroxetine" type="active-ingredient" /><entity charOffset="82-90" id="quantitative.s295.e3" text="phenytoin" type="active-ingredient" /><pair ddi="true" e1="quantitative.s295.e2" e2="quantitative.s295.e3" id="quantitative.s295.p0" /></sentence><sentence id="quantitative.s296" text="When lansoprazole delayed-release capsules were administered concomitantly with theophylline (CYP1A2, CYP3A), a minor increase (10%) in the clearance of theophylline was seen. Because of the small magnitude and the direction of the effect on theophylline clearance, this interaction is unlikely to be of clinical concern. Nonetheless, individual patients may require additional titration of their theophylline dosage when lansoprazole delayed-release capsules is started or stopped to ensure clinically effective blood levels."><entity charOffset="5-16" id="quantitative.s296.e0" text="lansoprazole" type="active-ingredient" /><entity charOffset="422-433" id="quantitative.s296.e1" text="lansoprazole" type="active-ingredient" /><entity charOffset="80-91" id="quantitative.s296.e2" text="theophylline" type="active-ingredient" /><entity charOffset="153-164" id="quantitative.s296.e3" text="theophylline" type="active-ingredient" /><entity charOffset="242-253" id="quantitative.s296.e4" text="theophylline" type="active-ingredient" /><entity charOffset="397-408" id="quantitative.s296.e5" text="theophylline" type="active-ingredient" /><pair ddi="true" e1="quantitative.s296.e1" e2="quantitative.s296.e5" id="quantitative.s296.p0" /></sentence><sentence id="quantitative.s297" text="When multiple doses of LIPITOR and digoxin were coadministered, steady state plasma digoxin concentrations increased by approximately 20%."><entity charOffset="23-29" id="quantitative.s297.e0" text="LIPITOR" type="drug-product" /><entity charOffset="35-41" id="quantitative.s297.e1" text="digoxin" type="active-ingredient" /><entity charOffset="84-90" id="quantitative.s297.e2" text="digoxin" type="active-ingredient" /><pair ddi="true" e1="quantitative.s297.e0" e2="quantitative.s297.e2" id="quantitative.s297.p0" /></sentence><sentence id="quantitative.s298" text="When voriconazole (400 mg Q12h x 1 day, then 200 mg x 6 days) was given with omeprazole (40 mg once daily x 7 days) to healthy subjects, it significantly increased the steady-state Cmax and AUC0-24 of omeprazole, an average of 2 times (90% CI: 1.8, 2.6) and 4 times (90% CI: 3.3, 4.4) respectively as compared to when omeprazole was given without voriconazole."><entity charOffset="5-16" id="quantitative.s298.e0" text="voriconazole" type="active-ingredient" /><entity charOffset="347-358" id="quantitative.s298.e1" text="voriconazole" type="active-ingredient" /><entity charOffset="77-86" id="quantitative.s298.e2" text="omeprazole" type="active-ingredient" /><entity charOffset="201-210" id="quantitative.s298.e3" text="omeprazole" type="active-ingredient" /><entity charOffset="318-327" id="quantitative.s298.e4" text="omeprazole" type="active-ingredient" /><pair ddi="true" e1="quantitative.s298.e1" e2="quantitative.s298.e4" id="quantitative.s298.p0" /></sentence><sentence id="quantitative.s299" text="Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials. Zonisamide did not inhibit mixed-function liver oxidase enzymes (cytochrome P450), as measured in human liver microsomal preparations, in vitro. Zonisamide is not expected to interfere with the metabolism of other drugs that are metabolized by cytochrome P450 isozymes"><entity charOffset="82-90" id="quantitative.s299.e0" text="phenytoin" type="active-ingredient" /><entity charOffset="0-9" id="quantitative.s299.e1" text="zonisamide" type="active-ingredient" /><entity charOffset="145-154" id="quantitative.s299.e2" text="zonisamide" type="active-ingredient" /><entity charOffset="290-299" id="quantitative.s299.e3" text="zonisamide" type="active-ingredient" /><pair ddi="false" e1="quantitative.s299.e0" e2="quantitative.s299.e3" id="quantitative.s299.p0" /></sentence><sentence id="quantitative.s300" text="Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials. Zonisamide did not inhibit mixed-function liver oxidase enzymes (cytochrome P450), as measured in human liver microsomal preparations, in vitro. Zonisamide is not expected to interfere with the metabolism of other drugs that are metabolized by cytochrome P450 isozymes."><entity charOffset="93-105" id="quantitative.s300.e0" text="carbamazepine" type="active-ingredient" /><entity charOffset="0-9" id="quantitative.s300.e1" text="zonisamide" type="active-ingredient" /><entity charOffset="145-154" id="quantitative.s300.e2" text="zonisamide" type="active-ingredient" /><entity charOffset="290-299" id="quantitative.s300.e3" text="zonisamide" type="active-ingredient" /><pair ddi="false" e1="quantitative.s300.e0" e2="quantitative.s300.e3" id="quantitative.s300.p0" /></sentence><sentence id="quantitative.s301" text="Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials. Zonisamide did not inhibit mixed-function liver oxidase enzymes (cytochrome P450), as measured in human liver microsomal preparations, in vitro. Zonisamide is not expected to interfere with the metabolism of other drugs that are metabolized by cytochrome P450 isozymes."><entity charOffset="0-9" id="quantitative.s301.e0" text="zonisamide" type="active-ingredient" /><entity charOffset="145-154" id="quantitative.s301.e1" text="zonisamide" type="active-ingredient" /><entity charOffset="290-299" id="quantitative.s301.e2" text="zonisamide" type="active-ingredient" /><entity charOffset="111-119" id="quantitative.s301.e3" text="valproate" type="active-ingredient" /><pair ddi="false" e1="quantitative.s301.e2" e2="quantitative.s301.e3" id="quantitative.s301.p0" /></sentence><sentence id="quantitative.s302" text="Zonisamide single dose pharmacokinetic parameters were not affected by cimetidine (300 mg four times a day for 12 days)."><entity charOffset="71-80" id="quantitative.s302.e0" text="cimetidine" type="active-ingredient" /><entity charOffset="0-9" id="quantitative.s302.e1" text="zonisamide" type="active-ingredient" /><pair ddi="false" e1="quantitative.s302.e0" e2="quantitative.s302.e1" id="quantitative.s302.p0" /></sentence></document>